ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 32 DECEMBER 1988 NUMBER 12 Robert C. Moellering, Jr., Christine C. Sanders, Editor (1989) Editor in Chief (1990) Creighton University School of New England Deaconess Hospital Jack M. Gwaltney, Jr., Editor (1990) Medicine Boston, Mass. University of Virginia School of Omaha, Neb. Michael Barza, Editor (1990) Medicine John A. Washington II, Editor (1991) New England Medical Center Charlottesville Cleveland Clinic Foundation Hospitals George A. Jacoby, Jr., Editor (1990) Cleveland, Ohio Boston, Mass. Massachusetts General Hospital Peter G. Welling, Editor (1988) Lawrence E. Bryan, Editor (1992) Boston Warner-Lambert Co. University of Calgary Ann Arbor, Mich. Calgary, Alberta, Canada EDITORIAL BOARD Vincent T. Andriole (1990) Robert J. Fass (1988) Stephen A. Lerner (1989) Jerome J. Schentag (1988) Bascom F. Anthony (1988) Stuart Feldman (1988) Stuart B. Levy (1989) Raymond F. Schinazi (1989) Gordon L. Archer (1989) Sydney Finegold (1988) David R. Luke (1990) Fritz D. Schoenknecht (1989) George R. Aronoff (1989) Martin Forbes (1989) Joan Lusk (1989) Robert T. Schooley (1990) Rashmi H. Barbhaiya (1989) John N. Galgiani (1990) R. Luthy (1989) F. C. Sciavolino (1988) Arthur L. Barry (1989) Dale N. Gerding (1988) Gerald L. Mandell (1989) William M. Shannon (1989) John G. Bartlett (1990) Allan Godfrey (1990) Gary R. Matzke (1989) Charles Shipman, Jr. (1988) Arnold S. Bayer (1988) Irving H. Goldberg (1988) George H. McCracken (1990) David M. Shlaes (1988) William M. Bennett (1990) Thomas D. Gootz (1988) Antone A. Medeiros (1990) Robert W. Sidwell (1990) Michel G. Bergeron (1989) Stephen B. Greenberg (1989) Michael Miller (1990) Herbert M. Sommers (1989) Richard F. Bergstrom (1988) Scott M. Hammer (1989) Barbara E. Murray (1990) P. Frederick Sparling (1990) Karen K. Biron (1990) Margaret R. Hammerschlag (1989) Henry W. Murray (1990) Harold Standiford (1988) Gerald P. Bodey (1989) Robert E. W. Hancock (1989) John D. Nelson (1989) David A. Stevens (1989) Ward Bullock (1990) W. Lee Hand (1989) Harold C. Neu (1989) Stephen E. Straus (1990) Tsun Chang (1989) H. Hunter Handsfield (1989) Lawrence A. Pachla (1990) R. Sutherland (1988) Anthony Chow (1988) Frederick G. Hayden (1990) Joseph S. Pagano (1990) Morton N. Swartz (1988) C. Glenn Cobbs (1989) Leonid B. Heifets (1990) James E. Pennington (1989) Richard B. Sykes (1988) Paul S. Cohen (1989) Michael L. Higgins (1989) T. J. Perun (1989) Francis P. Tally (1990) William A. Craig (1990) David C. Hooper (1990) Lance R. Peterson (1988) Fred C. Tenover (1988) Naomi Datta (1990) Richard Hornick (1989) W. H. G. Richards (1989) Alexander Tomasz (1988) Lawrence E. Day (1989) George Gee Jackson (1989) Douglas D. Richman (1990) Roger D. Toothaker (1988) William E. Dismukes (1990) Michael R. Jacobs (1990) Glenn D. Roberts (1989) Francis L. S. Tse (1989) Gary V. Doern (1990) James H. Jorgensen (1990) Richard Roberts (1988) Michael Waring (1990) Susan M. Dorrbecker (1989) William J. Jusko (1989) Ian M. Rollo (1988) Bernard Weisblum (1988) R. Gordon Douglas, Jr. (1989) A. W. Karchmer (1988) Allan Ronald (1990) Peter F. Weller (1989) John C. Drach (1990) Donald Kaye (1988) John P. Rosazza (1989) Richard Wise (1989) George L. Drusano (1990) Mark S. Klempner (1989) Jon E. Rosenblatt (1988) John S. Wolfson (1990) Theodore Eickhoff (1988) George S. Kobayashi (1988) Robert H. Rubin (1990) David J. Wyler (1989) Gertrude B. Elion (1990) Jeffrey R. Koup (1990) Merle Sande (1988) Lowell Young (1988) George M. Eliopoulos (1988) Donald J. Krogstad (1989) W. Eugene Sanders, Jr. (1990) Pauline K. W. Yu (1988) Arthur English (1989) Philip Todd Lavin (1989) W. Michael Scheld (1989) Helen R. Whiteley, Chairman, Publications Board Kirk Jensen, Director ofPublications Linda M. Illig, Managing Editor, Journals Carol J. Neff, Production Editor

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., N.W., Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial, antiparasitic, and anticancer agents and chemotherapy. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Publications Department. Antimicrobial Agents and Chemotherapy is published monthly, one volume per year. The nonmember subscription price is $220 per year; single copies are $30. The member subscription price is $35 (foreign, $56 [air drop shipping]) per year; single copies are $8. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Department, 1913 I St., N.W., Washington, DC 20006 (phone: 202 833-9680). Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed. Second-class postage paid at Washington, DC 20006, and at additional mailing offices. POSTMASTER: Send address changes to Antimicrobial Agents and Chemotherapy, ASM, 1913 I St., N.W., Washington, DC 20006. Made in the United States of America. Copyright C) 1988, American Society for Microbiology. 43*:I^ &'iAK,J L Um{f,1; ( I13'f All Rights Reserved. The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., 21 Congress St., Salem, MA 01970, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Author Index

Abele, Gunnar, 1807 Feldberg, Ross S., 1763 Lemon, Eloise, 1780 Saikawa, Isamu, 1848 Akabane, Taro, 1864 Ferro, Adolph J., 1904 Leone, R., 1875 Sakuma, Takashi, 1839 Arnold, Barbara H., 1784 Ferronato, G., 1875 Levy, Stuart B., 1797, 1801 Sanders, Christine C., 1893 Fitchen, John H., 1904 Lindborg, Bjorn, 1807 Sanders, W. Eugene, Jr., 1893 Barg, Neil L., 1834 Flaherty, John F., 1825 Lindqvist, Lennart, 1869 Schinazi, Raymond F., 1784 Beale, Angela S., 1830 Fleishaker, Joseph C., 1825 Love, Kathryn R., 1899 Schluederberg, Susan, 1801 Benoni, G., 1875 Fletcher, Courtney V., 1899 Selitrennikoff, Claude P., 1901 Bertrand, G., 1875 Fracasso, M. E., 1875 Maddaus, Michael A., 1769 Sierra-Madero, Juan, 1754, Blumer, Jeffrey L., 1780 Franzblau, Scott G., 1758 Marshall, Bonnie, 1801 1896 Boehme, Richard E., 1887 Simmons, Richard L., 1769 1825 Martino-Saltzman, David, Brown, David C., 1899 Gambertoglio, John G., 1784 Smith, John M., 1776 Bubrick, Melvin P., 1845 Gates, Mark L., 1893 Snoeck, Robert, 1839 John, 1830 Marx, Preston A., 1887 Budtz-J0rgensen, Ejvind, 1859 Gisby, Masuda, Midori, 1864 Soike, Kenneth F., 1807 Goldfarb, Johanna, 1780 Matsuoka, Takafumi, 1864 Stark, Tracey, 1901 Call, N. Branson, 1820 Guglielmo, B. Joseph, 1825 Steele, Lorraine C., 1776 Linda 1813 Matthews, Thomas R., 1887 Cannon, Deborah L., 1784 Gustavson, E., Matzke, Gary R., 1845 Sumter, Gwendolyn, 1776 Casas, Ivan A., 1854 McGinnis, E., 1788 Sundstrom, David C., 1763 Chang, Stephen C., 1763 Hastings, Robert C., 1758 Suttmann, Rebecca T., 1887 Chen, Ming S., 1887 Hayden, Frederick G., 1813 McRoberts, Mary Jane, 1887 Chernow, Marlene, 1887 Heim-Duthoy, Karen L., 1845 Mitsuhashi, Susumu, 1848 Holmstrup, Palle, 1859 Mitsuyama, Junichi, 1848 Taft, Cathy S., 1901 Chuang, Ronald Y., 1887 Talarico, Todd L., 1854 Chung, Tung C., 1854 Holy, Antonin, 1839 Murata, Kenjiro, 1864 Hori, Ritsuko, 1848 Thompson, Nathan H., 1763 Cocchetto, David M., 1845 Tominack, Rebecca L., 1813 Consolo, U., 1875 Nadler, Marcus, 1763 Townsend, Raymond J., 1825 Cornford, Richard J., 1879 Inoue, Matsuhisa, 1848 Neuwirth, Zeev, 1763 Isayama, Yasuro, 1891 Nord, Carl Erik, 1869 Turner, Ronald B., 1820 Courvalin, Patrice, 1793 Ishikawa, Hitoshi, 1891 Crenshaw, Deborah, 1780 Walker, Linda A., 1879 Cunningham, Eloise, 1788 Jacobson, Jay A., 1820 Ohmae, Kenichi, 1891 Wallace, Richard J., Jr., 1776 Curtis, Nigel A. C., 1879 Jechorek, Robert P., 1769 O'Horo, Jennifer, 1780 Washington, John A., 1754, Cuzzolin, L., 1875 Jones, Ronald N., 1747 1896 Joyce, Lyle D., 1899 Datema, Roelf, 1807 Papadopoulou, Barbara, 1793 Wells, Carol L., 1769 Parham, Christine, 1788 White, Anthony J., 1879 Davis, Joanne, 1801 Karaffa, Camile, 1754 de Clercq, Erik, 1839 Park, Britt H., 1797 Wills, Robert J., 1813 Kasworm, Evelyn M., 1820 Prisbe, Ernest J., 1887 Wu, John C., 1887 Dirks, Monte S., 1820 Knapp, Cynthia, 1754, 1896 Dobrogosz, Walter J., 1854 Pritzker, Marc R., 1899 Komiyama, Atsushi, 1864 Puchetti, V., 1875 Doern, Gary V., 1747 Kotik, Alan N., 1763 Yamazaki, Munehiro, 1864 Krogh, Palle, 1859 Yasuda, Takashi, 1848 East, Simon J., 1879 Riscoe, Michael K., 1904 Yasui, Kozo, 1864 Edlund, Charlotta, 1869 Lake, Kathleen D., 1899 Rodondi, Lisa C., 1825 Yotsuji, Akira, 1848 Eisenstadt, Rosemary L., Lake-Bakaar, Desmond M., Rosenberg, Ivan, 1839 1879 1807 Rowse, Deborah, 1801 Zilhao, Rita, 1793 ACKNOWLEDGMENT

The following persons served as invited special reviewers for the journal during 1988, and their help is greatly appreciated. Charles A. Alford, Jr. Eric De Clercq Gerri S. Hall R. H. Neubauer Simon Silver J. Davis Allen David Diuguid J. Owen Hendley Franklin Neva John Sixbey R. Anderson Thomas Dougherty Martin Hirsch Ernest Newbrun Craig A. Smith F. S. Archibald Kathleen M. Downey Jan V. Hirschmann Thalia Nicas Thomas Smith Devron Averett Richard Duma Glen R. Hodger H. Nikaido Jack Sobel Carl-Erik Nord Kenneth F. Soike Johan S. Bakken Paul H. Edelstein B. Houwen Pam Sokol Robert M. Bannatyne Roslyn Eisenberg Walter Hughes Richard Novick Tom Specter Jules Baum Suzanne U. Emerson Pentti Huovinen Paul O'Keefe David Speert Robert Beahner Richard H. K. Eng J. Michael Janda Andrew Onderdonk Magel Spitz Michael Bennish Lawrence Eron Susan Jensen Michael Otto Brian Spratt J. D. Berman J. 0. Falkinham Dave Johns W. Paranchych Walter Stamm Robert F. Betts Barry M. Farr Allen Kaiser Roberta Parente Victor Stollar A. Bock David Feingold Earl R. Kern J. T. Parisi Barbara Styrt John M. Boyce Robert Fekety A. Kerr T. Parr J. W. Suttie Volkman Braun A. Ferrante W. M. M. Kirby Robert Pass Richard L. Sweet Sam Broder A. Kirk Field Saul Kit Gerald Peir Francis P. Szoka Kenneth Brown Cay Fitch T. R. Klaenhammer L. Piddock H. Taber Karen Bush Robert J. Fitzgerald Vernon Knight Philip Pizzo Janson M. Tanzer C. Preheim Martin Tauber Peter Canonico Cecil W. Forsberg M. Kozak Laurel Raymond Testa Stephen J. Cavalier A. Forsgren Donald Leblanc Alice Prince Charles Thoen Henry Chambers Eben Fox William Ledger Peter J. Quesenberry Clyde Thornsberry John Chapman I. Fridovich Tim Lee Jonathan I. Ravdin Richard Tidwell Stephen A. Chartrand K. P. Fu Roland A. Levandowski D. J. Reed Carmelita Tuazon Ming S. Chen Philip Furman J. J. Lipsky Jack Remington E. Tuomanen Yung-Chi Cheng James Fyfe L. F. Liu K. L. Rinhart, Jr. Ronald B. Turner Ian Chopra Denise Galloway David Livermore Marilyn Roberts M. Vaara Gordon Christensen Peter Gemski G. Lopez-Berestein William Robinson Leo Vining Richard B. Clark Nafsika Georgopapada- Lionel A. Mandell Hans G. Sahl Edward E. Walsh Donald Coen kou Joseph Marr Irving Salit Richard J. Whitley Patrice Courvalin Donald K. Giger J. R. Martin K. Sanderson Kirk Wilhelmis W. A. Cramer David Gilbert Kenneth Mayer Prem Sarin Murray Wittner Lawrence R. Crane Michael Glauser J. K. McClatchy Priscilla Schaeffer Emanuel Wolinsky Jorge Crosa Joseph Glorioso Mark A. McKinlay Charles J. Schleupner Brian Wong Clyde Crumpacker Richard V. Goering Colin McLaren A. Schryvers D. E. Woods George Cuchural, Jr. Myles Gombert Cody Meissner Warren Shaw Philip Wyde Thomas Curran Robert C. Good Miklos H. Muller G. Shockman Robert Yarchoan Richard Davey John E. Greenlee William N. Murphy Robert Shoemaker Stephen Zinner Bernard Davis Jerome E. Groopman Kenrad E. Nelson Robert E. Shope M. Zweerink AUTHOR INDEX VOLUME 32

Abele, G., 1137, 1807 Barriere, Steven L., 298 Boyd, James C., 1644 Abraham, Soman N., 1274 Barry, Arthur L., 150, 346, 443, 752, 1576 Boyd, Malcolm R., 358 Acar, J. F., 9, 195 Bartlett, J. C., 598 Bradley, S. G., 962 Adinolfi, Luigi E., 1012 Bartlett, Karen H., 782 Brajtburg, Janina, 327, 702 Adloff, M., 1360 Bartlett, Marilyn S., 897 Brafia, Alfredo F., 1552 Aguirre, Tania, 1237 Bartosek, IVan, 1541 Brandicourt, Olivier, 250 Aikawa, M., 1655 Bartucci, F., 1461 Brandt, Roger, 573 Aizawa, Noboru, 1648 Bassford, Philip J., Jr., 164 Broadhurst, Anne V., 814 Akabane, Taro, 1864 Baumann, Russell J., 1119 Brogard, J. M., 1360 Akerfeldt, Stig, 1720 Bayer, Arnold S., 141, 231 Brown, David C., 1899 Akimoto, Yoshiaki, 566 Beachey, Edwin H., 1274, 1370, 1603, Brown, Michael R. W., 364 Alarc6n, Balbino, 1257, 1412 1609 Brown, Robert, 1269 Albrecht, Janice K., 47, 224 Beale, Angela S., 1830 Brown, S. Anthony, 595 Alcina, Antonio, 1412 Beauchamp, Denis, 992 Brown, William J., 385 Aidridge, Kenneth, 717 Beckman, Howard B., 510 Brunner, H., 57 Allais, Jean M., 1327, 1740 Beggs, William H., 209 Brust, Paula, 1640 Allegra, Carmen J., 324, 430 Bellin, Eran Y., 1113 Bryan, L. E., 498 Allison, Patricia E., 137 Bemis, A. Todd, 63 Bubrick, Melvin P., 1845 Alonso, Marie-Jose, 1204 Bennett, D. B., 758 Budtz-J0rgensen, Ejvind, 1859 Alvarez, Emilio, 1061 Bennett, John E., 1619 Bull, Herbert G., 319 An, Florence Y., 547 Bennett, Renee L., 209 Bundy, J. McCall, 882 Anand, Rita, 684 Bennett, William M., 844 Bush, Larry M., 877 Andrade, J., 780 Benoni, G., 1875 Byrne, Sean K., 1441 Andremont, Antoine, 1204 Berger-Bachi, Brigitte, 1494 Andrews, J. M., 617, 1251, 1508 Bergeron, Michel G., 354, 561, 736, 1227, Cabeza Meckert, Patricia, 241 Andrews, Kenneth J. M., 814 1231, 1433, 1515 Cacalano, Grace Soong, 838 Andry, G., 1557 Bergman, Jan, 1720 Cafarell, Robert F., 777 Ansehn, Steffan, 1208 Berk, Shirley, 78 Calame, Wim, 1456 Antikainen, Riitta, 1019 Berk, Steven, 78 Call, N. Branson, 182Q Anwar, Hosmin, 364 Berkey, Peter, 1078 Campos, Jos4, 477, 706 Aoyagi, Teruo, 110 Bermudez, Luiz Eduardo M., 1149 Canawati, Hanna N., 81 Aoyama, Hiroshi, 104, 922 Bernard, E. M., 780, 1676 Cannon, Deborah L., 1784 Apicella, Michael A., 777 Bernareggi, Alberto, 246, 1223 Cantoral, Jesus M., 1061 Appelbaum, Frederick R., 271 Bernstein, David I., 761 Canupp, Kay C., 1500 Arai, Mamoru, 110 Berthe, Jackie, 250 Carbon, C., 1590 Arai, Susumu, 1040, 1396 Bertino, Joseph S., Jr., 236, 1446 Carlet, J., 9 Arai, Toshihiko, 110 Bertrand, G., 1875 Carlisle, Ricarda, 997 Arakawa, Soichi, 1080 Berube, Denise, 354, 1227 Carr, Mary E., 844 Arathoon, Eduardo G., 369 Beyer, Jill M., 1710 Carrasco, Luis, 1257 Araujo, Fausto G., 755 Bia, Frank J., 1182 Carret, G., 454 Arca, Pilar, 1552 Bianchi, A., 1350 Casadaban, Malcolm, 1379 Armstrong, D., 780, 1676 Billot-Klein, D., 9, 195 Casalino, Mariassunta, 1262 Arnold, Barbara H., 1784 Biron, Karen, 265 Casas, Ivan A., 1854 Arnold, John, 42 Biron, Simon, 1231 Casey, Sharon W., 337 Aronoff, Stephen C., 395, 1636 Bishop, Monica, 1565 Casin, I., 1350 Ashby, J. P., 617, 1251, 1508 Bittner, Marvin J., 1327 Cassano, Karen, 1031 Ashdown, Leslie R., 1435 Black, William A., 1441 ,Cassell, Gail H., 1500 Asmar, Basim I., 1375 Blasecki, John W., 1699 Castellano, S., 592 Auclair, Pierre, 736 Blickens, Donald, 42 Catherall, Elaine J., 1705 Azuma, Masanobu, 1547 Blickle, J. F., 1360 Catlin, B. Wesley, 971 Blum, Robert A., 848 Cattier, Blandine, 147 Baba, Masanori, 1025, 1742 Blumer, Jeffrey L., 1780 Cavenaghi, Luigi, 246, 1223 Babin-Chevaye, C., 1124 Bocquet, V., 1590 Chabner, Bruce A., 324, 430 Bachmann, Kenneth, 75, 730 Bodey, Gerald P., 1365 Chaffin, Donald O., 706 Bacon, Teresa H., 358 Bodhidatta, Ladaporn, 723 Chalkley, Lynda J., 24 Baker, Cynthia B., 374 Boeckh, Michael, 92 Chamb6, Jorge G., 241 Baker, Pamela J., 1521 Boehm, Diane M., 137 Chamorro, Roxana M., 1416 Baker, Richard H., 462 Boehme, Richard, 1154, 1887 Champlin, Franklin R., 1354 Boelaert, J., 1595 1231 Bakken, Johan S., 1314 Bohme, Ekkehard H., 1119 Chan, gobert, Bakker, Leendert J., 473 Bongaerts, Ger P. A., 740 Chanal, Catherine M., 626, 1660 Bakker-Woudenberg, Irma A.J.M., 1560 B3onventre, Peter F., 1012 Chang, Hernan R., 524 Balis, Frank M., 324 Boot, J. M., 426 Chang, Stephen C., 1763 Baltch, Aldona L., 1450, 1565 Bornemann, L. D., 592 Chanock, Robert M., 1269 Balzarini, Jan, 1025 Borner, Klaus, 92 Chantrain, G., 1557 Baqar, Shahida, 462 Borsa, Francoise, 938 Chapman, John S., 438 Barber, William E., 814 Boscia, Jerome A., 262, 877 Chastang, Claude, 303 Barg, Neil L., 202, 1834 Boslego, John W., 775 Chen, Man, 678 Barnett, Bill B., 331 Bottner, Wayne A., 1446 Chen, Ming S., 1887 Baron, Patricia A., 1269 Bower, Robert R., 27 Cheng, Nick, 788 Barredo, Jose L., 1061 Bowles, Susan K., 510 Chernow, Marlene, 1887 ii AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Chin, Nai Xing, 838 Datema, Roelf, 1807 Exposto, F. da L., 1458 Chin, Nai-Xun, 84, 580, 656, 663, 671, Daum, Robert S., 1034 1666 Davis, Joanne, 1801 Fardel, G., 454 Chitwarakorn, Anupong, 723 Davis, Robin L., 274 Farinotti, R., 1590 Chongsuphajaisiddhi, T., 250 Debbia, Eugenio, 279 Fasco, Michael J., 1446 Chow, AnthonyNW., 782, 788 De Beule, K., 1595 Fass, Robert J., 1082 Chow, Raymond T., 1113 Debs, Robert J., 1404 Fattal, Elias, 1204 Christenson, James G., 1005 de Clercq, Erik, 906, 1025, 1742, 1839 Faurisson, Francois, 568 Chu, Chun-Jung, 858 Deeg, H. Joachim, 271 Feld, Ron, 1231 Chu, D. T. W., 27 Deffrennes, Dominique, 467 Feldberg, Ross S., 1763 Chuang, Ronald Y., 1887 de Groot, Ronald, 477 Feldman, P. A., 1218 Chung, Menger, 42 de las Heras, Federico G., 1257 Fernandes, Prabhavathi B., 27, 1500, 1710 Chung, Tung C., 1854 Delgado, Rafael, 1598 Fernandez-Guerrero, Manuel, 747 Citron, Diane M., 213, 1143 Deloron, Philippe, 391 Ferraro, Frank M., 1740 Clark, Richard B., 689, 1314 Derouin, Francis, 303 Ferrea, Giuseppe, 1223 Clarkson, Allen B., Jr., 1158 Desmyter, Jan, 1025 Ferro, Adolph J., 1904 Clavier, Francoise, 568 Diez, Bruno, 1061 Ferronato, G., 1875 Clayton, Christopher, 1213 DiGiovanni, Maria A., 982 Fesik, Stephen W., 308 Cleary, Timothy, 717 DiMattia, Arthur, 882 Fetchick, Richard, 1310 Cleeland, Roy, 770 Dirks, Monte S., 1820 Fidalgo, S., 420 Clewell, Don B., 547 Dismukes, William E., I Fillastre, Jean-Paul, 919, 938, 942 Cluzel, Roger A., 626, 1660 Divo, Alan A., 1182 Finegold, Sydney M., 403, 601, 611, 717 Cocchetto, David M., 1845 Dix, Barbara A., 770 Cohen, L. A., 1655 Dobrogosz, Walter J., 1854 Finnerty, Edmund F., 882 Cohen, Paul S., 770 Doern, Gary V., 180, 259, 1747 Fischer, James H., 848 Cohen, Seth P., 1187 Dohtsu, Yasumasa, 1427 Fitchen, John H., 1904 Cohn, Robert C., 395 Dolan, Margaret M., 350 Flaherty, John F., 1825 Cole, Gerald A., 462 Dolan, Stephen A., 928 Flandrois, J. P., 454 Coll, Ram6n, 636 Dor, P., 1557 Fleishaker, Joseph C., 1825 Collaborative Antimicrobial Susceptibility Dornbusch, Katherine, 1484 Fletcher, Courtney V., 1899 Testing Group, 346 Dorrington, Susan M., 518 Fleurette, J., 873 Collatz, E., 195, 1289 Dougherty, Steven H., 337 Foddis, Giovanni, 552 Comereski, C. R., 758 Dougherty, Thomas J., 1113 Folan, David W., Jr., 882 Conroy, Joseph V., 1450, 1565 Douwes-Idema, Nora, 1456 Fong, Ignatius W., 834, 1231 Consolo, U., 1875 Draft, Kenneth, 773 Forrest, Alan, 1537 Conte, John E., Jr., 1490 Drake, James C., 324, 430 Foster, Timothy J., 1174 Cook, Sandra, 1439 Drucker, William R., 882 Foucault, Paule, 1433 Corada, Monica, 1541 Druilhe, Pierre, 250 Fourgeaud, M., 1094 Cornaglia, Giuseppe, 552 Drusano, George L., 289, 1537 Foxall, Carrol, 710 Corner, Anne-Marie, 350 Dubach, Ulrich C., 573 Foy, Jilanna, %, 896 Cormford, Richard J., 1879 Dudley, Michael N., 128 Fracasso, M. E., 1875 Courtney, Harry S., 1370 Dufresne, Julien, 819 Courvalin, Patrice, 15, 945, 1107, 1174, Durica, David, 391 Fraimow, Henry S., 1113 1793 Durkin, Michelle M., 807 Frances, Cathy A., 773 Couvreur, Patrick, 1204 Durnell, Monty, 882 Frank, U., 930 Craig, William A., 51 Duroux, Michel H., 298 Franzblau, Scott G., 1583, 1758 Crawford, Carol E., 1441 Duzgunes, Nejat, 1404 Franzus, Bettylene, 78 Crenshaw, Deborah, 1780 Dworzack, David L., 1740 Freimer, E. H., 530 Crokaert, F., 1632 Frelon, Jean-Hughes, 942 Crook, Derrick, 717 East, Simon J., 1879 French, G. L., 20 Crosa, Jorge H., 1416 Ebert, S., 37 Freney, J., 276, 873 Crossley, Kent B., 848 Echeverria, Peter, 723 Fresno, Manuel, 1412 Croteau, Daniel, 561, 1227 Edelstein, Howard, 1031 Fuchs, Peter C., 346 Cuchural, George J., Jr., 717 Edlund, Charlotta, 1869 Fujii, Akira, 566, 1080 Cuevas, Thomas A., 1327 Edmondson, Diane G., 68 Fujii, Tadashi, 104, 922 Cullmann, Wolfgang, 1090 Edwards, David J., 510 Fujimaki, Kazuo, 104, 827, 922 Cunningham, Eloise, 1788 Edwards, F., 780 Fujimoto, Teruo, 1336 Curran, James W., 684 Ehret, Josephine M., 773, 1295 Fung-Tomc, Joan, 1443 Curtis, Nigel A. C., 1879 Eisenstadt, Rosemary L., 1879 Fuse, Aisaku, 587 Cushion, Melanie T., 96, 896 Elberg, Svetlana, 327, 702 Cuzzolin, L., 1875 Eliopoulos, G. M., 434, 1341, 1528 Gadebusch, Hans, 319 Elvrum, Patricia M., 1170 Gaffey, Michael J., 1644 Daghlian, Charles P., 1627 Elwell, Lynn P., 1086 Galioto, G. B., 1461 Daikos, George L., 785 Elzinga, Lawrence W., 844 Gambertoglio, John G., 298, 1825 Dajani, Adnan S., 1375 Enthoven, D., 592 Gangadharam, Pattisapu R. J., 886, 1400, Daly, Jennifer S., 1341 Eriksson, B., 1137 1404 Daneau, D., 1557 Escajadillo, A., 1655 Garcia-Lopez, M. Teresa, 1257 Daneels, R., 1595 Espinoza, Ana Maria, 663 Gargallo, Domingo, 636 Danese, Antonio, 246, 1223 Esteve, Montserrat, 636 Garry, Franklyn B., 595 Dangor, Y., 1458 Eustice, D. C., 1218 Gates, Mark L., 1893 Darfeuille-Richaud, Arlette, 1282 Everett, E. Dale, 928 Gaudebout, Claude, 568 Daschner, F. D., 930 Evron, Ruth, 1586 Gavignet, Martine, 147 VOL . 32, 1988 AUTHOR INDEX iii

Gavini, F., 873 Harkonen, Scott, 710 Huovinen, Saara, 134, 175, 1730 Gaylord, Janet C., 1699 Harmenberg, J., 1100, 1137, 1533, 1720 Hussoh, M. O., 873 Gaynes, Robert, 1379 Harris, Jeffrey P., 865 Geddes, Glenna L., 1441 Hart, Mark E., 1354 Iaconis, Joseph P., 1365 Georgopapadakou, Nafsika H., 438 Hartstein, Alan I., 369 Iannini, Paul, 717 Gerard, M., 1557 Hastings, Robert C., 1758 Ihler, Garret M., 391 Gerbaud, Guy, 15, 626 Haug, Alfred, 308, 649 Ikeda, Fumiaki, 1243 Gibbs, Ronald S., 853 Hauser, M., 1676 Ikeda, Haruo, 282 Gibson, Gene A., 1320 Hayakawa, Tomihiro, 726 Ikeda, Yasushi, 1073 Gilbert, Brian E., 117, 890 Hayasaka, Hiroshi, 1588 Inoue, Matsuhisa, 104, 587, 827, 922, 1097, Gilbert, Peter, 1693 Hayashi, Shoryo, 1040, 1396 1421, 1848 Ginunas, Virginia J., 81 Hayashi, Toshiaki, 1427 Isayama, Yasuro, 1891 Girard, Arthur E., 1347 Hayashi, Toshikatsu, 458 Iseman, Michael D., 886, 1400 Gisby, John, 1830 Hayashi, Toshio, 912 Ishiguro, Edward E., 1247 Glupczynski, Y., 276, 1632 Hayden, Frederick G., 224, 409, 1644, Ishiguro, Junzo, 1648 Godin, Michel, 938, 942 1813 Ishii, Junko, 378 Goering, Richard V., 1164 Hecht, David, 717 Ishikawa, Hitoshi, 1891 Golden, Jeffrey A., 1490 Heeres-Weststrate, P. L., 426 Ito, Kazuyuki, 726 Goldfarb, Johanna, 1780 Heifets, Leonid, 1002, 1131 Ito, Yasuo, 156 Goldmann, D., 1528 Heim-Duthoy, K. L., 485, 1845 Izard, D., 873 Goldspiel, Barry R., 853 Helsel, Valerie L., 1082 Goldstein, Ellie J. C., 213, 1143 Hemming, Val G., 1269 Jackson, George Gee, 785 Goldstein, F. W., 9, 195 Hengstler, Bruno, 364 Jacobs, Michael, 395 Goldstein, Jayne A., 1404 Henry, Nancy, 747 Jacobs, Nicholas J., 1627 Golenbock, D. T., 37 Hensey, Dena M., 1710 Jacobs, Richard F., 1481 Golper, Thomas A., 844 Hentges, David J., 337 Jacobson, Jay A., 1820 Gonzalez, M. Eugenia, 1257 Herwaldt, Barbara L., 793, 799, 953, 957 Jacobson, Kirk D., 882 Gootz, Thomas D., 159 Heykants, J., 1595 Jacobus, Nilda V., 584, 717 Goransson, Evelyn, 1484 Hicks, R., 589 Jacoby, George A., 134, 175 Gorbach, Sherwood L., 1439 Higashi, Katsuyoshi, 726 Janicke, David M., 777 Gordin, Ariel, 1019 Higgins, J. T., Jr., 530 Jauregui, Luis, 75, 730 Goudeau, Alain, 147 Hill, Carter D., 882 Jay, Margaret A., 807 Graham, Theodore, 271 Hill, Gale, 717 Jechorek, Robert P., 1769 Graybill, John R., 1310 Hill, James M., 978 Jehl, F., 1360 Grayston, J. Thomas, 257 Hill, Lori, 1565 Jevons, S., 646 Graziani, Amy L., 1320 Hirai, Keiji, 922 Jiang, Baoming M., 986 Greenberg, Richard, 710 Hirano, Lance, 141, 231 Johnson, Carolyn R., 1640 Gresser-Burns, Mary E., 513 Hirata, Koichi, 1588 Johnson, Curtis A., 51 Griffith, Brigitte P., 678 Hirota, Masaki, 1427 Johnson, Steven R., 765 Griggs, D., 1508 Hitchcock, Michael J. M., 186 Johnston, Michael, 1196 Groisman, Eduardo, 1379 Hoban, Daryl J., 1292 Joly, Bernard H., 1282 Gross, M. L., 530 Hobden, Jeffery A., 978 Jones, Ronald N., 346, 443, 752, 1576, Guay, D. R. P., 485 Hoepelman, Andy I. M., 473 1747 Guglielmo, B. Joseph, 298, 1511, 1825 Hoffken, Gert, 92 Jonsson, Monica, 1278 Guinea, Jesus, 636 Hoffman, Howard E., 1699 Jorgensen, James H., 180, 1477 Guizie, Miriam, 1586 Hoffner, Sven E., 1208 Joshi, Bharati, 285 Guptill, Douglas R., 755 Hohl, P., 1593 Joyce, Lyle D., 1899 Gurwith, Dorothy, 802 Holden, Patricia, 450 Judson, Franklyn N., 773, 1295 Gurwith, Marc, 802 Holmstrup, Palle, 1859 Junakovic, Nikolaj, 1262 Gustavson, Linda E., 1813 Holy, Antonin, 1025, 1839 Jusko, William J., 777 Gutmann, L., 9, 195 Hook, Edward W., III, 773 Gwaltney, Jack M., Jr., 1644 Hooper, David C., 1187 Kadurugamuwa, Jagath L., 364 Hooton, Thomas M., 1640 Kaiser, Allen B., 202 Haase, David A., 1292 Hopewell, Philip C., 1057 Kaiser, Donald L., 224 Hadley, W. K., 1392 Hori, Michael, 1314 Kam, K. M., 20 Hall, Gerti S., 1331 Hori, Ritsuko, 1097, 1848 Kamidono, Sadao, 1080 Hall, Michael J., 814 Horowitz, Edward A., 1740 Kamimura, Toshiaki, 1243 Hamati, Fawwaz, 78 Hoshino, Makoto, 726 Kan, Virginia L., 1619 Hammer, Mark C., 1450, 1565 Hosotsubo, Hideo, 1103 Kane, James G., 882 Hancock, Robert E. W., 649 Hosotsubo, Kikumi, 1103 Kaneda, Yoshimasa, 966 Handsfield, H. Hunter, 773 Hostetter, Marcia K., 689 Hottendorf, G. H., 314 Kaneko, Kenji, 566 Haneishi, Tatsuo, 110 Howard, R. J., 1655 Karaffa, Camile, 1754 Hanger, D. P., 646 HPA-23 Cooperative Study Group, 1300 Karasawa, Gakuyo, 1588 Hanna, Charles B., 882 Hsiung, G. D., 678 Karchmer, Adolf W., 434 Hansen, W., 276 Huczko, Elizabeth, 1443 Karle, Isabella L., 540 Hanson, Charles W., 27 Huffman, John H., 331 Karle, Jean M., 540 Hanson, Linda H., 369 Huggins, John W., 1304 Karlsson, A., 1100 Hara, Kohei, 1427 Hughes, Carolyn E., 209 Karlsson, Inga, 1484 Hardin, Thomas C., 1310 Hughes, Walter T., 623, 1057 Kasworm, Evelyn M., 1820 Harding, Godfrey K., 1231, 1292 Hull, Richard, 768 Katagiri, Kenji, 726 Hardisson, C., 420, 1552 Humbert, Guy, 919 Katahira, Junichi, 912 Hardy, Dwight J., 27, 1710 Huovinen, Pentti, 134, 175 Katayama, Toshiaki, 110 iv AUTHOR INDEX ANTIMICROB. AGENTS CHEMOTHER.

Kato, Hideo, 190 Labedan, Bernard, 153 Marble, Dwight A., 503 Kato, Naoki, 1437 Labia, Roger, 626, 1660 Marciano-Cabral, F., 962 Katsu, Kanemasa, 693 Labro, M. T., 1124 Marini, Patricia M., 1416 Kawahapa, Yukinori, 110 Labroo, V. M., 1655 Marshall, Bonnie, 1801 Kaye, Donald, 262, 877 Laforest, H., 1094 Martel, Jean-Louis, 1282 Kayser, Fritz H., 1494 Lagrange, P. H., 1094 Martin, Juan F., 1061 Kearns, Gregory L., 148i Laguens, Ruben P., 241 Martin, Mary E., 730 Keeler, Girard H., 1347 Lake, Kathleen D., 1899 Martino-Saltzman, David, 1784 Keith, Dennis D., 1005 Lake-Bakaar, Desmond M., 1807 Martra, A., 873 Kennedy, Donald, 710 Lally, Richard T., 513 Marx, Preston A., 1887 Kennedy, James K., 1292 Lam, A. W., 20 Masecar, Barbara L., 122 Kernodle, Douglas S., 202 Lam, Y. W. Francis, 298 Masuda, Midori, 1864 Kernutt, Ian, 1705 Lambert, Thierry, 15 Masur, Henry, 324, 430 Kesavalu, L., 886, 1400, 1404 Lane, H. Clifford, 324 Mateos-Mora, Miguel, 170 Kessler, Robert E., 1443 Laska, D. A., 314 Matsui, Hidefumi, 33 Khan, Waheed N., 775 Laughon, B. E., 598 Matsumoto, Y., 1243, 1655 Kim, C. Kurtis, 96, 8% Laux, David C., 770 Matsuoka, Takafumi, 1864 Kimura, Hiromichi, 1588 Lawson, Lisa A., 1320 Matthews, R. S., 617 Kirihara, Jean, 1392 Lazardi, Keyla, 1237 Matthews, Thomas R., 1154, 1887 Kirk, K. L., 1655 LeBel, Marc, 354, 561, 1227, 1515 Matthys, E., 1595 Kirouac, Daniel, 1227 Leclerc, H., 873 Mattie, Herman, 1456 Kitayama, Rieko, 912 Lee, A. T., 1655 Matzke, G. R., 485, 1845 Kitoh, Kyosuke, 693 Leggett, James E., 51 McCabe, Robert, 1031 Kitzis, M. D., 9 Lemeland, Jean-Francois, 919 McChesney, Daniel G., 775 Klamerus, Karen J., 631 Lemon, Eloise, 1780 McClain, J. Bruce, 285 Klastersky, J., 1557 Leone, R., 1875 McCormack, William M., 773 Knapp, Cynthia, 131, 170, 1754, 1896 Leoung, Gifford, 1057 McDonald, Edith'J., 1710 Knapp, J. S., 426, 488, 765, 1430 Lerner, Stephen A., 1196, 1379 McGinnis, E., 1788 K'night, Vernon, 890 Leroy, Annie, 938 McGroarty, Estelle J., 308, 649 Knodel, Leroy C., 853 Leslie, James, 1537 McIntyre, 0. Ross, 1627 Kobasa, William D., 262 Lessard, Celine, 736, 1433 McKee, Kelly T., Jr., 1304 Kobayashi, George S., 327, 702 Lettieri, John, 75 McMurry, Laura M., 1187 Kobayashi, Shinzo, 1046, 13% Levesque, Roger C., 819 McRoberts, Mary Jane, 1887 Kdeppe, Peter, 92 Levine, Bernard E., 369 Medina, Ileana, 1057 Koga, Hironobu, 1427 Levitsky, Sidney, 63i Medoff, Gerald, 327, 702 Kohno,'Shigeru, 1427 Levy, Mordekhai, 1586 Mellencamp, Martha A., 1327 Kokkonen, Paula, 1019 Levy, Stuart B., 1187, 1797, 1801 Mendelman, Paul M., 706 Kolnig, Anne-Marie, 936 Liebowitz, Lynne D., 24 Mendelson, Jack, 1231 Komiya, Masamichi, 566 Lin, A. H., 592 Mendez, F. J., 420 Komiyama, Atsushi, 1864 Lin, Jung-Chung, 265, 1068 Mendez-Castrill6n, Paloma P., 1257 Kondo, Eiko, 110 Lindborg, Bjorn, 1807 Meunier, F., 1557 Lindner, David L., 159 Mevio, E., 1461 Kondo, Sinichi, 1421 Lindqvist, Lennart, 1869 Meyers, Joel D., 271 Konno, Kenji, 906 Ling, Julia, 20 Michel, M. F., 426 Koornhof, H. J., 24, 1458 Linke, Michael J., 96, 98% Michelsen, Phyllis, 1565 Koseki, Yuichi, 110 Lismont, M. J., 1632 Mikami, Hidetada, 587 Kosuzume, Hiroshi, 1648 Livermore, David M., 1385 Miller, Michael H., 1113 Kotaki, Hiromichi, 282 Livrelli, Valerie 0., 1282 Miller, S. D., 1458 Kotik, Alan N., 1763 Lloyd, William J., 814 Mills, John, 1057 Koubaa, Nedra, 147 Lode, Hartmut, 92 Mine, Yasuhiro, 1243 Koup, Jeffrey R., 274, 573 Lokerse, A. F., 1560 Mintzer, C. L., 391 Kovacs, Joseph A., 430 Lolans, Valentina T., 785 Mischak, Ronald P., 710 Kreindler, Thdmas G., 882 London, William T., 1269 Mitelman, Felix, 936 Kresken, M.; 1285 Love, Kathryn R., 1899 Mitsuhashi, Susumu, 104, 587, 827, 922, Krogh, Palle, 1859 Lower, Johannes, 1733 1097, 1421, 1848 Krogstad, Donald J., 793, 799, 953, 957 Loy, Anna, 1223 Mitsuyama, Junichi, 1097, 1848 Kromann-Andersen, Bjarne, 936 Lucia, Helen L., 678 Miyaji, Makoto, 726 Kronvall, G6ran, 1484 Lundblad, Leif, 1720 Miyauchi, Masayuki, i437 Kuhn, Jbhn G., 1310 Mizen, Linda, 1705 Kumada, Teppei, 912 MacGregor, Rob Roy, 1320 Mobashery, Shahriar, 1196 Kumano, 912 1046, 1547 Mochida, Ei, 1648 Katsuhiko, Machida, H., 1068, Mochizuki, Hidenori, 1648 Kumar, Ashir, 882 Maddaus, Michael A., 1769 Moellering, R. C., Jr., 434, 1341, 1528 Kume, Yothihiro, 190 Madier, S., 873 Moncla, Bernard J., 1271 Kunka, R. L., 1503 Maeda, Hiroshi, 1080 Monteil; H., 1360 Kunz, Samuel, 364 Maher, Louise A., 180, 1477 Montgomerie, John Z., 81 Kuo, Cho-chou, 257 Mahlandt, Bill G., 1304 Monto, Arnold S., 47 Kurihara, Kozo, 110 Maimorie, Francesco, 1262 Moore, pavid, 1078 Kurth, Reinhard, 1733 MalamUld, Daniel, 350 Moore, Jennifer L., 684 Kurzynski, Terrence A., 137 Malouin, F., 498 Moosdeen, F., 925 kusmiesz, Helen, 1738 Mandell, Lionel, 1231 Morand, Annick, 1660 Kusser, Wolfgang C., 1247 Mannisto, Pekka T., 1019 Moriyama, Megumi, 693 Kuvanont, Krit, 723 Mant, T. G. K., 1503 Moros, Mariano, 636 VOL. 32, 1988 AUTHOR INDEX v

Morrison, P. J., 1503 Ortisi, G., 1461 Raoult, D., 255 Morse, Stephen A., 765 Osada, Yasuaki, 1336 Rash, Jay J., 1347 Mosadomi, H. A., 598 Oster, Sharon, 1031 Rashad, Abdel L., 844 Moseley, Steve L., 477 O'Sullivan, John F., 1583 Rauramaa, Veikko, 1019 Moskovitz, Bruce L., 1300 Otero, Joaquin R., 1598 Redding, Judith S., 180, 1477 Moulin, Bruno, 938, 942 Ouellette, Marc, 397 Rehavi, M., 1624 Mounier, J., 195 Reiszner, E., 1528 Mullany, Peter, 1213 Pacheco, F., 589 Reitberg, Donald P., 42, 51, 503, 730 Mummaw, Nancy, 1323 Pagano, Joseph S., 265 Remington, Jack S., 755 Murakami, Kimihiro, 1648 Pakiz, Cathy B., 689 Rescott, Denise L., 450 Murata, Kenjiro, 1864 Panneton, Anne-Claire, 354, 1515 Reuman, Peter D., 761 Murphy, James R., 462 Panton, L. J., 1655 Reynolds, Janet, 63 Murphy, Robert F., 324 Papadopoulou, Barbara, 945, 1793 Reynolds, Peter, 1494 Murray, Barbara E., 547, 768 Pares, Juan, 636 Rice, Robert, 285 Murray, Dennis L., 882 Parham, Christine, 1788 Rice-Ficht, Allison, 391 Muto, Yoshinori, 1437 Park, Britt H., 1797 Rich, Chantal D., 1282 Myles, Camille, 1331 Parker, Steven W., 777 Richardson, James D., 807 Parrillo, Joseph E., 324, 430 Richet, H., 1094 Nadler, Marcus, 1763 Parry, Michael F., 982 Richman, Douglas D., 865 Nagata, Osamu, 156, 190 Patchett, Arthur A., 319 Richwald, Gary A., 213 Nagayama, Ariaki, 1735 Patel, I. H., 592 Rico, Manuel, 1552 Nakae, Taiji, 378, 966 Patterson, Jan Evans, 122 Riff, Louise J., 848 Nakajima, Mutsuo, 110 Patterson, Jean L., 492 Rikihisa, Yasuko, 986 Nakamura, Kiyoto, 906 Patton, Curtis L., 1182 Rinaldi, Michael G., 1310 Nakao, Tomokazu, 1735 Paul, Gerard C., 397 Ringertz, Signe, 1484 Nakata, Katsuhisa, 1080 Pauwels, Rudi, 1025, 1742 Riscoe, Michael K., 1904 Narukawa, Noriaki, 458 Pearce, Maria, 1443 Rittenhouse, Brian R., 834 Nassos, Patricia, 1392 Pechere, Jean-Claude F., 524 Rivera, Mildred, 649 Nelson, Eric, 1379 Pelletier, Lawrence L., Jr., 374 Roberts, Elizbeth, 462 Nelson, John D., 268, 1738 Peltier, G. L., 485 Roberts, Marilyn C., 488, 765, 1271, 1430 Neu, Harold C., 84, 580, 656, 663, 671, Perol, Y., 1350 Robillard, Norman J., 535 1666 Perumal, Veluchamy K., 886, 1400, 1404 Robinson, J., 1503 Neuwirth, Zeev, 1763 Pesce, Adelaide, 279 Roblot-Treupel, Liliane, 1204 Nichols, James S., 1119 Petit, Agnes, 626, 1660 Roccaforte, Jane S., 1327 Nichols, Wright W., 518 Pettigrew, Martine, 992 Rocque, Warren J., 308 Nickell, Steven P., 462 Philippon, Alain M., 397 Rodondi, Lisa C., 1511, 1825 Nicolau, Claude, 391 Phillipson, J. David, 1725 Rodvold, Keith A., 631, 848 Nicoletti, Mauro, 1262 Pierson, Carl, 717 Roerdink, F. H., 1560 Nightingale, Charles H., 128 Pifat, Dominique Y., 331 Roessner, Charles A., 391 Nilsson, Lennart E., 1208 Piras, Marta M., 1237 Rogers, Paul, 324 Nishimura, Hitoshi, 566 Piras, Romano, 1237 Rolston, Kenneth, 1078 Nishino, Takeshi, 1073, 1192 Plaisance, Karen I., 1537 Ronald Allan R., 1292 Nishiyama, Yukihiro, 1053 Podapati, N. Rao, 1400 Roon, Richard A., 274 Nix, David E., 450 Polacheck, Itzhack, 1586 Root, Carol J., 773 Nord, Carl Erik, 1869 Pompei, Raffaello, 552 Root, Jennifer L., 1627 Norman, G. T. 1503 Poplack, David G., 324 Rootman, David S., 978 Norrby, Ragnar, 936 Popovski, Zagorka, 510 Rosenberg, Carl, 1158 Norrby, S. Ragnar, 1278 Portnoy, J., 589 Rosenberg, Ivan, 1025, 1839 Norris, Steven J., 68 Prainito, Marie, 1375 Rosina, Rita, 1223 Norton, James A., 63 Pratt, Kathleen J., 1331 Rossan, R. N., 1655 Noumi, Toshihiko, 827 Preheim, Laurel C., 1327 Rotimi, V. O., 598 Novelli, Andrea, 580, 656, 663, 1666 Preston, David A., 180 Rotschafer, John C., 848 Prince, Alice, 838 Rott-Petri, Jean A., 137 Oberg, Bo, 1733 Prince, Gregory A., 1269 Rouse, Mark, 747 O'Callaghan, Richard J., 978 Prisbe, Ernest J., 1887 Roussellier, P., 255 Ochi, James W., 865 Pritzker, Marc R., 1899 Rowse, Deborah, 1801 O'Connell, Kevin, 492 Privitera, G., 1461 Roy, Paul H., 397 Ogborne, Kevin T., 186 Proctor, R. A., 37 Roy, Rejean, 1433 O'Hara, Denise, 1494 Pruess, David L., 1005 Rubinstein, E., 1624 O'Hare, J., 144 Puchetti, V., 1875 Russo, T., 717, 1439 Ohmae, Kenichi, 1891 Pussard, Eric, 568 Rutala, William A., 642 O'Horo, Jennifer, 1780 Rybak, Michael J., 510 Oikawa, Yoshihiro, 1648 Queener, Sherry F., 807 Okamoto, Ryoichi, 1421 Quentin, Roland, 147 Saag, Michael S., I O'Keefe, J. Paul, 717 Quinn, John P., 1267 Saez-Nieto, Juan A., 706 Okezaki, Eiichi, 156, 190 Quintiliani, Richard, 128 Saha, Gita, 580 Okuda, Takao, 33 Quiros, L. M., 420 Saikawa, Isamu, 827, 912, 1097, 1848 Olson, L., 589 Saino, Yushi, 587 Omnes, Anne, 1204 Rachlis, Anita, 1231 Saito, Akira, 156 Omura, Satoshi, 282 Radstrom, Peter, 1684 Saito, Atsushi, 1427 O'Neill, Melanie J., 1725 Ramer, Nancy R., 27 Saito, Hajime, 400 Opheim, Kent, 274, 1640 Rao, Podapati N. R., 886 Sakaguchi, Takashi, 1040, 1396 Vi AUTHOR INDEX ANTIMICROB. AGENTS CHEMOTHER.

Sakuma, Takashi, 1046, 1547, 1839 Simbul, Moises, 834 Syriopoulou, Vassiliki P., 1034 Salas, J. A., 420 Simmons, Richard L., 1769 Szoka, Francis C., Jr., 858 Salfinger, Max, 1002 Simon, Francois, 568 Salmeron, C. M., 1350 Sirot, Danielle L., 626, 1660 Tabaqchali, Soad, 1213 Samonis, George, 1365 Sirot, Jacques L., 626, 1660 Tachibana, Hiroshi, 966 Sanders, Christine C., 689, 1314, 1365, Six, Howard R., 890 Taen, Haruko, 1735 1740, 1893 Slack, Mary P. E., 518 Taenaka, Nobuyuki, 1103 Sanders, Cynthia, 1392 Slee, A. M., 1218 Taft, Cathy S., 1901 Sanders, W. Eugene, Jr., 1740, 1893 Sligh, James E., Jr., 702 Takahara, Yoshio, 156 Sapico, Francisco L., 81 Smego, Douglas A., 982 Takahash, Katsutoshi, 1053 Sartorelli, Alan C., 1182 Smeltzer, Brian D., 236 Takahata, Masahiro, 1192 Sassella, D., 1461, 1541 Smith, Arnold L., 477, 706, 1034 Takano, Mitsuo, 1680 Sato, Hitoshi, 190 Smith, Arnold N., 274 Takeuchi, Toshihiko, 726 Sato, Kenichi, 104, 922, 1336 Smith, Gary G., 595 Takezawa, Jun, 1103 Satta, Giuseppe, 552 Smith, J. Kelly, 78 Talarico, Todd L., 1854 Saunders, Jean, 24 Smith, James W., 63, 807 Talbot, M. Kelly, 1005 Sauzieres, Jacques, 1204 Smith, John M., 1776 Tally, Francis P., 584, 717 Saviteer, Susan M., 642 Smith, M. Carolyn, 265 Tamai, Ikumi, 190 Savolainen, Seppo, 1019 Smith, Raymond P., 1450, 1565 Tamalet, J., 255 Sawyer, Janet G., 649 Smithwick, Ronald W., 125 Tamura, Atsushi, 1421 Scannon, Patrick, 710 Snoeck, Robert, 1742, 1839 Tamura, Toyoyuki, 566 Scarpa, Alphonse L., 535 Soike, Kenneth F., 1807 Tamura, Yuka, 932 Schalla, W. O., 426 Sokol-Anderson, Marcia, 702 Tanaka, Haruo, 282 Scheifele, David W., 1034 Somani, P., 530 Tancrede, Cyrille, 1204 Schell, Ronald F., 137 Someya, Tetsufumi, 1588 Tartaglione, Teresa A., 1640 Schentag, Jerome J., 450, 503 Sommadossi, Jean-Pierre, 997 Taub, David, 319 Schiff, Gilbert M., 761 Sommer, Peter, 936 Tay, L. K., 314 Schifferli, Dieter M., 1603, 1609 Sookpranee, Mondej, 1740 Taylor, David N., 723 Schinazi, Raymond F., 997, 1784 Souza, Kathleen S., 1187 Taylor, Diane E., 1107 Schindler, M., 930 Sperber, Steven J., 409 Tenover, Fred C., 1170 Schito, Gian Carlo, 279 Spillner, G., 930 Terragna, Alberto, 1223 Schlesinger, Paul H., 793, 799, 953, 957 Spitler, Lynn E., 710 Tesch, Wolfgang, 1494 Schlosser, V., 930 Spitzer, Peter G., 434 Thal, Wendy R., 337 Schluederberg, Susan, 1801 Srinivasan, A., 684 Thauvin, Claudie, 919 Schmidt-Eisenlohr, E., 930 Stamm, John M., 27 Thomann, Charlotte A., 642 Schmitt, B., 780 Stamm, Lola V., 164 Thompson, Nathan H., 1763 Schmitt, H. J., 780, 1676 Stamm, Walter E., 1640 Thomson, Margaret J., 1292 Schols, Dominique, 1025 Standiford, Harold C., 1537 Thomberry, Nancy A., 319 Schuening, Friedrich, 271 Stankewich, Joseph P., 1347 Thornsberry, Clyde, 180, 752 Schultz, Robert W., 503 Stapleton, Jack T., 164 Tokunaga, Tohru, 110 Schurgers, M., 1595 Stark, Tracey, 1901 Tolmasky, Marcelo E., 1416 Schwartz, Jules, 75, 730 Steele, Lorraine C., 1776 Toltzis, Philip, 492 Schwartz, Stanley A., 47 Stein, Gary E., 802 Tomich, Paul K., 1465, 1472 Schwartzman, Michael S., 236 Steinberg, Marvin A., 1320 Tominack, Rebecca L., 1813 Scieux, C., 1350 Stenberg, Kjell, 1533 Tomioka, Haruaki, 400 Scott, Virginia R., 1154 Stevens, David A., 369 Torikata, Akio, 110 Sears, S. D., 144 Stieglitz, Michaela, 1090 Townsend, Raymond J., 1825 Segal, Neil B., 1231 Stoeckel, Klaus, 573 Trahan, Creighton J., 1304 Segev, S., 1624 Stolz, E., 426 Tran Ba Huy, Patrice, 467 Selitrennikoff, Claude P., 1901 Stone, J. W., 1508 Tran Van Nhieu, G., 9, 1289 Serfass, Debra A., 706 Storb, Rainer, 271 Treger, Thomas, 63 Shalaby, Lamaat M., 1699 Storrs, Michele J., 1174 Trouvin, J. H., 1590 Shands, Joseph W., 773 Strassle, Anni, 1494 Tsuchido, Tetsuaki, 1680 Sharp, Patricia A., 865 Strombeck, Bodil, 936 Tsuji, Akira, 190 Shaw, J. T. B., 646 Struck, Douglas K., 391 Tsukada, Katsuhiko, 726 Shearer, Glenmore, Jr., 341 Studemeister, Alex E., 1267 Tubert, Tracey, 180, 259 Sheehan, Gerard J., 1292 Suarez, Juan E., 1552 Tucker, Richard M., 369 Shelton, Sharon, 268, 1738 Subashi, Timothy A., 159 Tuna, Ishik C., 209 Shepherd, Julia A., 1693 Suenaga, Itaru, 458 Turley, C. Patrick, 1481 Sherwood, James R., 761 Sugarman, Barrett, 1323 Turner, Ronald B., 1820 Shigeta, Shiro, 906 Sugimoto, Kyoko, 595 Shimada, Nobuyoshi, 1053 Suh, Byungse, 1571 Shimizu, Kihachiro, 912 Sumter, Gwendolyn, 1776 Ueno, Kazue, 1437 Shinners, Elizabeth N., 971 Sun, Daxi, 1274, 1370 Une, Tsutomu, 1336 Shiraishi, Akio, 110 Sundstrom, David C., 1763 Urbina, Julio A., 1237 Shiramatsu, Koji, 1588 Suttmann, Rebecca T., 1887 Urias, Barbara, 1292 Shyu, Wen Chyi, 128 Sutton, David, 358 Usuki, Toshihiro, 1588 Siber, George R., 1034 Suzutani, Tatsuo, 1046, 1547 Sidwell, Robert W., 331 Swan, Judith C., 430 Vaal, Mark, 1119 Sieradzan, Raymond R., 1446 Swanson, Robert N., 27 Valiant, Mary E., 319 Sierra-Madero, Juan, 1754, 1896 Swarz, Herbert, 42 Vall6e, Francois, 354 Silva, Eric J., 865 Swedberg, Gote, 1684 Vandenbroucke, Arthur C., 834 Silverman, Norman A., 631 Sypherd, Paul S., 341 Van der Auwera, P., 1557 VOL. 32, 1988 AUTHOR INDEX vii van der Linden, M. P., 1632 Wentworth, Berttina B., 216 Yamada, Hidehiko, 1648 van der Waals, Ron, 1456 Wexler, Hannah M., 403, 601, 611 Yamada, Takehisa, 156 van der Willigen, A. H., 426 Whall, Thomas J., 42, 51, 503 Yamada, Takeshi, 1588 van Furth, Ralph, 1456 Wheat, Lawrence J., 63 Yamaguchi, Keizo, 1427 van Klingeren, B., 426 White, Anthony J., 1879 Yamamoto, Haruo, 1421 Van Peer, A., 1595 Whitney, Charles C., Jr., 1699 Yamamoto, Naohiko, 1053 Vavra, James J., 216 Wiedemann, B., 1285 Yamamoto, Tatsuo, 932 Verdier, Francoise, 568 Will, J. A., 37 Yamamoto, Toshiyuki, 726 Verdon, Michael S., 773 Willey, Sandra, 1341 Yamazaki, Munehiro, 1864 Verghese, Abraham, 78 Williams, Deborah E., 1158 Yamazaki, Toshiyuki, 458 Verhoef, Jan, 473 Williams, J. D., 925 Yang, Youjun, 1385 Vermerie, N., 1590 Williams, P. D., 314, 758 Yankell, Samuel L., 350 Vezina, Guy, 819 Williams, Paul L., 369 Yasuda, Takashi, 912, 1097, 1848 Villa, Pia, 1541 Williamson, R., 9, 195 Yasui, Kozo, 1864 Villar, Claudio J., 1552 Wills, Robert J., 1813 Yih, Jennifer, 141, 231 Vliegenthart, John S., 740 Wilson, Mark E., 1521 Ylikoski, Jukka, 1019 Vojtko, Charlene, 1710 Wilson, Samuel Z., 890 Yokota, Takeshi, 932 von Graevenitz, A., 1593 Wilson, Walter, 747 Yokota, Tomoyuki, 906 Vrang, Lotta, 1733 Winton, Mark D., 928 Yokota, Yoshiko, 1243 Wise, R., 617, 1251, 1508 Yoshida, Takashi, 1421 Wadstein, Jan, 936 Wiseman, Jeffrey S., 1119 Yoshihara, Eisaku, 966 Wadsworth, Sandra J., 1571 Woestenborghs, R., 1310, 1595 Yoshiya, Ikuto, 1103 Wagenvoort, J. H. T., 426 Wofsy, Constance, 1057 Yotsuji, Akira, 1097, 1848 Wagner, Jutta, 92 Wolfson, John S., 1187 Young, Elizabeth C., 761 Wahren, B., 1137, 1720 Wong, Justina, 782 Young, Lowell S., 1149 Waigh, Roger D., 1693 Wong-Kai-In, Philippe, 814 Yourassowsky, E., 276, 1632 Waites, Ken B., 1500 Wood, Mark S., 838 Youssef, Mohammad, 1204 Walker, Linda A., 1879 Woodley, Charles L., 125 Wallace, Richard J., Jr., 1776 Woodnutt, Gary, 1705 Zajac, I., 1218 Walmsley, Harold L., 518 Woods, Gail L., 1614 Zak, Oto, 364 Walton, Leslie, 1086 Woolf, Nigel K., 865 Zehavi, Uri, 1586 Walzer, Peter D., 96, 8% Woolfrey, Bert F., 513 Zeiler, H.-J., 57 Warhurst, David C., 1725 Wren, Brendan W., 1213 Zenilman, Jonathan M., 765 Washington, John A., 131, 170, 1331, 1754, Wright, Colin W., 1725 Zervos, Marcus J., 122 1896 Wu, John C., 1887 Zhang, Lei, 962 Watanabe, Kunitomo, 1437 117, 890 Watanabe, Nao-Aki, 693 Wyde, Philip R., Zhang, Zhen-Xi, 265 Watanabe, Yasuo, 912 Wyss, Ronald, 573 Zhou, Zhu, 997 Waxman, Kenneth, 882 Zighelboim-Daum, S., 1528 Weber, David A., 1164 Xicota, M. Angels, 636 Zilhao, Rita, 1793 Weber, David J., 642 Zimmerman, Stephen W., 51 Weir, Matthew, 1537 Yagi, Betty Hannon, 216 Zokufa, Humphrey Z., 848 Weissberger, Barbara, 319 Yajko, David M., 1392 Zollinger-Iten, J., 1593 Wells, Carol L., 1769 Yam, Paul, 1614 Zscheck, Karen K., 768 Wennersten, C., 1528 Yamabe, S., 925 Zurenko, Gary E., 216 SUBJECT INDEX VOLUME 32

A723U rifamycin, 1354 ceftazidime, 276 herpes simplex virus type 1, 1100 Actinomyces spp. ceftriaxone, 276 A40926 daptomycin, 788 cefuroxime, 276 pharmacokinetics, 246 paldimycin, 788 ciprofloxacin, 276 A-56268 Actinomycin D gentamicin, 276 H. ducreyi, 1458 A. lignieresii, 1354 imipenem, 276 T. gondii, 524 P. multocida, 1354 netilmicin, 276 A-56620 Acyclovir norfloxacin, 276 M. tuberculosis, 1441 combinations ofloxacin, 276 Nocardia spp., 1078 3'-azido-3'-deoxythymidine, 265 pefloxacin, 276 P. maltophilia, 782 AZT, 265 piperacillin, 276 A-61827 Epstein-Barr virus, 265 temocillin, 276 B. fragilis, 27 comparative activity ticarcillin-clavulanic acid, 276 C. jejuni, 27 I-3-D-arabinofuranosyl-E-5-(2-bromo- tobramycin, 276 E. coli, 27 vinyl)uracil and trimethoprim-sulfamethoxazole, 276 Enterobacteriaceae, 27 E-5(2-bromovinyl)-2'-deoxyuridine, Alcaligenes faecalis H. influenzae, 27 1068 diffusion pore, 378 L. pneumophila, 27 Epstein-Barr virus, 1068 Alginate N. gonorrhoeae, 27 guinea pig embryonic fibroblasts, 1533 P. aeruginosa P. aeruginosa, 27 herpes simplex virus type 1, 1100, 1533 tobramycin binding, 518 S. aureus, 27 monophosphate Allicin S. pyogenes, 27 guinea pig embryonic fibroblasts, 1533 mechanism of action, 1763 S. typhimurium, 27 herpes simplex virus type 1, 1533 S. typhimurium, 1763 Staphylococcus spp., 27 triphosphate Alpha-2b interferon Streptococcus spp., 27 DNA polymerases, 1137 influenza A virus, 47 A-62254 varicella-zoster virus, 1137 influenza B virus, 47 Nocardia spp., 1078 (RS)-3-Adenin-9-yl-2-hydroxypropanoic rhinovirus, 47 A-62671 acid AM-833 comparative activity, 1710 influenza viruses, 906 C. trachomatis, 1080, 1735 A-63075 Adenovirus comparative activity comparative activity sulfated polysaccharides, 1742 doxycycline and minocycline, 1735 erythromycin, 1500 type 5 Amdinocillin M. hominis, 1500 P-536, 1257 A. denitrificans subsp. xylosoxidans, 276 M. pneumoniae, 1500 Adhesion, bacterial combinations U. urealyticum, 1500 antibiotic modulation, 1603, 1609 ceftazidime, 1632 Acetyltransferase folate pathway, 1609 E. cloacae, 1632 chloramphenicol membrane structures, 1609 E. cloacae, 1632 C. difficile, 1213 nucleic acid synthesis, 1609 Amdinocillin pivoxil 3-V-acetyltransferase peptidoglycan synthesis, 1609 pharmacokinetics gene probe, 1834 protein synthesis, 1603 influence of food, 592 6'-N-Acetyltransferase type 4 minireviews, 1603, 1609 Amicarbalide Enterobacteriaceae, 1289 Aerobic bacteria P. carinii, 896 S. marcescens, 1289 pristinamycin, 1094 Amifloxacin Acinetobacter spp. Aerobic-anaerobic infections comparative activity 3'-aminoglycoside phosphotransferase, minireview, 611 ciprofloxacin, enoxacin, norfloxacin, 15 Aeromonas hydrophila and ofloxacin, 928 E1040, 693 CS-807, 1082 Nocardia spp., 1078 PD 117,596, 1450 tigemonam, 84 P. falciparum, 1182 R plasmid, 15 U-76,252, 1082 P. pseudomallei, 928 tigemonam, 84 Aeromonas spp. Amikacin U-76,253A, 443 ,B-lactam resistance, 1314 A. denitrificans subsp. xylosoxidans, 276 Acquired immunodeficiency syndrome 13-lactamases, 1314 B. catarrhalis, 259 HPA-23, 1300 Agar dilution plate count method combinations M. avium complex, 1392 effect of temperature on inoculum, 513 ceftazidime, 231 P. carinii, 1057 errors, 513 ciprofloxacin, 782 Acriflavin (RS)-AHPA clindamycin, 1557 S. aureus resistance, 932 influenza viruses, 906 clofazimine, 1400 Acrinol Alanine racemase endocarditis, 231 S. aureus resistance, 932 halovinylglycine compounds, 319 head and neck surgery in cancer pa- Acrolein L-norvalyl peptide derivatives, 319 tients, 1557 amoebic meningoencephalitis, 962 Alcaligenes denitrificans subsp. xylosoxi- M. avium complex, 1149, 1400 N. fowleri, 962 dans P. aeruginosa, 231 Actinobacillus actinomycetemcomitans amdinocillin, 276 P. maltophilia, 782 clindamycin, 1521 amikacin, 276 resistance, development of, 231 neutrophil killing, 1521 amoxicillin-clavulanic acid, 276 rifabutin, 1400 Actinobacillus lignieresii ampicillin, 276 tumor necrosis factor, 1149 actinomycin D, 1354 cefamandole, 276 wound infections, 1557 daptomycin, 1354 cefazolin, 276 dysgonic fermenter 2, 78 novobiocin, 1354 ceforanide, 276 E. coli phospholipid composition, 1354 cefotaxime, 276 lipopolysaccharide, 1247 polymyxin, 1354 cefotetan, 276 Enterobacteriaceae, 873 viii VOL. 32, 1988 SUBJECT INDEX ix

resistance, 1289 comparative activity bacteremia, 710 K. pneumoniae resistance, 1379, 1416 miconazole, 1864 immunogenicity, 710 liposome encapsulated high-performance liquid chromatogra- pharmacokinetics, 710 M. avium-M. intracellulare, 1404 phy, 1103 toxicity, 710 M. avium, 1131 polymorphonuclear leukocytes, 1864 Antifungal agents M. avium complex, 886, 1149, 1400 pulmonary aspergillosis, 1676 jasplakinolide, 1154 M. avium-M. intracellulare, 1404 S. schenckii, 1619 minireview, I N. asteroides, 1776 sporotrichosis, 1619 T. vaginalis, 144 P. maltophilia, 782 T. vaginalis, 1323 Antimalarial drugs pharmacokinetics, 236 Ampicillin polymorphonuclear neutrophils, 1124 S. aureus resistance, 932 A. denitrificans subsp. xylosoxidans, 276 Apalcillin S. marcescens resistance, 1289, 1379 B. bronchiseptica, 1891 nephrotoxicity, 942 Shigella spp., 20 B. catarrhalis, 259 pharmacokinetics, 942 Amikacin-ceftazidime bite wound bacteria, 1143 9-p-D-Arabinofuranosyladenine comparative activity Chlamydia sp. strain TWAR, 257 herpes simplex virus type 1, 1046 pefloxacin, 23i combinations 1-,-D-Arabinofuranosyl-E-5-(2-bromovinyl) endocarditis, 231 B. fragilis-E. coli, 1830 uracil P. aeruginosa, 231 biliary tract infections, 1231 comparative activity resistance, development of, 231 sulbactam, 1830 acyclovir and E-5-(2-bromovinyl)-2'- Amiloride tobramycin, 1231 deoxyuridine, 1068 combinations dental granuloma, 566 Epstein-Barr virus, 1068 Pseudomonas spp., 395 E. coli, 450, 552 herpes simplex virus type 1, 1547 tobramycin, 395 Enterobacteriaceae, 873 herpes simplex virus type 2, 1547 Pseudomonas spp., 395 fecal flora resistance, 1801 nucleosides, effect of, 1547 y-Aminobutyric acid binding H. influenzae, 180 1-4-D-Arabinofuranosyl-E-(2-bromovinyl) BMY-262252 758 in vitro simulation of serious infections, uracil cefazolin, 758 552 herpes simplex virus type 1, 1046 imipenem-cilastatin, 758 L. monocytogenes, 1204, 1560 1-P-D-Arabinofuranosylthymine inhibition of liposome entrapped herpes simplex virus type 1, 1046 quiholones, 190 L. monocytogenes, 1560 Argentine hemorrhagic fever rat model, 758, lipid composition, 1560 ribavirin, 1304 Aminoglycoside 3-V-acetyltransferase M. morganii, 1385 Arthrobacter spp, gene probe, 1834 N. asteroides, 1776 carbomycin, 420 3'-Aminoglycoside phosphotransferase nanoparticle polyisohexylcyanoacrylate celesticetin, 420 Acinetobacter spp., 15 bound clindamycin, 420 Aminoglycoside-modifying enzymes L. monocytogenes, 1204 erythromycin, 420 reaction rates, 740 P. aeruginosa, 552 josamycin, 420 Aminoglycosides P. carinii, 896 lincomycin, 420 cochlear binding sites, 467 P. multocida, 213 lincosamide resistance, 420 P. aeruginosa resistance, 689 P. vulgaris, 1385 oleandomycin, 420 S. faecalis resistance, 1528 postantibiotic effect, 450 rosaramicin, 420 T. vaginalis, 144 S. paratyphi A, resistant, 195 spiramycin, 420 Amodiaquine S. pneumoniae, 552 tylosin, 420 polymorphonuclear neutrophils, 1124 Shigella spp., 20 vernamycin B, 420 Ainoebic meningoencephalitis Ampicillin-gulbactam Aspergillus spp. acrolein, 962 B. catarrhalis, 259 amphotericin B, 1676 cyclophosphamide, 962 B. fragilis-E. coli, 1830 terbinafine, 780 Amopyroquin comparative activity Astiban comparative activity amoxicillin-clavulanic acid, 1830 P. carinii, 896 chloroquine and monodesethylamodia- Shigella spp., 20 ATP quine, 568 Ampicillin-tobramycin M. tuberculosis bioluminescence assay, P. falciparum, 568 biliary tract infections, 1231 1208 pharmacokinetics, 568 comparative activity Avermectins Amooxicillin cefoperazone, 1231 glucose metabolism, 282 Bordetella spp., 137 Anesthetics 3'-Azido-3'-deoxythymidine H. ducreyi, 1458 E. coli permeability, 153 combinations P. pseudomallei, 1435 Anisomycin acyclovir, 265 Amoxicillin-clavulanic acid T. vaginalis, 144 Epstein-Barr virus, 265 A. denitrificans subsp. xylosoxidans, 276 Anogeissus leiocurpus human immunodeficiency virus type 1, B. catarrhalis, 259 B. gingivalis, 598 1784 B. fragilis-E. coli, 1830 B. melaninogenicus, 598 isoprinosine, 1784 bite wound bacteria, 1143 Antacids cytomegalovirus, 265 comparative activity ciprofloxacin, 949 Epstein-Barr virus, 265 ampicillin-sulbactam, 1830 letter to the editor, 949 herpes simplex virus type 1, 265 Enterobacteriaceae, 873 Antibiotic biosynthetic genes herpes simplex virus type 2, 265 H. ducreyi, 1458 minireview, 1472 human immunodeficiency virus type 1, P. multocida, 213 Streptomyces spp., 1472 1784 P. pseudomallei, 1435 Antibodies toxicity Amphotericin B monoclonal uridine, 997 Aspergillus spp'., 1676 C. trachomatis, 1295 varicella-zoster virus, 265 C. albicans minireview, 1295 3'-Azido-3'-deoxythymidine triphosphate 2-chloroethyl-1-nitrosoureas, 327 P. aeruginosa, 649 human immunodeficiency virus type 1, resistance, 702 monoclonal anti-lipid A 1733 x SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

human immunodeficiency virus type 2, ciprofloxacin, 642 chewing sticks, 598 1733 clindamycin, 642 D. benthamianus, 598 simian immunodeficiency virus, 1733 daptomycin, 642 F. zanthoxyloides, 598 Azithromycin erythromycin, 642 M. accuminata, 598 B. catarrhalis, 752 gentamicin, 642 N. latifolia, 598 combinations imipenem, 642 Nigerian chewing sticks, 598 M. avium complex, 1149 mezlocillin, 642 S. werneckei, 598 tumor necrosis factor, 1149 oxacillin, 642 T. glaucescens, 598 comparative activity, 1710 penicillin, 642 V. amygdalina, 598 clarithromycin, clindamycin, erythro- tetracycline, 642 Bacteroides melaninogenicus mycin, and roxithromycin, 752 ticarcillin-clavulanate, 642 A. leiocarpus, 598 H. influenzae, 752 trimethoprim-sulfamethoxazole, 642 B. paradoxum, 598 L. monocytogenes, 752 vancomycin, 642 chewing sticks, 598 L. pneumophila, 752 Bacillus stearothermophilus D. benthamianus, 598 M. avium complex, 1149 etoposide, 1456 F. zanthoxyloides, 598 N. gonorrhoeae, 752 Bacillus subtilis M. accuminata, 598 N. meningitidis, 752 etoposide, 1456 N. latifolia, 598 T. gondii, 524, 755 letter to the editor, 949 Nigerian chewing sticks, 598 Azlocillin streptomycin adenylyltransferase, 949 S. werneckei, 598 B. catarrhalis, 259 Bacteremia T. glaucescens, 598 Azoles monoclonal anti-lipid A antibody, 710 V. amygdalina, 598 minireview, 1 Bacterial adhesion Bacteroides spp. AZT antibiotic modulation, 1603, 1609 E-1040, 1666 combinations folate pathway, 1609 R-3746, 671 acyclovir, 265 membrane structures, 1609 tigemonam, 84 Epstein-Barr virus, 265 nucleic acid synthesis, 1609 trospectomycin, 216, 584 human immunodeficiency virus type 1, peptidoglycan synthesis, 1609 Benzalkonium chloride 1784 protein synthesis, 1603 S. aureus resistance, 932 isoprinosine, 1784 minireviews, 1603, 1609 Berberine sulfate cytomegalovirus, 265 Bactericidal testing E. coli Pap fimbrial adhesion, 1274 Epstein-Barr virus, 265 oxacillin, 1614 S. pyogenes herpes simplex virus type 1, 265 S. aureus, 1614 fibronectin, 1370 herpes simplex virus type 2, 265 Bacteroides fragilis hexadecane, 1370 human immunodeficiency virus type 1, A-61827, 27 host cell adherence, 1370 1784 P-lactam resistance, 1437 P-Lactamases toxicity P-lactamase, 1848 Aeromonas spp., 1314 uridine, 997 cefamandole, 1097, 1848 B. fragilis, 1848 triphosphate cefazolin, 1097, 1848 13C nuclear magnetic resonance spec- human immunodeficiency virus type 1, cefoperazone, 1097, 1848 troscopy, 1196 1733 cefoperazone-sulbactam, 403 CTX-1, 9 human immunodeficiency virus type 2, cefotetan, 601 DNA probes, 175 1733 cefoxitin, 1511 E-1040, 1666 simian immunodeficiency virus, 1733 ceftezole, 1097, 1848 E. coli, 1243 varicella-zoster virus, 265 ceftizoxime, 1511 Enterobacteriaceae, 1365 Aztreonam cephalosporins H. influenzae, 180 B. catarrhalis, 259 outer membrane permeation, 1097 isoelectric focusing, 397, 1730 combinations resistance, 1848 K. pneumoniae, 626, 1660 ciprofloxacin, 782 cephalothin, 1097, 1848 letter to the editor, 158 P. maltophilia, 782 ciprofloxacin, 1437 M. morganii, 1385 dysgonic fermenter 2, 78 clindamycin, 1825 ME1207, 1421 E. coli, 552 DR-3355, 1336 N. asteroides, 1776 hyperbilirubinemia DuP 105, 580 N. gonorrhoeae, 158, 1430 centrifugal ultrafiltration, 1571 DuP 721, 580 oligonucleotide probes, 397 in vitro simulation of serious infections,. enoxacin, 1437 oxacillin susceptibility, 1754 552 fluoroquinolone resistance, 1437 oxyimino-cephalosporins, 1243 P. aeruginosa, 552 lomefloxacin, 617 P. aeruginosa, 1443 P. maltophilia, 782 mixed infection with E. coli heterogeneity, 1893 S. pneumoniae, 552 amoxicillin-clavulanic acid, 1830 P. cepacia, 838 ampicillin-sulbactam, 1830 P. maltophilia B-220 norfloxacin, 1437, 1869 cloning of operon in E. coli, 819 1720 NY-198, 1437 P. vulgaris, 1073, 1385 cytomegalovirus, ofloxacin, 1437 PADAC assay, 1040 herpes simplex virus type 1, 1720 PD 127,391, 1251 Pasteurella spp., 1282 mechanism of action, 1720 penicillin-binding proteins, 1848 PhastSystem, 1730 varicella-zoster virus, 1720 susceptibility patterns plasmid mediated, 175 Babesia microti analysis by site of isolation, 717 PSE-2 sequence, 134 inositol hexaphosphate, 391 T-3262, 663, 1437 pyridinium-2-azo-p-dimethylaniline chro- Bacillus spp. tetracycline mophore assay, 1040 cefazolin, 642 resistance, 1271 S. aureus, 1614, 1754 cefotaxime, 642 trospectomycin, 584 transposon, 1164 cefoxitin, 642 Bacteroides gingivalis S.faecalis, 122, 547 cefuroxime, 642 A. leiocarpus, 598 hybridization studies, 768 chloramphenicol, 642 B. paradoxum, 598 restriction mapping, 768 VOL. 32, 1988 SUBJECT INDEX xi

staphylococci, coagulase negative, 1754 tetracycline, 1891 herpes simplex virus type 1, 358 YTR 830, 925 Bordetella spp. herpes simplex virus type 2, 358 P-Lactams amoxicillin, 137 2-Bromo-2-nitropropane-1,3-diol Aeromonas resistance, 1314 ciprofloxacin, 137 E. coli, 1693 -y-aminobutyric acid binding, 758 enoxacin, 137 mechanism of action, 1693 B. fragilis, 1437 erythromycin, 137 2-Bromo-L-histidine K. pneumoniae resistance, 1660 norfloxacin, 137 P. falciparum, 1655 M. morganii, 1385 ofloxacin, 137 E-5-(2-Bromovinyl)-2'-deoxyuridine P. cepacia resistance, 1636 rifampin, 137 comparative activity P. vulgaris, 1385 roxithromycin, 137 acyclovir and l-P-D-arabinofuranosyl- paradoxical effect, 1073 sulfamethoxazole-trimethoprim, 137 E-5-(2-bromovinyl)uracil, 1068 pentylenetetrazole convulsive threshold, tetracycline, 137 Epstein-Barr virus, 1068 758 Branhamella catarrhalis Bromovinyl nucleoside analogs T. vaginalis, 144 amikacin, 259 comparative activity Bifidobacterium spp. amoxicillin-clavulanic acid, 259 acyclovir, 1068 daptomycin, 788 ampicillin, 259 Epstein-Barr virus, 1068 paldimycin, 788 ampicillin-sulbactam, 259 Bromovinyldeoxyuridine Biliary drainage azithromycin, 752 guinea pig embryonic fibroblasts, 1533 cefotiam, 726 azlocillin, 259 herpes simplex virus type 1, 1533 sulbenicillin, 726 aztreonam, 259 Bronopol ursodeoxycholate, 726 carbenicillin, 259 E. coli, 1693 Biliary tract infections cefaclor, 259 mechanism of action, 1693 ampicillin-tobramycin, 1231 cefamandole, 259 Brucea javanica cefoperazone, 1231 cefixime, 259, 1896 B. javanica, 1725 ceftazidime, 1588 cefonicid, 259 E. histolytica, 1725 tobramycin-ampicillin, 1231 cefoperazone, 259 quassinoids, 1725 Bioassay cefotaxime, 259 Buciclovir sulbactam, 1347 cefoxitin, 259 DNA polymerases, 1137 Biofilms cefpodoxime, 1896 guinea pig embryonic fibroblasts, 1533 E. coli, 770 ceftazidime, 259 herpes simplex virus type 1, 1533 radiochemical method, 770 ceftibuten, 1576 monophosphate Bioluminescence assay ceftizoxime, 259 guinea pig embryonic fibroblasts, 1533 M. tuberculosis ATP, 1208 ceftriaxone, 259, 1896 herpes simplex virus type 1, 1533 Biosynthetic genes cefuroxime, 259 varicella-zoster virus, 1137 minireview, 1472 cephalexin, 259 4-(tert-Butyl)2-(tert-butylaminomethyl)-6- Streptomyces spp., 1472 cephalothin, 259 (4-chlorophenyl)phenol dihydrogen Bite wound bacteria chloramphenicol, 259 phosphate amoxicillin-clavulanic acid, 1143 ciprofloxacin, 259 crystal and molecular structure, 540 ampicillin, 1143 CS-807, 1082 BW A855U cefadroxil, 1143 erythromycin, 259 cleavable-complex assay, 1086 cefuroxime, 1143 erythromycin estolate, 1227 Bytyrospermum paradoxum cephalexin, 1143 erythromycin ethylsuccinate, 1227 B. 598 ciprofloxacin, 1143 erythromycin-sulfisoxazole, 259 gingivalis, enoxacin, 1143 gentamicin, 259 B. melaninogenicus, 598 ofloxacin, 1143 imipenem, 259 penicillin G, 1143 LY163892, 268 C31G tetracycline, 1143 mezlocillin, 259 C. albicans, 350 BMY-26225 minireview, 1747 comparative activities y-aminobutyric acid binding, 758 moxalactam, 259 chlorhexidine, Fluorigard, Listerine, pentylenetetrazole convulsive threshold, netilmicin, 259 and Viadent, 350 758 PD 117,596, 1450 S. sobrinus, 350 Bordetella bronchiseptica pefloxacin, 259 Streptococcus spp., 350 ampicillin, 1891 penicillin, 259 13C nuclear magnetic resonance spectros- antigenic modulation, 1891 piperacillin, 259 copy carbenicillin, 1891 rifampin, 259 P-lactamases, 1196 cephalothin, 1891 sulfisoxazole, 259 Calcium fosfomycin chloramphenicol, 1891 susceptibility testing, 1747 pharmacokinetics, 938 chlortetracycline, 1891 T-3262, 663 young and elderly adults, 938 colistin, 1891 tetracycline, 259 Campylobacter coli doxycycline, 1891 ticarcillin, 259 kanamycin resistance, 1170 erythromycin, 1891 ticarcillin-clavulanic acid, 259 R plasmid, 1170 gentamicin, 1891 tigemonam, 84 kanamycin, 1891 tobramycin, 259 Campylobacterjejuni nalidixic acid, 1891 trimethoprim-sulfamethoxazole, 259 A-61827, 27 neomycin, 1891 trospectomycin, 216 kanamycin resistance, 1170 novobiocin, 1891 U-76,252, 1082 PD 117,596, 1450 oxolinic acid, 1891 U-76,253A, 443 R plasmid, 1170 oxytetracycline, 1891 Branhamella spp. Campylobacter spp. phase variation, 1891 lomefloxacin, 656 DNA annealing, 945 polymyxin B, 1891 R-3746, 671 kanamycin resistance, 945 rifampin, 1891 BRL 39123 minireview, 1107 sulfadimethoxine, 1891 comparative activity resistance mechanisms, 1107 sulfamonomethoxine, 1891 acyclovir, 358 tetracycline resistance gene, 1793 xii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Cancer patients pharmacokinetics, 354 N. gonorrhoeae, 426 clindamycin-amikacin, 1557 urinary tract infections, 473 Cefonicid head and neck surgery, 1557 Catechol-cephalosporins B. catarrhalis, 259 ticarcillin-clavulanic acid, 1557 mechanisms of action, 1879 high-performance liquid chromatogra- wound infections, 1557 Catheters phy, 485 Candida albicans disodium EDTA, 1627 M. tuberculosis, 1441 amphotericin B, 327 S. epidermidis, 1627 pharmacokinetics, 485 resistance, 702 vancomycin, 1627 protein binding, 128 C31G, 350 Cefaclor skin infections, 485 2-chloroethyl-1-nitrosoureas, 327 B. catarrhalis, 259 skin structure infections, 485 cilofungin, 1331, 1901 H. influenzae, 180 Cefoperazone denture stomatitis, 1859 P. multocida, 213 B. catarrhalis, 259 ergosterol, 702 Cefadroxil B. fragilis, 403, 1848 fluconazole, 209, 1859 bite wound bacteria, 1143 outer membrane permeation, 1097 (1-3)-3-D-glucan synthase P. maltocida, 213 biliary tract infections, 1231 cilofungin, 1901 Cefamandole combinations jasplakinolide, 1154 A. denitrificans subsp. xylosoxidans, 276 B. fragilis, 403 ketoconazole, 209 B. catarrhalis, 259 ceftazidime, 298 stomatitis, denture, 1859 B. fragilis, 1848 ciprofloxacin, 782 Candida parapsilosis outer membrane permeation, 1097 intra-abdominal infections, 730 cilofungin, 1331 comparative activity P. aeruginosa, 298 Candida spp. cefazolin, daptomycin, and vancomy- P. maltophilia, 782 jasplakinolide, 1154 cin, 63 pharmacokinetics, 730 Candida tropicalis dysgonic fermenter 2, 78 sulbactam, 403, 730 cilofungin, 1331 endocarditis, 63 comparative activity Capnocytophaga ochracea H. influenzae, 180 ampicillin-tobramycin, 1231 clindamycin, 1521 S. epidermidis, 63 dysgonic fermenter 2, 78 neutrophil killing, 1521 Shigella spp., 20 high-pressure liquid chromatography, Capreomycin Cefazolin 298 M. avium, 1131 A. denitrificans subsp. xylosoxidans, 276 hyperbilirubinemia Carbapenems y-aminobutyric acid binding, 758 centrifugal ultrafiltration, 1571 [14C]dimethyl sulfate labeling, 186 B. fragilis, 1848 nephrotoxicity, 314 high-performance liquid chromatogra- outer membrane permeation, 1097 P. maltophilia, 782 phy, 186 Bacillus spp., 642 P. vulgaris, 1073 Carbenicillin comparative activity pharmacokinetics, 42 B. bronchiseptica, 1891 cefamandole, daptomycin, and vanco- protein binding, 298 B. catarrhalis, 259 mycin, 63 Shigella spp., 20 hyperbilirubinemia difloxacin and enoxacin, 262 Cefoperazone-sulbactam centrifugal ultrafiltration, 1571 dysgonic fermenter 2, 78 B. fragilis, 403 M. morganii, 1385 endocarditis, 63, 262 comparative activity N. asteroides, 1776 nephrotoxicity, 314 cefoperazone, cefoxitin, chloramphen- P. maltophilia, 782 pentylenetetrazole convulsive threshold, icol, clindamycin, imipenem, me- P. vulgaris, 1385 758 tronidazole, and penicillin G, 403 Carbocyclin 3-deazaadenosine pharmacokinetics, 33 pharmacokinetics, 42, 503 influenza viruses, 906 S. aureus, 262 continuous ambulatory peritoneal dial- Carbodine S. epidermidis, 63 ysis, 51 influenza viruses, 906 Cefbuperazone renal failure, 503 Carbomycin P. vulgaris, 1073 Ceforanide Arthrobacter spp., 420 Cefepime A. denitrificans subsp. xylosoxidans, 276 Staphylococcus spp., 420 Nocardia spp., 1078 M. tuberculosis, 1441 Cardiac surgery P. aeruginosa resistance, 1443 Cefotaxime Staphylococcus infection, 202 Cefetamet A. denitrificans subsp. xylosoxidans, 276 Cardiopulmonary bypass pharmacokinetics, 573 B. catarrhalis, 259 netilmicin, 631 Cefetamet pivoxil Bacillus spp., 642 vancomycin, 631 pharmacokinetics, 573 combinations Caromonam Cefixime chloramphenicol, 1375 comparative activity B. catarrhalis, 259, 18% E. coli, 1375 ceftazidime, 1031 comparative activity gram-negative bacteria, 1375 urinary tract infections, 1031 cefpodoxime and ceftriaxone, 18% S. aureus, 1375 Carrageenans Enterobacteriaceae, 18% streptococci, group B, 1375 cytomegalovirus, 1742 Enterococcus spp., 18% comparative activity herpes simplex virus, 1742 H. influenzae, 18% cefodizime, 426 human immunodeficiency virus, 1742 N. meningitidis, 18% dysgonic fermenter 2, 78 vesicular stomatitis virus, 1742 P. aeruginosa, 18% Enterobacteriaceae, 873 Carumonam Staphylococcus spp., 18% gonorrhea, 426 comparative activity Cefmenoxime H. ducreyi, 1458 gentamicin, 473 P. vulgaris, 1073 M. morganii, 1385 Enterobacteriaceae, 1593 Cefmetazole M. tubetculosis, 1441 high-pressure liquid chromatography, P. vulgaris, 1073 N. asteroides, 1776 354 Cefodizime N. gonorrhoeae, 426 L. pneumophila, 1593 comparative activity P. aerugindsa resistance, 1443 P. aeruginosa, 1593 cefotaxime, 426 P. pseudomallei, 1435 P. pseudomallei, 1435 gonorrhea, 426 P. vulgaris, 1073, 1385 VOL. 32, 1988 SUBJECT INDEX xiii

pharmacokinetics combinations streptococci, group B, 1375 protein binding, 128 amdinocillin, 1632 comparative activity Shigella spp., 20 amikacin, 231 cefixime and cefpodoxime, 1896 Cefotetan cefoperazone, 298 E. coli, 552 A. denitrificans subsp. xylosoxidans, 276 ciprofloxacin, 782 Enterobacteriaceae, 1896 B. fragilis, 601 E. cloacae, 1632 Enterococcus spp., 1896 C. difficile, 601 endocarditis, 231 H. ducreyi, 1458 comparative activity P. aeruginosa, 231, 298 H. influenzae, 1896 cefoxitin, ceftizoxime, chlorampheni- P. maltophilia, 782 home parenteral therapy, 1439 col, clindamycin, and metronida- resistance, development of, 231 hyperbilirubinemia zole, 601 comparative activity centrifugal ultrafiltration, 1571 prothrombin, 1446 carumonam, 1031 in vitro simulation of serious infections, vitamin K metabolism, 1446 concentrations in bile and gallbladder 552 Cefotiam wall, 1588 lidocaine reconstitution, 1439 biliary excretion dysgonic fermenter 2, 78 M. morganii, 1385 ursodeoxycholate, 726 E. cloacae, 1632 N. asteroides, 1776 P. vulgaris, 1073 resistance, 1632 N. meningitidis, 1896 percutaneous transhepatic biliary drain- high-performance liquid chromatogra- P. aeruginosa, 552, 1896 age, 726 phy, 1845 P. pseudomallei, 1435 Cefoxitin high-pressure liquid chromatography, P. vulgaris, 1073, 1385 B. catarrhalis, 259 298 S. pneumoniae, 552 B. fragilis, 1511 nephrotoxicity, 314 Shigella spp., 20 Bacillus spp., 642 P. aeruginosa resistance, 1443 Staphylococcus spp., 1896 comparative activity P. maltophilia, 782 Cefuroxime ceftizoxime, 1511 P. pseudomallei, 1435 A. denitrificans subsp. xylosoxidans, 276 E. coli, 1511 P. vulgaris, 1073 B. catarrhalis, 259 Enterobacteriaceae, 873 pharmacokinetics, 1845 Bacillus spp., 642 H. ducreyi, 1458 protein binding, 298 bite wound bacteria, 1143 M. morganii, 1385 Shigella spp., 20 hyperbilirubinemia P. vulgaris, 1385 urinary tract infections, 1031 centrifugal ultrafiltration, 1571 prothrombin, 1446 Ceftazidime-amikacin P. multocida, 213 serum bactericidal activity, 1511 comparative activity P. vulgaris, 1073 vitamin K metabolism, 1446 pefloxacin, 231 Shigella spp., 20 Cefpiramide endocarditis, 231 Cefuzonam hepatic excretion, 1360 P. aeruginosa, 231 P. vulgaris, 1073 high-performance liquid chromatogra- resistance, development of, 231 Celesticetin phy, 1360 Ceftazidime-vancomycin Arthrobacter spp., 420 pharmacokinetics, 33, 1360 pharmacokinetics, 92 Staphylococcus spp., 420 Cefpirome Ceftetrame Cell cultures comparative activity H. ducreyi, 1458 human immunodeficiency virus type 1, cefoperazone, cefotaxime, Ceftezole 684 ceftazidime, and moxalactam, B. fragilis, 1848 Cephalexin 1396 outer membrane permeation, 1097 B. catarrhalis, 259 croton oil-induced rat granuloma pouch, Ceftibuten bite wound bacteria, 1143 1396 B. catarrhalis, 1576 H. influenzae, 180 E. coli, 1396 comparative activity P. multocida, 213 high-performance liquid chromatogra- amoxicillin, amoxicillin-clavulanic Cephalexin hydrochloride phy, 1481 acid, cefaclor, cefixime, and cef- comparative activity M. tuberculosis, 1441 uroxime, 1576 cephalexin monohydrate, 882 Nocardia spp., 1078 Enterobacteriaceae, 1576 gram-negative bacteria, 882 P. aeruginosa, 1396 H. influenzae, 1576 S. aureus, 882 pharmacokinetics, 1396 Neisseria spp., 1576 S. pyogenes, 882 S. aureus, 1396 Streptococcus spp., 1576 skin infections, 882 Cefpodoxime susceptibility testing, 1576 soft tissue infections, 882 B. catarrhalis, 1896 Ceftizoxime Staphylococcus spp., 882 comparative activity B. catarrhalis, 259 Cephalexin monohydrate cefixime and ceftriaxone, 1896 B. fragilis, 1511 comparative activity Enterobacteriaceae, 1896 comparative activity cephalexin hydrochloride, 882 Enterococcus spp., 1896 cefoxitin, 1511 gram-negative bacteria, 882 H. influenzae, 1896 E. coli, 1511 S. aureus, 882 N. meningitidis, 1896 M. tuberculosis, 1441 P. aeruginosa, 1891 P. vulgaris, 1073 S. pyogenes, 882 Staphylococcus spp., 1896 pharmacokinetics skin infections, 882 Cefsulodin protein binding, 128 soft tissue infections, 882 combinations serum bactericidal activity, 1511 Siaphylococcus spp., 882 ciprofloxacin, 782 Ceftriaxone Cephaloglycin P. maltophilia, 782 A. denitrificans subsp. xylosoxidans, 276 nephrotoxicity, 314 P. maltophilia, 782 B. catarrhalis, 259, 1896 Cephaloridine Ceftazidime combinations K. pneumoniae, 364 A. denitrificans subsp. xylosoxidans, 276 chloramphenicol, 1375 M. morganii, 1385 B. catarrhalis, 259 E. coli, 1375 nephrotoxicity, 314 biliary tract infections, 1588 gram-negative bacteria, 1375 piperacillin protective effect, 912 cholelithiasis, 1588 S. aureus, 1375 P. vulgaris, 1073, 1385 xiv SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Cephalosporins Chlamydiazyme S. cerevisiae, 1331 B. fragilis, 1848 evaluation, 1350 T. glabrata, 1331 outer membrane permeation, 1097 Chloramphenicol Cinchonidine catechol substituted acetyltransferase P. falciparum, 250 mechanism of action, 1879 C. difficile, 1213 Cinchonine K. pneumoniae resistance, 1660 H. influenzae, 180 P. falciparum, 250 oxyimino B. bronchiseptica, 1891 Cinoxacin 3-lactamase, 1243 B. catarrhalis, 259 S. aureus, 1192 E. coli, 1243 Bacillus spp., 642 Ciprofloxacin S. aureus, 170 C. trachomatis, 1350 A. denitrificans subsp. xylosoxidans, 276 Cephalothin combinations antacids, 949 B. bronchiseptica, 1891 cefotaxime, 1375 B. catarrhalis, 259 B. catarrhalis, 259 ceftriaxone, 1375 B. fragilis, 1437 B. fragilis, 1848 E. coli, 1375 Bacillus spp., 642 outer membrane permeation, 1097 gram-negative bacteria, 1375 biliary excretion and metabolism, 982 Enterobacteriaceae, 873 S. aureus, 1375 bite wound bacteria, 1143 H. influenzae, 180 streptococci, group B, 1375 Bordetella spp., 137 nephrotoxicity, 314 comparative activity C. trachomatis, 1080, 1350, 1735 P. vulgaris, 1073 ciprofloxacin and gentamicin, 285 chancroid, 723, 723 S. aureus MBCs, 374 dysgonic fermenter 2, 78 cleavable-complex assay, 1086 Shigella spp., 20 E. coli combinations Cephapirin heat treatment, 1680 amikacin, aztreonam, cefoperazone, M. tuberculosis, 1441 Enterobacteriaceae, 873 cefsulodin, ceftazidime, gentami- CGP 17520 fecal flora resistance, 1801 cin, imipenem, mezlocillin, pipe- K. pneumoniae, 364 H. ducreyi, 1458 racillin, and tobramycin, 782 Chagas' disease H. influenzae, 180 clofazimine, 1392 ketoconazole, 1237 susceptibility testing, 1484 erythromycin, 1392 SF 86-327, 1237 P. carinii, 8% ethambutol, 1392 Charcoal P. multocida, 213 M. avium complex, 1392 tobramycin clearance, effect on, 274 scrub typhus, 285 P. maltophilia, 782 Chemotaxis Shigella spp., 20 rifabutin, 1392 T. vaginalis, 1323 Chlorhexidine rifampin, 1392 Chewing sticks S. aureus resistance, 932 comparative activity B. gingivalis, 598 Chlorhexidine digluconate A-56620, amikacin, aztreonam, car- B. melaninogenicus, 598 Enterobacteriaceae, 873 benicillin, cefoperazone, cefsulo- Chlamydia trachomatis 3-Chlorodiaminopimelic acid din, ceftazidime, difloxacin, gen- AM-833, 1080, 1735 diaminopimelic acid epimerase, 1119 tamicin, imipenem, mezlocillin, antibodies E. coli, 1119 norfloxacin, piperacillin, Sch monoclonal, 1295 2-Chloroethyl- I-nitrosoureas 34343, ticarcillin, and tobramycin, Chlamydiazyme, 1350 amphotericin B 782 chloramphenicol, 1350 C. albicans, 327 amifloxacin, enoxacin, norfloxacin, ciprofloxacin, 1080, 1350, 1735 2-Chloro-L-histidine and ofloxacin, 928 doxycycline, 1350, 1735 P. falciparum, 1655 ampicillin and chloramphenicol, 57 enoxacin, 1080 Chloroquine chloramphenicol and gentamicin, 285 erythromycin, 1350 malaria, 799 doxycycline and minocycline, 1735 fleroxacin, 1080 minireview, 799 gentamicin, imipenem, nafcillin, and imipenem-cilastatin, 773 P. falciparum, 799 vancomycin, 747 josamycin, 1350 polymorphonuclear neutrophils, 1124 trimethoprim-sulfamethoxazole, 1327 minireview, 1295 resistance, 799 cytogenetic effects, 936 minocycline, 1080, 1350, 1735 5-Chlorotubercidin dysgonic fermenter 2, 78 norfloxacin, 1080, 1350, 1735 influenza viruses, 906 E. coli, 450 NY-198, 1080, 1735 Chlorovinylglycine endocarditis, 747 ofloxacin, 1080, 1350, 1735 comparative activity, 319 Enterobacteriaceae, 1327 PD 127,391, 1251 gram-positive bacteria, 319 GABA receptor, 1624 pefloxacin, 1350 Staphylococcus spp., 319 H. ducreyi, 723, 723, 1458 pipemidic acid, 1080 Chlorpromazine Haemophilus spp., 147 rifampin, 1350 E. coli permeability, 153 high-pressure liquid chromatography, rikamycin, 1350 P. carinii, 8% 1537 RO 23-6240, 1080 Chlortetracycline letter to the editor, 949 rosoxacin, 1350 B. bronchiseptica, 1891 N. asteroides, 1776 roxithromycin, 1350 Cholelithiasis N. meningitidis, 1740 sulfamethoxazole, 1350 ceftazidime, 1588 Nocardia spp., 1078 susceptibility testing, 1295, 1350 CI-934 P. aeruginosa resistance, 535 T-3262, 1080 cleavable-complex assay, 1086 P. falciparum, 1182 tetracycline, 1350 Cilofungin P. maltophilia, 782 trospectomycin, 216 C. albicans, 1331 P. pseudomallei, 928, 1435 Chlamydia sp. strain TWAR (1-3)-p-D-glucan synthase, 1901 pharmacokinetics, 949, 982, 1537 ampicillin, 257 C. parapsilosis, 1331 polycystic kidney disease, 844 erythromycin, 257 C. tropicalis, 1331 postantibiotic effect, 450 penicillin, 257 comparative activity renal cyst infection, 844 sulfisoxazole, 257 amphotericin B, flucytosine, and keto- S. aureus, 747, 1192 tetracycline, 257 conazole, 1331 S. typhimurium, 57 trospectomycin, 257 Cryptococcus spp., 1331 scrub typhus, 285 VOL. 32, 1988 SUBJECT INDEX xv

Shigella spp., 20 wound infections, 1557 Coumermycin A theophylline pharmacokinetics, effect Clindamycin-gentamicin P. falciparum, 1182 on, 75 comparative activity Coxsackievirus urinary tract infections, 1327 cost analysis, 853 sulfated polysaccharides, 1742 Citrobacter diversus moxalactam, 853 Cryptococcus spp. CS-807, 1082 endomyometritis, 853 cilofungin, 1331 R-3746, 671 Clofazimine Cryptosporidium sp. tigemonam, 84 combinations letter to the editor, 1907 U-76,252, 1082 amikacin, 1400 sulfadimethoxine, 1907 Citrobacter freundii ciprofloxacin, 1392 Crystal violet DNA gyrase, 922 ethambutol, 1392 E. coli E1040, 693 M. avium complex, 1392, 1400 heat treatment, 1680 norfloxacin resistance, 922 rifabutin, 1392 CS-807 ofloxacin resistance, 922 M. leprae, 1583 A. hydrophila, 1082 quinolone resistance, 922 structure-activity relationship, 1583 B. catarrhalis, 1082 R-3746, 671 Cloning C. diversus, 1082 R plasmid, 9 antibiotic biosynthetic genes, 1472 comparative activity YTR 830, 925 biosynthetic genes, 1472 amoxicillin, amoxicillin-clavulanic Citrobacter spp. minireviews, 1465, 1472 acid, cefaclor, cefuroxime, cepha- E-1040, 1666 Streptomyces spp., 1465, 1472 lexin, and erythromycin, 1082 Clarithromycin Clostridium difficile E. coli, 1082 comparative activity, 1710 cefotetan, 601 E. faecalis, 1082 erythromycin, 1500 chloramphenicol acetyltransferase deter- Enterobacteriaceae, 1082 erythromycin and roxithromycin, minant H. influenzae, 1082 1758 genetic analysis, 1213 Klebsiella spp., 1082 M. hominis, 1500 molecular cloning, 1213 P. aeruginosa, 1082 M. leprae, 1758 R plasmid, 1213 P. mirabilis, 1082 M. pneumoniae, 1500 trospectomycin, 216 Staphylococcus spp., 1082 U. urealyticum, 1500 Clostridium spp. Streptococcus spp., 1082 Cleavable-complex assay daptomycin, 788 5-Cyano- I-P-D-ribofuranosyl-imidazole-4- BW A855U, 1086 DuP 105, 580 carboxamide CI-934, 1086 DuP 721, 580 influenza viruses, 906 ciprofloxacin, 1086 paldimycin, 788 5-Cyanoimidazole-4-carboxamide nalidixic acid, 1086 R-3746, 671 influenza viruses, 906 norfloxacin, 1086 trospectomycin, 216 Cyclohexane triones ofloxacin, 1086 13C nuclear magnetic resonance spectros- comparative activity oxolinic acid, 1086 copy cetrimide, chlorohexidine, FCCP, he- quinolones, 1086 P-lactamases, 1196 xachlorophene, and tribromosa- Clindamycin Coccidioidal meningitis lan, 814 A. actinomycetemcomitans, 1521 fluconazole, 369 gram-positive bacteria, 814 Arthrobacter spp., 420 Colistin H. influenzae, 814 B. fragilis, 1825 B. bronchiseptica, 1891 M. smegmatis, 814 Bacillus spp., 642 Enterobacteriaceae, 873 mechanisms of action, 814 C. ochracea, 1521 Common colds Cycloheximide combinations letters to the editor, 605, 606, 608 M. racemosus, 341 amikacin, 1557 zinc, 605, 606, 608 Cyclopentenyl cytosine cost analysis, 853 Conjunctivitis influenza viruses, 906 endomyometritis, 853 H. influenzae, 1820 Cyclophosphamide enterococci, 1769 norfloxacin, 1820 amoebic meningoencephalitis, 962 gentamicin, 853 S. aureus, 1820 N. fowleri, 962 head and neck surgery in cancer pa- S. pneumoniae, 1820 Cyclosporine tients, 1557 Staphylococcus spp., 1820 P. berghei, 462 P. carinii, 807 streptococci, alpha-hemolytic, 1820 Cystic fibrosis primaquine, 807 tobramycin, 1820 P. cepacia, 1636 streptomycin, 1769 Coronary angioplasty Cystitis wound infections, 1557 Staphylococcus infection, 202 E-3846, 636 dysgonic fermenter 2, 78 Corynebacterium group JK E. coli, 1640 E. corrodens, 1521 DuP 105, 580 ofloxacin, 1640 enterococci, 1769 DuP 721, 580 trimethoprim-sulfamethoxazole, 1640 high-performance liquid chromatogra- gentamicin-teicoplanin, 434 Cytogenetic effects phy, 1825 gentamicin-vancomycin, 434 ciprofloxacin, 936 neutrophil killing, 1521 teicoplanin, 434 ofloxacin, 936 P. carinii, 807 teicoplanin-gentamicin, 434 Cytomegalovirus P. multocida, 213 teicoplanin-tobramycin, 434 3'-azido-3'-deoxythymidine, 265 periodontal bacteria, 1521 tobramycin-teicoplanin, 434 AZT, 265 pharmacokinetics, 1825 tobramycin-vancomycin, 434 B-220, 1720 serum inhibitory activity, 1825 vancomycin, 434 carrageenans, 1742 Staphylococcus spp., 420 vancomycin-gentamicin, 434 cochlear pathophysiology, 865 Clindamycin-amikacin vancomycin-tobramycin, 434 dextran sulfate, 1742 comparative activity Corynebacterium spp. fucoidan, 1742 ticarcillin-clavulanic acid, 1557 PD 117,596, 1450 ganciclovir, 865 head and neck surgery in cancer Co-trimoxazole (S)-HPMPC, 1839 patients, 1557 H. ducreyi, 1458 (S)-1-(3-hydroxy-2-phosphonylmethoxy- xvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

propyl)cytosine, 1839 Dehydropeptidase I Dihydropteroate synthase gene interferon, 678 purification and characterization, 587 nucleotide sequence, 1684 labyrinthitis, 865 Demeclocycline 9-(3,4-Dihydroxybutyl)guanine oxetanocin G, 1053 comparative activity triphosphate pentosan polysulfate, 1742 doxycycline, erythromycin, minocy- DNA polymerases, 1137 S26308, 678 cline, nalidixic acid, oxytetracy- varicella-zoster virus, 1137 sulfated polysaccharides, 1742 cline, rifampin, and tetracycline, (S)-9-(2,3-Dihydroxypropyl)adenine 986 influenza viruses, 906 Dapsone E. risticii, 986 2,3,Dimethyl(dimethylaminoethyl)5H-in- combinations Dental granuloma dolo-(2,3-b)quinoxaline P. carinii, 623 ampicillin, 566 cytomegalovirus, 1720 pneumonia, 623 talampicillin, 566 herpes simplex virus type 1, 1720 trimethoprim, 623 Denture stomatitis mechanism of action, 1720 comparative activity C. albicans, 1859 varicella-zoster virus, 1720 pentamidine, trimethoprim-dapsone, fluconazole, 1859 ['4C]dimethyl sulfate and trimethoprim-sulfamethox- 5'-Deoxy-5-fluorouridine carbapenem labeling, 186 azole, 623 influenza viruses, 906 Diminazene P. carinii, 96, 623, 1057, 1158 Dermatophytes P. carindi, 8% pneumonia, 623, 1057 G2, 1586 Diminazene aceturate Daptomycin Dextran sulfate P. carinii, 1158 A. lignieresii, 1354 cytomegalovirus, 1742 Dirithromycin Actinomyces spp., 788 herpes simplex virus, 1742 comparative activity, 1710 Bacillus spp., 642 human immunodeficiency virus, Disodium EDTA Bifidobacterium spp., 788 1742 catheters, 1627 Clostridium spp., 788 vesicular stomatitis virus, 1742 S. epidermidis, 1627 combinations (S)-DHPA Distemonanthus benthamianus amikacin, fosfomycin, imipenem, net- influenza viruses, 906 B. gingivalis, 598 ilmicin, rifampin, teicoplanin, and Diallyl thiosulfinate B. melaninogenicus, 598 vancomycin, 279 mechanism of action, 1763 DNA gyrase endocarditis, 877 S. typhimurium, 1763 C. freundii, 922 Enterococcus spp., 279 Diaminopimelic acid epimerase cleavable-complex assay, 1086 gentamicin, 81, 877 3-chlorodiaminopimelic acid, 1119 inhibitors pyelonephritis, 81 E. coli, 1119 N. gonorrhoeae, 1788 S. aureus, 279 Diaveridine quinolones, 1086 S. epidermidis, 279 P. carinii, 96 resistance, 104 S. faecalis, 81, 877 Dibucaine S. aureus, 1192 E. coli permeability, 153 DNA polymerases Staphylococcus spp., 279 Diclofenac varicella-zoster virus, 1137 comparative activity GABA receptor, 1624 DNA probes cefamandole, cefazolin, and vancomy- y-aminobutyric acid receptor, 1624 ,B-lactamases, 175 cin, 63 Dicloxacillin DNA synthesis daptomycin-gentamicin, penicillin G hyperbilirubinemia E. coli, 1113 procaine, penicillin G procaine- centrifugal ultrafiltration, 1571 quinolones, 1113 gentamicin, vancomycin, vanco- Difloxacin Doxycycline mycin-gentamicin, 877 comparative activity B. bronchiseptica, 1891 paldimycin, penicillin, and vancomy- cefazolin and enoxacin, 262 C. trachomatis, 1350 cin, 788 erythromycin, 1500 comparative activity penicillin G, 141 endocarditis, 262 demeclocycline, erythromycin, mino- vancomycin, 454 H. ducreyi, 1458 cycine, nalidixic acid, E. faecalis, 24 M. hominis, 1500 oxytetracycline, rifampin, and E. faecium, 24 M. pneumoniae, 1500 tetracycline, 986 endocarditis, 63, 141, 877 M. tuberculosis, 1441 E. risticii, 986 Enterococcus spp., 279 Nocardia spp., 1078 Enterobacteriaceae, 873 Eubacterium spp., 788 P. maltophilia, 782 H. ducreyi, 1458 Lactobacillus spp., 788 S. aureus, 262 DR-3355 P. multocida, 1354 U. urealyticum, 1500 B. fragilis, 1336 Peptostreptococcus spp., 788 Difluoromethylornithine comparative activity Propionibacterium spp., 788 P. carinii, 896 ciprofloxacin, fleroxacin, methicillin, pyelonephritis, 81 DL-a-Difluoromethylornithine NY-198, and ofloxacin, 1336 S. aureus, 279, 454 combinations Peptococcus spp., 1336 P. carinii, 1158 Staphylococcus spp., 1336 S. epidermidis, 63, 279 suramin, 1158 DuP 105 S. faecalis, 81, 877 comparative activity B. fragilis, 580 translocation, 337 dapsone, diminazene aceturate, sura- Clostridium spp., 580 S. pneumoniae, 24 min, and trimethoprim-sulfameth- comparative activity Staphylococcus spp., 24, 279 oxazole, 1158 amoxicillin-clavulanic acid, Streptococcus spp., 141 P. carinii, 1158 cephalexin, teicoplanin, and van- 3-Deazaguanine Dihydromycoplanecin A comycin, 580 influenza viruses, 906 comparative activity ampicillin, cefaclor, ciprofloxacin, 3-Deazauridine isoniazid, ofloxacin, rifampin, and erythromycin, and vancomycin, influenza viruses, 906 streptomycin, 110 150 Dehydroemetine Mycobacterium spp., 110 Corynebacterium group JK, 580 P. carinii, 896 pharmacokinetics, 110 E. faecalis, 580 VOL. 32, 1988 SUBJECT INDEX xvii

Enterobacteriaceae, 580 Morganella spp., 1666 Bordetella spp., 137 Enterococcus spp., 150 Neisseria spp., 1666 C. trachomatis, 1080 L. monocytogenes, 150, 580 P. aeruginosa, 693, 1666 comparative activity P. aeruginosa, 580 P. cepacia, 1666 amifloxacin, ciprofloxacin, norflox- S. aureus, 580 Pseudomonas spp., 1666 acin, and ofloxacin, 928 S. epidermidis, 580 Serratia spp., 1666 cefazolin and difloxacin, 262 Staphylococcus sop., 150 Staphylococcus spp., 1666 endocarditis, 262 Streptococcus spp., 150, 580 Streptococcus spp., 1666 Haemophilus spp., 147 DuP 721 X. maltophilia, 1666 high-pressure liquid chromatography, B. fragilis, 580 E-3846 834 Clostridium spp., 580 comparative activity Nocardia spp., 1078 comparative activity ciprofloxacin and norfloxacin, 636 osteomyelitis, 834 amoxicillin-clavulanic acid, cystitis, 636 P. falciparum, 1182 cephalexin, teicoplanin, and van- E. coli, 636 P. pseudomallei, 928 comycin, 580 Enterobacteriaceae, 636 prostatic tissue concentrations, 1433 ampicillin, cefaclor, ciprofloxacin, K. pneumoniae, 636 S. aureus, 262 erythromycin, and vancomycin, P. aeruginosa, 636 Shigella spp., 20 150 P. mirabilis, 636 Entamoeba histolytica Corynebacterium group JK, 580 pyelonephritis, 636 B. javanica, 1725 E. faecalis, 580 S. faecalis, 636 quassinoids, 1725 Enterobacteriaceae, 580 Staphylococcus spp., 636 S. amara, 1725 Enterococcus spp., 150 Ehrlichia risticii Enterobacter aerogenes gram-positive bacteria, 1218 demeclocycline, 986 E1040, 693 L. monocytogenes, 150, 580 doxycycline, 986 R-3746, 671 mechanism of action, 1218 erythromycin, 986 R plasmid, 9 P. aeruginosa, 580 minocycline, 986 tigemonam, 84 protein synthesis, 1218 nalidixic acid, 986 Enterobacter cloacae S. aureus, 580 oxytetracycline, 986 amdinocillin, 1632 S. epidermidis, 580 rifampin, 986 ceftazidime, 1632 Staphylococcus spp., 150 tetracycline, 986 resistance, 1632 Streptococcus spp., 150, 580 Eikenella corrodens ceftazidime-amdinocillin, 1632 Dysgonic fermenter 2 clindamycin, 1521 E1040, 693 amikacin, 78 neutrophil killing, 1521 R-3746, 671 aztreonam, 78 R plasmid, 765 tigemonam, 84 cefamandole, 78 tetracycline resistance, 765 YTR 830, 925 cefazolin, 78 Encephalomyocarditis virus Enterobacter spp. cefoperazone, 78 P-536, 1257 E-1040, 1666 cefotaxime, 78 Endocarditis lomefloxacin, 656 ceftazidime, 78 amikacin-ceftazidime, 231 PD 117,596, 1450 chloramphenicol, 78 cefamandole, 63 tigemonam, 84 ciprofloxacin, 78 cefazolin, 63, 262 Enterobacteriaceae clindamycin, 78 ceftazidime-amikacin, 231 A-61827, 27 erythromycin, 78 ciprofloxacin, 747 6'-N-acetyltransferase type 4, 1289 gentamicin, 78 daptomycin, 63, 141, 877 amikacin, 873 imipenem, 78 daptomycin-gentamicin, 877 resistance, 1289 methicillin, 78 difloxacin, 262 aminoglycoside resistance, 1289 penicillin G, 78 enoxacin, 262 amoxicillin-clavulanic acid, 873 piperacillin, 78 fosfomycin, 919 ampicillin, 873 rifampin, 78 fosfomycin-pefloxacin, 919 P-lactamases, 1365 ticarcillin, 78 gentamicin-daptomycin, 877 carumonam, 1593 trimethoprim-sulfamethoxazole, 78 gentamicin-penicillin G procaine, 877 cefixime, 1896 vancomycin, 78 gentamicin-vancomycin, 877 cefotaxime, 873 P. aeruginosa, 231 cefoxitin, 873 E1040 pefloxacin, 231, 919 cefpodoxime, 1896 Acinetobacter spp., 693 pefloxacin-fosfomycin, 919 ceftibuten, 1576 141 ceftriaxone, 1896 Bacteroides spp., 1666 penicillin G, penicillin G procaine, 877 cephalothin, 873 P-lactamases, 1666 G 877 chloramphenicol, 873 C. freundii, 693 penicillin procaine-gentamicin, S. aureus, 262, 747, 919 chlorhexidine digluconate, 873 Citrobacter spp., 1666 S. epidermidis, 63 ciprofloxacin, 1327 comparative activity S. faecalis, 877 colistin, 873 cefazolin, cefmenoxime, cefotiam, Streptococcus spp., 141 CS-807, 1082 ceftazidime, and methicillin, vancomycin, 63, 877 doxycycline, 873 693 vancomycin-gentamicin, 877 DuP 105, 580 cefepime, cefpirome, ceftazidime, Endomyometritis DuP 721, 580 gentamicin, and imipenem, cesarean section, 853 E1040, 693, 1666 1666 clindamycin-gentamicin, 853 E-3846, 636 E. aerogenes, 693 gentamicin-clindamycin, 853 fluoroquinolone resistance, 1285 E. cloacae, 693 moxalactam, 853 gentamicin, 873 E. coli, 693 treatment cost analysis, 853 iodine alcohol, 873 Enterobacter spp., 1666 Enoxacin lomefloxacin, 617 Enterobacteriaceae, 693, 1666 B. fragilis, 1437 PD 127,391, 1251 Haemophilus spp., 1666 bite wound bacteria, 1143 polyvinylpyrrolidone, 873 xviii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

R plasmid, 1289 Erythromycin biofilms sodium hypochlorite, 873 acistrate radiochemical method, 770 susceptibility testing, 1365 tonsillar and plasma concentrations, 2-bromo-2-nitropropane-1,3-diol, 1693 T-3262, 663, 827 1019 bronopol, 1693 ticarcillin, 873 Arthrobacter spp., 420 cefotaxime-chloramphenicol, 1375 ticarcillin-potassium clavulanate resis- B. bronchiseptica, 1891 cefoxitin, 1511 tance, 1365 B. catarrhalis, 259 cefpirome, 13% tigemonam, 84 Bacillus spp., 642 ceftizoxime, 1511 tobramycin, 873 base ceftriaxone, 552 trimethoprim, 873 toxicity, 1541 ceftriaxone-chloramphenicol, 1375 trimethoprim-sulfamethoxazole, 1327 uptake and distribution, 1541 cephalosporins trospectomycin, 216 Bordetella spp., 137 catechol substituted, 1879 U-76,252, 1082 C. trachomatis, 1350 3-chlorodiaminopimelic acid, 1119 U-76,253A, 443 Chlamydia sp. strain TWAR, 257 ciprofloxacin, 450 urinary tract infections, 1327 combinations cloning of P. maltophilia ,B-lactamase Enterococcus faecalis ciprofloxacin, 1392 operon, 819 CS-807, 1082 ethambutol, 1392 CS-807, 1082 daptomycin, 24 M. avium complex, 1392 cystitis, 636, 1640 DuP 105, 580 rifampin, 1392 diaminopimelic acid epimerase, 1119 DuP 721, 580 comparative activity, 1710 DNA synthesis, 1113 fluoroquinolone resistance, 1285 clarithromycin and roxithromycin, E1040, 693 T-3262, 663 1758 E-3846, 636 U-76,252, 1082 demeclocycline, doxycycline, minocy- etoposide, 1456 Enterococcus faecium cline, nalidixic acid, oxytetracy- gentamicin, 552 daptomycin, 24 cline, rifampin, and tetracycline, hypersusceptible norfloxacin, 1869 986 gentamicin, 308 Enterococcus spp. mupirocin, 1780 lipopolysaccharide polycation affinity Campylobacter resistance gene, 1793 dysgonic fermenter 2, 78 and binding, 308 cefixime, 18% E. risticii, 986 polymyxin, 308 cefpodoxime, 1896 H. ducreyi, 1458 spermine, 308 ceftriaxone, 18% H. influenzae, 180 imipenem sub-MICs clindamycin, 1769 impetigo, 1780 killing, 1012 clindamycin-streptomycin, 1769 M. leprae, 1758 phagocytosis, 1012 daptomycin, 279 N. asteroides, 1776 serum sensitivity, 1012 DuP 105, 150 P. multocida, 213 in vitro simulation of serious infections, DuP 721, 150 R. conorii, 255 552 intestinal colonization and translocation, R. rickettsii, 255 lipopolysaccharide 1769 S. faecalis resistance, 547 amikacin, 1247 metronidazole, 1769 Staphylococcus spp., 420 gentamicin, 1247 metronidazole-streptomycin, 1769 stearate kanamycin, 1247 PD 117,5%, 1450 tonsillar and plasma concentrations, spectinomycin, 1247 R-3746, 671 1019 tobramycin, 1247 R plasmids, 1793 T. pallidum, resistant, 164 lomefloxacin, 656 S-6123, 1341 Erythromycin estolate LY163892, 268 T-3262, 827 B. catarrhalis, 1227 M14659, 1648 tigemonam, 84 comparative activity ME1207, 1421 translocation, 1769 erythromycin ethylsuccinate, 1227 mixed infection with B. fragilis U-76,253A, 443 high-pressure liquid chromatography, amoxicillin-clavulanic acid, 1830 Enviroxime 561 ampicillin-sulbactam, 1830 aerosol, 890 pharmacokinetics, 561 norfloxacin, 1292 liposomes, 890 plasma bactericidal activity, 1227 endogenous active efflux, 1187 rhinoviruses, 890 Streptococcus spp., 1227 ofloxacin, 1640 toxicity, 890 toxicity, 1541 outer membrane proteins Enzyme immunoassays uptake and distribution, 1541 iron regulated, 1879 Chlamydiazyme, 1350 Erythromycin ethylsuccinate oxyimino-cephalosporins, 1243 Enzyme-linked immunosorbent assays B. catarrhalis, 1227 Pap fimbrial adhesion, 1274 T. gondii, 303 comparative activity PD 117,5%, 1450 Epidermophyton floccosum erythromycin estolate, 1227 permeability, increased G2, 1586 high-pressure liquid chromatography, anesthetics, 153 Epstein-Barr virus 561 chlorpronmazine, 153 acyclovir, 1068 pharmacokinetics, 561 dibucaine, 153 acyclovir-AZT, 265 plasma bactericidal activity, 1227 procaine, 153 1-P-D-arabinofuranosyl-E-5-(2-bromo- Streptococcus spp., 1227 quinine, 153 vinyl)uracil, 1068 Erythromycin-sulfisoxazole tetracaine, 153 3'-azido-3'-deoxythymidine, 265 B. catarrhalis, 259 postantibiotic effect, 450 3'-azido-3'-deoxythymidine-acyclovir, Erythromycylamine pyelonephritis, 636 265 comparative activity, 1710 quinolone permeation, 438 AZT, 265 Escherichia coli quinolones, 1113 AZT-acyclovir, 265 A-61827, 27 R-3746, 671 E-5-(2-bromovinyl)-2'-deoxyuridine, 1068 ampicillin, 450, 552 R plasmids, 9, 1243, 1552 bromovinyl nucleoside analogs, 1068 aztreonam, 552 S-6123, 1341 Ergosterol berberine sulfate, 1274 sensitization by heat treatment C. albicans, 702 ,-lactamase, 1243 chloramphenicol, 1680 VOL. 32, 1988 SUBJECT INDEX xix

crystal violet, 1680 coccidioidal meningitis, 369 y-Aminobutyric acid receptor fatty acids, 1680 comparative activity diclofenac, 1624 malachite green, 1680 ketoconazole, 209, 646 quinolones, 1624 p-hydroxybenzoic acid, 1680 denture stomatitis, 1859 theophylline, 1624 rifampin, 1680 meningitis, coccidioidal, 369 Ganciclovir tylosin, 1680 pharmacokinetics, 209, 369 cochlear pathophysiology, 865 vancomycin, 1680 stomatitis, denture, 1859 cytomegalovirus, 865 T-3262, 663, 827 testosterone, 646 high-pressure liquid chromatography, tigemonam, 84, 346 2-Fluoro-L-histidine 865 tobramycin, 450 P. falciparum, 1655 labyrinthitis, 865 trimethoprim-sulfamethoxazole, Fluoroquinolones marrow transplantation, 271 1640 B. fragilis, 1437 pharmacokinetics, 1899 U-76,252, 1082 resistance, development of, 1285 Gene probes urinary tract infections, 1274 Fluorovinylglycine 3-V-acetyltransferase, 1834 YTR 830, 925 comparative activity, 319 Gentamicin Ethambutol gram-positive bacteria, 319 A. denitrificans subsp. xylosoxidans, 276 combinations Staphylococcus spp., 319 B. bronchiseptica, 1891 ciprofloxacin, 1392 Flurithromycin B. catarrhalis, 259 clofazimine, 1392 comparative activity, 1710 Bacillus spp., 642 erythromycin, 1392 pharmacokinetics, 1875 cerebrospinal fluid penetration, 1034 M. avium complex, 1392 Folate pathway cochlear binding sites, 467 rifabutin, 1392 bacterial adhesion, 1609 combinations rifampin, 1392 minireview, 1609 ciprofloxacin, 782 M. tuberculosis, 1208, 1441 Folic acid antagonists clindamycin, 853 Ethidium T. vaginalis, 144 cost analysis, 853 P. carinii, 896 Foscarnet daptomycin, 81 Ethidium bromide guinea pig embryonic fibroblasts, 1533 endomyometritis, 853 S. aureus resistance, 932 herpes simplex virus type 1, 1533 P. maltophilia, 782 Ethionamide human immunodeficiency virus type 1, pyelonephritis, 81 M. avium, 1131 1733 S. faecalis, 81 Etoposide human immunodeficiency virus type 2, comparative activity B. stearothermophilus, 1456 1733 carumonam, 473 B. subtilis, 1456 simian immunodeficiency virus, 1733 chloramphenicol and ciprofloxacin, comparative activity Fosfomycin 285 cloxacillin, 1456 calcium dysgonic fermenter 2, 78 E. coli, 1456 pharmacokinetics, 938 E. coli, 308, 552 K. pneumoniae, 1456 young and elderly adults, 938 lipopolysaccharide, 1247 P. aeruginosa, 1456 combinations Enterobacteriaceae, 873 S. aureus, 1456 endocarditis, 919 fecal flora resistance, 1801 S. lutea, 1456 pefloxacin, 919 H. influenzae, 1034 S. sanguis, 1456 S. aureus, 919 in vitro simulation of serious infections, Eubacterium spp. endocarditis, 919 552 daptomycin, 788 glutathione adduct, 1552 K. pneumoniae resistance, 1379 paldimycin, 788 plasmid-borne resistance, 1552 meningitis, 1034 tetracycline S. aureus, 919 N. asteroides, 1776 resistance, 1271 tromethamine nephrotoxicity pharmacokinetics, 938 hydrocortisone, influence of, 992 Fagara zanthoxyloides young and elderly adults, 938 piperacillin protective effect, 912 B. gingivalis, 598 Fucoidan P. aeruginosa, 552 B. melaninogenicus, 598 cytomegalovirus, 1742 P. carinii, 896 Fatty acids herpes simplex virus, 1742 P. maltophilia, 782 E. coli human immunodeficiency virus, 1742 pharmacokinetics, 467, 736 heat treatment, 1680 vesicular stomatitis virus, 1742 pyelonephritis, 81, 736 M. avium complex, 400 Furazolidone S. aureus resistance, 932, 1174 Fecal flora T. vaginalis, 144 S. faecalis, 81, 736 antimicrobial resistance, 1801 Fusobacterium nucleatum resistance, 547, 1528 Feces tetracycline S. marcescens resistance, 1379 norfloxacin binding, 1869 resistance, 1271 S. pneumoniae, 552 quinolone binding, 1869 scrub typhus, 285 G2 Shigella spp., 20 Fibronectin sodium hydroxide digestion method, 595 S. pyogenes, 1370 E. floccosum, 1586 T. vaginalis, 1323 Fleroxacin Microsporum spp., 1586 urinary tract infections, 473 C. trachomatis, 1080 structure, 1586 Gentamicin-clindamycin high-pressure liquid chromatography, toxicity, 1586 comparative activity 1515 Trichophyton spp., 1586 cost analysis, 853 letter to the editor, 791 GABA receptor moxalactam, 853 pharmacokinetics, 1515 diclofenac, 1624 endomyometritis, 853 S. typhimurium, 791 quinolones, 1624 Giardia lamblia Flucloxacillin theophylline, 1624 5-methylthioribose analogs, 1904 open-heart surgery, 930 f-Galactosidase (1-3)-p-D-Glucan synthase Fluconazole P. chryosogenum C. albicans, 1901 C. albicans, 209, 1859 glucokinase-deficient mutant, 1061 cilofungin, 1901 xx SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Glucose cephalothin, 180 monophosphate, 1533 avermectin production, 282 chloramphenicol 2,3,dimethyl(dimethylaminoethyl)SH- Glutathione acetyltransferase, 180 indolo-(2,3-b)quinoxaline, 1720 adduct formation, 1552 conjunctivitis, 1820 foscarnet, 1533 fosfomycin modification, 1552 CS-807, 1082 GMP, 1533 GMP cyclohexane triones, 814 guanosine analogs, 1533 guinea pig embryonic fibroblasts, 1533 erythromycin, 180 9-4-(hydroxy-3-hydroxymethylbut-1 -yl) herpes simplex virus type 1, 1533 gentamicin, 1034 guanine, 358 Gonorrhea lomefloxacin, 617, 656 9-(2-hydroxyethoxymethyl)guanine, 1046 cefodizime, 426 LY163892, 131, 268 indoloquinoxaline derivatives, 1720 cefotaxime, 426 ME1207, 1421 5-iodo-2'-deoxyuridine, 1046 imipenem-cilastatin, 773 meningitis, 1034 iododeoxyuridine, 1533 spectinomycin minireview, 1747 P-536, 1257 disk zone diameter as predictor of out- norfloxacin, 1820 pyrimidine deoxynucleotide metabolism, come, 775 ocular infections, 1820 1100 Gram-negative bacteria PD 127,391, 1251 ribonucleotide reductase inhibition, cefotaxime-chloramphenicol, 1375 penicillin G, 498 1100 ceftriaxone-chloramphenicol, 1375 penicillin-binding proteins, 498 Herpes simplex virus type 2 cephalexin hydrochloride, 882 R-3746, 671 1-P-D-arabinofuranosyl-E-5-(2-bromo- cephalexin monohydrate, 882 rifampin, 180 vinyl)uracil, 1547 norfloxacin, 1292 S-6123, 1341 3'-azido-3'-deoxythymidine, 265 PD 127,391, 1278 sulfisoxazole, 180 AZT, 265 S-6123, 1341 susceptibility testing, 1747 BRL 39123, 358 susceptibility testing, 385 chloramphenicol, 1484 9-4-(hydroxy-3-hydroxymethylbut-1-yl) Gram-positive bacteria T-3262, 663 guanine, 358 cyclohexane triones, 814 tetracycline, 180 phosphonoacetate, 858 DuP 721, 1218 tobramycin, 1820 phosphonoformate, 858 halovinylglycine compounds, 319 trimethoprim resistance, 477 Hexadecane L-norvalyl peptide derivatives, 319 trimethoprim-sulfamethoxazole, 180 S. pyogenes, 1370 norfloxacin, 1292 trospectomycin, 216 High-performance liquid chromatography PD 127,391, 1278 U-76,252, 1082 amphotericin B, 1103 Guanosine analogs U-76,253A, 443 carbapenem labeling, 186 guinea pig embryonic fibroblasts, 1533 Haemophilus spp. cefonicid, 485 herpes simplex virus type 1, 1533 ciprofloxacin, 147 cefpiramide, 1360 E-1040, 1666 cefpirome, 1481 Haemophilus ducreyi enoxacin, 147 ceftazidime, 1845 A-56268, 1458 norfloxacin, 147 clindamycin, 1825 amoxicillin, 1458 ofloxacin, 147 itraconazole, 1310 amoxicillin-clavulanic acid, 1458 PD 117,596, 1450 lomefloxacin, 1503, 1508 cefotaxime, 1458 pefloxacin, 147 reuterin, 1854 cefoxitin, 1458 tigemonam, 84 High-pressure liquid chromatography ceftetrame, 1458 Halovinylglycine compounds carumonam, 354 ceftriaxone, 1458 alanine racemase, 319 cefoperazone-ceftazidime, 298 chloramphenicol, 1458 comparative activities, 319 ceftazidime-cefoperazone, 298 ciprofloxacin, 723, 1458 gram-positive bacteria, 319 ciprofloxacin, 1537 co-trimoxazole, 1458 L-norvalyl peptide derivatives, 319 enoxacin, 834 difloxacin, 1458 Staphylococcus spp., 319 erythromycin estolate, 561 doxycycline, 1458 Head and neck surgery erythromycin ethylsuccinate, 561 erythromycin, 1458 cancer patients, 1557 fleroxacin, 1515 kanamycin, 1458 clindamycin-amikacin, 1557 ganciclovir, 865 minocycline, 1458 ticarcillin-clavulanic acid, 1557 trimetrexate, 324 penicillin, 1458 Herpes simplex virus Histidine analogs rifampin, 1458 carrageenans, 1742 P. falciparum, 1655 rosoxacin, 1458 dextran sulfate, 1742 ±2HM-HBG spectinomycin, 1458 fucoidan, 1742 pharmacokinetics, 1807 sulfamethoxazole, 1458 pentosan polysulfate, 1742 simian varicella-zoster virus, 1807 tetracycline, 1458 sulfated polysaccharides, 1742 Home parenteral therapy thiamphenicol, 1458 Herpes simplex virus type I ceftriaxone, 1439 trimethoprim, 1458 A723U, 1100 HPA-23 trimethoprim-sulfamethoxazole, 1458 acyclovir, 1100, 1533 acquired immune deficiency syndrome, Haemophilus influenzae monophosphate, 1533 1300 27 9-p-D-arabinofuranosyladenine, 1046 (S)-HPMPA A-61827, I -,-D-arabinofuranosyl-E-5-(2-bromo- influenza viruses, 906 ampicillin, 180 vinyl)uracil, 1547 (S)-HPMPC azithromycin, 752 1-0-D-arabinofuranosyl-E-(2-bromovinyl) cytomegalovirus, 1839 P-lactamase, 180 uracil, 1046 HRE 664 cefaclor, 180 I-P-D-arabinofuranosylthymine, 1046 comparative activity cefamandole, 180 3-azido-3'-deoxythymidine, 265 aztreonam, ceftazidime, ceftriaxone, cefixime, 1896 AZT, 265 imipenem, piperacillin, and Sch cefpodoxime, 1896 B-220, 1720 34343, 1090 ceftibuten, 1576 BRL 39123, 358 Human granulocytes ceftriaxone, 1896 bromovinyldeoxyuridine, 1533 P. aeruginosa cephalexin, 180 buciclovir, 1533 moxalactam-induced filamentous VOL. 32, 1988 SUBJECT INDEX xxi

forms, 1565 cefuroxime, 1571 3-deazaguanine, 906 Human immunodeficiency virus dicloxacillin, 1571 3-deazauridine, 906 carrageenans, 1742 2-hydroxybenzoylglycine, 1571 5'-deoxy-5-fluorouridine, 906 dextran sulfate, 1742 kanamycin, 1571 (S)-DHIPA, 906 fucoidan, 1742 mezlocillin, 1571 (S)-9-(2,3-dihydroxypropyl)adenine, 906 pentosan polysulfate, 1742 moxalactam, 1571 (S)-HPMPA, 906 phosphonylmethoxyethyl purines, 1025 nafcillin, 1571 (S)-9-(3-hydroxy-2-phosphonylmethoxy- reverse transcriptase, 1887 sulfamethoxazole, 1571 propyl)adenine, 906 sulfated polysaccharides, 1742 sulfisoxazole, 1571 3-methylhypoxanthine, 906 Human immunodeficiency virus type 1 3'-C-methyluridine, 906 3'-azido-3'-deoxythymidine, 1784 Imidazoles neplanocin A, 900 triphosphate, 1733 T. vaginalis, 1323 neplanocin C, 906 AZT, 1784 Imidocarb P-536, 1257 triphosphate, 1733 P. carinii, 896 pyrazofurin, 906 AZT-isoprinosine, 1784 Imipenem ribavirin, 906 cell cultures, 684 A. denitrificans subsp. xylosoxidans, 276 T-25, 906 foscarnet, 1733 B. catarrhalis, 259 T-26, 906 isoprinosine, 1784 Bacillus spp., 642 tubercidin, 906 isoprinosine-AZT, 1784 combinations xylotubercidin, 906 reverse transcriptase, 684, 1733 ciprofloxacin, 782 Inositol hexaphosphate rifabutin, 684 P. maltophilia, 782 virus-antigen assay, 684 B. microti, 391 comparative activity P. falciparum, 391 Human immunodeficiency virus type 2 piperacillin, 1012 3'-azido-3'-deoxythymidine triphosphate, dysgonic fermenter 2, 78 Interferon 1733 M. morganii, 1385 alfa-2b, recombinant AZT triphosphate, 1733 M. tuberculosis, 1441 rhinovirus, 224 foscarnet, 1733 N. asteroides, 1776 alpha-2a, recombinant reverse transcriptase, 1733 Nocardia spp., 1078 respiratory syncytial virus, 589 Human renal dehydropeptidase I P. aeruginosa resistance, 1267 cytomegalovirus, 678 purification and characterization, 587 P. maltophilia, 782 S26308, 678 Hydrocortisone P. pseudomallei, 1435 Intra-abdominal infections nephrotoxicity, gentamicin induced, 992 P. vulgaris, 1385 cefoperazone-sulbactam, 730 9-[4-Hydroxy-2(hydroxymethyl)butyl] sub-MICs Intravenous immunoglobulin guanine triphosphate E. coli, 1012 respiratory syncytial virus, 1269 DNA polymerases, 1137 killing, 1012 Iodine alcohol varicella-zoster virus, 1137 phagocytosis, 1012 Enterobacteriaceae, 873 (R,S)-9-[4-Hydroxy-2-(hydroxymethyl) S. aureus, 1012 5-Iodo-2'-deoxyuridine butyl]guanine serum sensitivity, 1012 herpes simplex virus type 1, 1046 pharmacokinetics, 1807 Imipenem-cilastatin Iododeoxyuridine simian varicella-zoster virus, 1807 -y-aminobutyric acid binding, 758 guinea pig embryonic fibroblasts, 1533 (S)-9-(3-Hydroxy-2-phosphonylmethoxy- C. trachomatis, 773 herpes simplex virus type 1, 1533 propyl)adenine gonorrhea, 773 influenza viruses, 906 N. gonorrhoeae, 773 2-Iodo-L-histidine (S)-1-(3-Hydroxy-2-phosphonylmethoxy- pentylenetetrazole convulsive threshold, P. falciparum, 1655 propyl)cytosine 758 lontophoresis comparative activity pharmacokinetics, 530 tobramycin, 978 9-(1,3-dihydroxy-2-propoxymethyl) Immunoblotting Ipratropium bromide guanine, (S)-9-(3-hydroxy-2-phos- P. aeruginosa, 649 rhinovirus, 1644 phonylmethoxypropyl)adenine, Immunoglobulin, intravenous Isoelectric focusing and phosphonoformate, 1839 respiratory syncytial virus, 1269 ,B-lactamases, 397, 1730 cytomegalovirus, 1839 Impetigo comparative studies, 397 9-(4-Hydroxy-3-hydroxymethyl-1-yl)guanine erythromycin, 1780 PhastSystem, 1730 comparative activity mupirocin, 1780 Isometamidium acyclovir, 358 Indoloquinoxaline P. carinii, 896 herpes simplex virus type 1, 358 derivatives, 1720 Isoniazid herpes simplex virus type 2, 358 herpes simplex virus type 1, 1720 M. avium, 1131 p-Hydroxybenzoic acids Influenza A virus M. tuberculosis, 1208, 1441 E. coli alpha-2b interferon, 47 Isoprinosine heat treatment, 1680 2-Hydroxybenzoylglycine Influenza B virus combinations hyperbilirubinemia alpha-2b interferon, 47 3'-azido-3'-deoxythymidine, 1784 centrifugal ultrafiltration, 1571 ribavirin small-particle aerosol, 761 AZT, 1784 9-(2-hydroxyethoxymethyl)guanine Influenza viruses human immunodeficiency virus type 1, herpes simplex virus type 1, 1046 (RS)-3-adenin-9-yl-2-hydroxypropanoic 1984 9-(2-Hydroxyethoxymethyl)guanine tri- acid, 906 human immunodeficiency virus type 1, phosphate (RS)-AHPA, 906 1984 DNA polymerases, 1137 carbocyclin 3-deazaadenosine, 906 Itraconazole varicella-zoster virus, 1137 carbodine, 906 high-performance liquid chromatogra- Hyperbilirubinemia 5-chlorotubercidin, 906 phy, 1310 aztreonam, 1571 5-cyanoimidazole-4-carboxamide, 906 pharmacokinetics, 1310, 1595 carbenicillin, 1571 5-cyano-1-,-D-ribofuranosyl-imidazole-4- renal dysfunction, 1595 cefoperazone, 1571 carboxamide, 906 S. schenckii, 1619 ceftriaxone, 1571 cyclopentenyl cytosine, 906 sporotrichosis, 1619 xxii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Jasplakinolide tobramycin resistance, 1379 gentamicin, 1247 antifungal agents, 1154 Klebsiella spp. kanamycin, 1247 C. albicans, 1154 CS-807, 1082 spectinomycin, 1247 Candida spp., 1154 PD 117,596, 1450 tobramycin, 1247 comparative activity tigemonam, 84 Liposomes clotrimazole and miconazole, 1154 U-76,252, 1082 amikacin Josamycin M. avium-M. intracellulare, 1404 Arthrobacter spp., 420 Labyrinthitis ampicillin, 1560 C. trachomatis, 1350 cytomegalovirus, 865 enviroxime, 890 comparative activity, 1710 ganciclovir, 865 L. monocytogenes, 1560 R. conorii, 255 Lactobacillus reuteri lipid composition, 1560 R. rickettsii, 255 production and isolation of reuterin, phosphonoacetate, 858 Staphylococcus spp., 420 1854 phosphonoformate, 858 Lactobacillus spp. stearylamine-phosphatidylcholine, 966 Kanamycin daptomycin, 788 T. b. gambiense, 966 B. bronchiseptica, 1891 paldimycin, 788 Liposome-swelling assay C. coli resistance, 1170 Legionella pneumophila P. aeruginosa, 1267 C. jejuni resistance, 1170 A-61827, 27 Listeria monocytogenes Campylobacter resistance, 945 azithromycin, 752 ampicillin, 1204 E. coli carumonam, 1593 nanoparticle polyisohexylcyanoacry- lipopolysaccharide, 1247 PD 117,596, 1450 late-bound, 1204 fecal flora resistance, 1801 Legionella spp. ampicillin, liposome entrapped H. ducreyi, 1458 NY-198, 1427 lipid composition, 1560 hyperbilirubinemia Legionnaires disease azithromycin, 752 centrifugal ultrafiltration, 1571 NY-198, 1427 DuP 105, 150, 580 K. pneumoniae resistance, 1379 Letters to the editor DuP 721, 150, 580 M. avium, 1131 antacids Listeria spp. N. asteroides, 1776 ciprofloxacin pharmacokinetics, 949 tigemonam, 84 S. aureus resistance, 932 B. subtilis Lomefloxacin S. marcescens resistance, 1379 streptomycin adenylyltransferase, 949 B. fragilis, 617 Shigella spp., 20 ciprofloxacin Branhamella spp., 656 Keratitis antacids, 949 comparative activity P. aeruginosa, 978 pharmacokinetics, 949 amoxicillin, ciprofloxacin, cefuroxime, tobramycin, 978 common cold therapy, 605, 606, 608 fleroxacin, ofloxacin, and trimeth- Ketoconazole Cryptosporidium sp., 1907 oprim, 617 C. albicans, 209 fleroxacin, 791 ciprofloxacin, enoxacin, norfloxacin, combinations in vitro simulation of serious infections, and ofloxacin, 656 SF 86-327, 1237 1600 E. coli, 656 T. (S.) cruzi, 1237 M. tuberculosis, 287 Enterobacter spp., 656 comparative activity N. gonorrhoeae Enterobacteriaceae, 617 fluconazole, 209 P-lactamase, 158 H. influenzae, 617, 656 pharmacokinetics, 209 R plasmid, 158 high-performance liquid chromatogra- T. (S.) cruzi, 1237 tetracycline resistance, 951 phy, 1503, 1508 T. vaginalis, 1323 pharmacokinetics K. pneumoniae, 656 testosterone, 646 ciprofloxacin, 949 Neisseria spp., 617 Kingella denitrificans puerperal infections, 407 P. aeruginosa, 617 R plasmid, 765 pyrazinamide, 287 pharmacokinetics, 1503, 1508 tetracycline resistance, 765 S. aureus, 1464 Pseudomonas spp., 656 Klebsiella aerogenes S. typhimurium, 791 Salmonella spp., 656 YTR 830, 925 streptomycin Shigella spp., 656 Klebsiella pneumoniae B. subtilis adenylyltransferase, 949 Staphylococcus spp., 617, 656 amikacin resistance, 1379 sulfadimethoxine, 1907 Streptococcus spp., 617 transposon mediated, 1416 susceptibility testing, 1464 tolerance, 1503 P-lactam resistance, 1660 tetracycline LY163892 ,-lactamases, 626, 1660 N. gonorrhoeae resistance, 951 B. catarrhalis, 268 cephaloridine, 364 ticarcillin-clavulanic acid, 407 chemical stability in storage, 1477 cephalosporin resistance, 1660 zinc for common cold, 605, 606, 608 comparative activity CGP 17520, 364 pH and free ion concentration, 608 amoxicillin, amoxicillin-clavulanic cystitis, 636 stability constants, 606 acid, and cefaclor, 268 E-3846, 636 Lidocaine cefaclor and cefuroxime, 131 etoposide, 1456 ceftriaxone reconstitution, 1439 cefaclor, cephalexin, cephalothin, and gentamicin resistance, 1379 Lincomycin cefuroxime, 1477 kanamycin resistance, 1379 Arthrobacter spp., 420 E. coli, 268 lomefloxacin, 656 Staphylococcus spp., 420 H. influenzae, 131, 268 meningitis, 1705 Lincosamides pediatric infections, 268 netilmicin resistance, 1379 Arthrobacter resistance, 420 pharmacokinetics, 1738 plasmids, 1660 Staphylococcus resistance, 420 S. aureus, 131 pyelonephritis, 636 Lipid X Streptococcus spp., 268 R-3746, 671 pharmacokinetics, 37 susceptibility test conditions, 1477 R plasmid, 9, 626, 1379, 1416 Lipopolysaccharides surface protein antigens, 364 E. coli M14659 temocillin, 1705 amikacin, 1247 comparative activity VOL. 32, 1988 SUBJECT INDEX xxiii

ceftazidime and ceftriaxone, 1648 P. maltophilia, 782 cefotaxime, 1385 E. coli, 1648 hyperbilirubinemia cefoxitin, 1385 low-iron environment, 1648 centrifugal ultrafiltration, 1571 ceftriaxone, 1385 Macrolides M. morganii, 1385 cephaloridine, 1385 comparative activity, 1710 P. maltophilia, 782 imipenem, 1385 T. vaginalis, 144 P. vulgaris, 1385 mezlocillin, 1385 Malachite green pharmacokinetics, 777 Morganella spp. E. coli Miconazole E-1040, 1666 heat treatment, 1680 comparative activity R-3746, 671 Malaria amphotericin B, 1864 tigemonam, 84 antimalarial agents polymorphonuclear leukocytes, 1864 Moxalactam mechanisms of action, 793 T. vaginalis, 1323 B. catarrhalis, 259 minireview, 793 Microsporum spp. comparative activity chemoprophylaxis, 953 G2, 1586 clindamycin-gentamicin, 853 chloroquine resistance, 799 Minireviews cost analysis, 853 minireviews, 793, 799, 953, 957 antibiotic biosynthetic genes, 1472 endomyometritis, 853 treatment, 957 antifungal agents, 1 hyperbilirubinemia Marrow transplantation antimalarial agents centrifugal ultrafiltration, 1571 ganciclovir, 271 mechanisms of action, 793 P. aeruginosa filamentous forms Massularia accuminata azoles, I human granulocytes, 1565 B. gingivalis, 598 B. catarrhalis P. vulgaris, 1073 B. melaninogenicus, 598 susceptibility testing, 1747 Shigella spp., 20 ME1207 bacterial adhesion, 1603, 1609 Mtr phenotype ,-lactamases, 1421 biosynthetic genes, 1472 N. gonorrhoeae, 971 comparative activity C. trachomatis Mucor racemosus cefaclor, cefixime, and T-2525, 1421 antibodies, monoclonal, 1295 cycloheximide efflux, 341 E. coli, 1421 susceptibility testing, 1295 trichodermin, 341 H. influenzae, 1421 Campylobacter spp. Mupirocin N. gonorrhoeae, 1421 resistance mechanisms, 1107 comparative activity P. cepacia, 1421 chloroquine erythromycin, 1780 P. rettgeri, 1421 mechanism of resistance, 799 impetigo, 1780 S. pneumoniae, 1421 H. influenzae Mycobacterium avium Staphylococcus spp., 1421 susceptibility testing, 1747 amikacin, 1131 Measles virus malaria, 793, 799 capreomycin, 1131 P-536, 1257 chemoprophylaxis, 953 ethionamide, 1131 Mebendazole treatment, 957 isoniazid, 1131 T. vaginalis, 144 mixed aerobic-anaerobic infections, 611 kanamycin, 1131 Mefloquine N. gonorrhoeae rifampin, 1131 polymorphonuclear neutrophils, 1124 susceptibility testing, 1747 streptomycin, 1131 Meningitis P. falciparum, 799 susceptibility testing, 1131 coccidioidal pharmacokinetics Mycobacterium avium complex fluconazole, 369 outcome of infections, 289 acquired immune deficiency syndrome, gentamicin Plasmodium spp., 793 1392 cerebrospinal fluid penetration, rhinovirus colds chemotherapy, 409 amikacin, 886, 1149, 1400 1034 Streptomyces spp. amikacin-clofazimine, 1400 H. influenzae, 1034 cloned genes, 1465, 1472 amikacin-clofazimine-rifabutin, 1400 K. pneumoniae, 1705 recombinant DNA systems, 1465 amikacin-rifabutin, 1400 temocillin, 1705 susceptibility testing amikacin-tumor necrosis factor, 1149 Methicillin B. catarrhalis, 1747 azithromycin, 1149 dysgonic fermenter 2, 78 H. influenzae, 1747 azithromycin-tumor necrosis factor, Methylenepenams N. gonorrhoeae, 1747 1149 antibacterial properties, 1005 triazoles, I clofazime-ethambutol, 1392 Methylglyoxal bis(guanylhydrazone) Minocycline clofazimine-ciprofloxacin, 1392 P. carinii, 896 C. trachomatis, 1080, 1350 ethambutol-ciprofloxacin, 1392 3-Methylhypoxanthine comparative activity ethambutol-erythromycin, 1392 influenza viruses, 906 demeclocycline, doxycycline, erythro- ethambutol-rifampin, 1392 5-Methylthioribose analogs mycin, nalidixic acid, oxytetracy- ethambutol-rifampin-ciprofloxacin, 1392 G. lamblia, 1904 cline, rifampin, and tetracycline, ethambutol-rifampin-ciprofloxacin-eryth- 0. malhamensis, 1904 986 romycin, 1392 P. falciparum, 1904 E. risticii, 986 ethambutol-rifampin-erythromycin, 1392 3'-C-Methyluridine H. ducreyi, 1458 fatty acids, 400 influenza viruses, 906 N. asteroides, 1776 model man, 886 Metronidazole P. multocida, 213 rifabutin-ciprofloxacin, 1392 combinations Miocamycin rifabutin-clofazimine, 1392 enterococci, 1769 comparative activity, 1710 rifabutin-ethambutol, 1392 streptomycin, 1769 Mixed infections rifampin-ciprofloxacin, 1392 enterococci, 1769 aerobic-anaerobic, 611 rifampin-erythromycin, 1392 T. vaginalis, 144, 1323 minireview, 611 roxithromycin, 1149 Mezlocillin Morganella morganii roxithromycin-tumor necrosis factor, B. catarrhalis, 259 ampicillin, 1385 1149 Bacillus spp., 642 P-lactam resistance, 1385 Mycobacterium avium-M. intracellulare combinations P-lactamase, 1385 amikacin, 1404 ciprofloxacin, 782 carbenicillin, 1385 liposome encapsulated, 1404 xxiv SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Mycobacterium leprae Nauclea latifolia Nifurtimox clarithromycin, 1758 B. gingivalis, 598 immune response, effect on, 241 clofazimine, 1583 B. melaninogenicus, 598 T. cruzi, 241 erythromycin, 1758 Neisseria gonorrhoeae Nigerian chewing sticks phenazines, 1583 A-61827, 27 B. gingivalis, 598 roxithromycin, 1758 azithromycin, 752 B. melaninogenicus, 598 Mycobacterium smegmatis ,B-lactamases, 158, 1430 Nitrosoureas cyclohexane triones, 814 cefodizime, 426 amphQtericin B Mycobacterium spp. cefotaxime, 426 C. albicans, 327 dihydromycoplanecin A, 110 DNA gyrase inhibitors, 1788 Nocardia asteroides Mycobacterium tuberculosis genetic transformation, 1788 amikacin, 1776 A-56620, 1441 imipenem-cilastatin, 773 ampicillin, 1776 ATP bioluminescence assay, 1208 letters to the editor, 158, 951 1-lactamase, 1776 cefonicid, 1441 ME1207, 1421 carbenicillin, 1776 ceforanide, 1441 minireview, 1747 cefotaxime, 1776 cefotaxime, 1441 Mtr phenotype, 971 ceftriaxone, 1776 cefpirome, 1441 PD 117,596, 1450 ciprofloxacin, 1776 ceftizoxime, 1441 R-3746, 671 erythromycin, 1776 cephapirin, 1441 R plasmids, 158, 488 gentamicin, 1776 difloxacin, 1441 transfer to Neisseria spp., 1430 imipenem, 1776 ethambutol, 1208, 1441 susceptibility testing, 1747 kanamycin, 1776 imipenem, 1441 T-3262, 663 minocycline, 1776 isoniazid, 1208, 1441 tetracycline resistance, 488, 951 sulfamethoxazole, 1776 letter to the editor, 287 trospectomycin, 216 susceptibility patterns, 1776 PD 127,391, 1251 Neisseria meningitidis Nocardia spp. pyrazinamide, 125, 287 azithromycin, 752 A-56620, 1078 pHs, different, 1002 cefixime, 1896 A-62254, 1078 radiometric method, 1002 cefpodoxime, 1896 amifloxacin, 1078 rifampin, 1208, 1441 ceftriaxone, 18% cefepime, 1078 SK&F 88070, 1441 ciprofloxacin, 1740 cefpirome, 1078 streptomycin, 1208, 1441 penicillin resistance, 706 ciprofloxacin, 1078 susceptibility testing, 125 R plasmid difloxacin, 1078 Mycoplasma hominis transfer from N. gonorrhoeae, 1430 enoxacin, 1078 A-63075, 1500 Neisseria perflava-N. sicca imipenem, 1078 clarithromycin, 1500 tetracycline PD-1 17558, 1078 difloxacin, 1500 resistance, 1271 RO 23-6240, 1078 erythromycin, 1500 Neisseria spp. S-25930, 1078 1500 ceftibuten, 1576 S-25932, 1078 temafloxacin, E-1040, 1666 Nonoxynol-9 Mycoplasma pneumoniae lomefloxacin, 617 T. vaginalis, 1323 A-63075, 1500 PD 127,391, 1251 Norfloxacin clarithromycin, 1500 R plasmid, 488, 765 A. denitrificans subsp. xylosoxidans, 276 difloxacin, 1500 transfer from N. gonorrhoeae, 1430 B.fragilis, 1437, 1869 erythromycin, 1500 tetracycline resistance, 488, 765 binding to feces, 1869 temafloxacin, 1500 tigemonam, 84 Bordetella spp., 137 U-76,253A, 443 C. trachomatis, 1080, 1350, 1735 Naegleria fowleri Neomycin C. freundii resistance, 922 acrolein, 962 B. bronchiseptica, 1891 cleavable-complex assay, 1086 cyclophosphamide, 962 Nephrotoxicity comparative activity Nafcillin apalcillin, 942 amifloxacin, ciprofloxacin, enoxacin, hyperbilirubinemia cefazolin, 314 and ofloxacin, 928 centrifugal ultrafiltration, 1571 cefoperazone, 314 doxycycline and minocycline, 1735 Nalidixic acid ceftazidime, 314 tobramycin, 1820 B. bronchiseptica, 1891 cephaloglycin, 314 conjunctivitis, 1820 cleavable-complex assay, 1086 cephaloridine, 314, 912 E. coli, 1292 cephalothin, 314 endogenous active efflux, 1187 comparative activity gentamicin, 912 E. faecium, 1869 ciprofloxacin, enoxacin, norfloxacin, hydrocortisone, influence of, 992 fecal binding, 1869 and ofloxacin, 1285 Neplanocin A gram-negative bacteria, 1292 demeclocycline, doxycycline, erythro- influenza viruses, 906 gram-positive bacteria, 1292 mycin, minocycline, oxytetracy- Neplanocin C H. influenzae, 1820 cline, rifampin, and tetracycline, influenza viruses, 906 Haemophilus spp., 147 986 Netilmicin ocular infections, 1820 E. faecalis resistance, 1285 A. denitrificans subsp. xylosoxidans, P. aeruginosa, 1292 E. risticii, 986 276 P. falciparum, 1182 Enterobacteriaceae resistance, 1285 B. catarrhalis, 259 P. maltophilia, 782 fecal flora resistance, 1801 cardiopulmonary bypass, 631 P. pseudomallei, 928, 1435 GABA receptor, 1624 K. pneumoniae resistance, 1379 S. aureus, 1192, 1820 P. aeruginosa resistance, 1285 pharmacokinetics, 631 S. pneumoniae, 1820 P. falciparum, 1182 S. marcescens resistance, 1379 Shigella spp., 20 S. aureus, 1192 Neutrophils Staphylococcus spp., 1820 resistance, 1285 clindamycin streptococci, alpha-hemolytic, 1820 Shigella spp., 20 periodontal bacteria, 1521 theophylline pharmacokinetics, 510 VOL. 32, 1988 SUBJECT INDEX xxv

urinary tract infections, 1292 Osteomyelitis cefaclor, 213 L-Norvalyl-L-chlorovinylglycine enoxacin, 834 cefadroxil, 213 comparative activity, 319 vancomycin bone concentrations, 1320 cefuroxime, 213 gram-positive bacteria, 319 Outer membrane cephalexin, 213 Staphylococcus spp., 319 permeability chloramphenicol, 213 Nosocomial infections P. aeruginosa, 1267 clindamycin, 213 Staphylococcus spp., 202 P. cepacia, 1636 daptomycin, 1354 Novobiocin proteins erythromycin, 213 A. lignieresii, 1354 E. coli, 1879 minocycline, 213 B. bronchiseptica, 1891 iron regulated, 1879 novobiocin, 1354 P. falciparum, 1182 Oxacillin oxacillin, 213 P. multocida, 1354 Bacillus spp., 642 penicillin, 213 Nucleic acid synthesis bactericidal testing, 1614 phospholipid composition, 1354 bacterial adhesion, 1609 coagulase-negative staphylococcal sus- polymyxin, 1354 minireview, 1609 ceptibility, 1754 rifamycin, 1354 NY-198 P. multocida, 213 tetracycline, 213 B. fragilis, 1437 S. aureus, 1614 trimethoprim-sulfamethoxazole, 213 C. trachomatis, 1080, 1735 MBCs, 374 Pasteurella spp. comparative activity susceptibility, 1754 P-lactamase, 1282 ciprofloxacin, 1427 Oxetanocin G R plasmid, 1282 doxycycline and minocycline, 1735 cytomegalovirus, 1053 PD-1 17558 Legionella spp., 1427 Oxolinic acid Nocardia spp., 1078 Legionnaires disease, 1427 B. bronchiseptica, 1891 PD 117,596 pharmacokinetics, 156, 1427 cleavable-complex assay, 1086 Acinetobacter spp., 1450 P. falciparum, 1182 B. catarrhalis, 1450 Ochromonas malhamensis Oxyimino-cephalosporins C. jejuni, 1450 5-methylthioribose analogs, 1904 ,B-lactamase, 1243 comparative activity Ocular infections E. coli, 1243 amikacin, aztreonam, cephalothin, CI H. influenzae, 1820 Oxytetracycline 934, ciprofloxacin, imipenem, and norfloxacin, 1820 B. bronchiseptica, 1891 piperacillin, 1450 S. aureus, 1820 comparative activity Corynebacterium spp., 1450 S. pneumoniae, 1820 demeclocycline, doxycycline, erythro- E. coli, 1450 Staphylococcus spp., 1820 mycin, minocycline, nalidixic Enterobacter spp., 1450 streptococci, alpha-hemolytic, 1820 acid, rifampin, and tetracycline, Enterococcus spp., 1450 tobramycin, 1820 986 Haemophilus spp., 1450 Ofloxacin E. risticii, 986 Klebsiella spp., 1450 A. denitrificans subsp. xylosoxidans, L. pneumophila, 1450 276 P-536 N. gonorrhoeae, 1450 B. fragilis, 1437 encephalomyocarditis virus, 1257 P. mirabilis, 1450 bite wound bacteria, 1143 influenza virus, 1257 Pseudomonas spp., 1450 measles virus, 1257 S. aureus, 1450 Bordetella spp., 137 S. marcescens, 1450 C. 1350, 1735 poliovirus type 1, 1257 trachomatis, 1080, T. cruzi, 1412 Streptococcus spp., 1450 C. freundii resistance, 922 type 5, 1257 PD 127,391 cleavable-complex assay, 1086 herpes simplex virus type 1, 1257 B. fragilis, 1251 comparative activity UDP-glucose analog, 1257 C. trachomatis, 1251 amifloxacin, ciprofloxacin, enoxacin, vaccinia virus, 1257 comparative activity and norfloxacin, 928 vesicular stomatitis virus, 1257 ceftazidime, ciprofloxacin, gentamicin, doxycycline and minocycline, 1735 PADAC and imipenem, 1278 cystitis, 1640 P-lactamase assay, 1040 cefuroxime, ciprofloxacin, gentamicin, cytogenetic effects, 936 Paldimycin nalidixic acid, and ofloxacin, 1251 DR-3355 isomer, 1336 Actinomyces spp., 788 Enterobacteriaceae, 1251 E. coli, 1640 Bifidobacterium spp., 788 gram-negative aerobes, 1278 GABA receptor, 1624 Clostridium spp., 788 gram-positive aerobes, 1278 Haemophilus spp., 147 comparative activity H. influenzae, 1251 P. falciparum, 1182 daptomycin, penicillin, and vancomy- M. tuberculosis, 1251 P. pseudomallei, 928 cin, 788 Neisseria spp., 1251 pharmacokinetics, 1590, 1640 Eubacterium spp., 788 P. aeruginosa, 1251, 1278 S. aureus, 1192 Lactobacillus spp., 788 Pseudomonas spp., 1278 spp., 788 S. pneumoniae, 1251 Shigella spp., 20 Peptostreptococcus Staphylococcus spp., 1251 Oleandomycin Propionibacterium spp., 788 Pediatric infections Arthrobacter spp., 420 Pap fimbrial adhesion LY163892, 268 Staphylococcus spp., 420 berberine sulfate, 1274 Pefloxacin Oligonucleotide probes Paradoxical effect A. denitrificans subsp. xylosoxidans, ,3-lactamases, 397 P-lactams, 1073 276 comparative studies, 397 P. vulgaris, 1073 B. catarrhalis, 259 Open-heart surgery Parainfluenza virus C. trachomatis, 1350 flucloxacillin, 930 sulfated polysaccharides, 1742 combinations Oral bacteria Pasteurella multocida endocarditis, 919 tetracycline resistance, 1271 actinomycin D, 1354 fosfomycin, 919 Ornithine decarboxylase inhibitors amoxicillin-clavulanic acid, 213 S. aureus, 919 T. gondii, 303 ampicillin, 213 comparative activity xxvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

amikacin-ceftazidime, 231 Percutaneous transhepatic biliary drainage norfloxacin, 510 ceftazidime-amikacin, 231 cefotiam, 726 tobramycin endocarditis, 231, 919 sulbenicillin, 726 charcoal, effect of, 274 GABA receptor, 1624 ursodeoxycholate, 726 trimethoprim-sulfamethoxazole, 1640 Haemophilus spp., 147 Periodontal disease trimetrexate, 324 P. aeruginosa, 231 A. actinomycetemcomitans, 1521 tromethamine fosfomycin, 938 resistance, development of, 231 C. ochracea, 1521 vancomycin, 92, 631, 848 P. falciparum, 1182 clindamycin, 1521 vancomycin-ceftazidime, 92 S. aureus, 919 E. corrodens, 1521 PhastSystem Shigella spp., 20 tetracycline resistance, 1271 13-lactamases, 1730 Penems Pharmacokinetics Phenazines protein binding, 159 A40926, 246 M. leprae, 1583 spectrophotometric assay, 159 amdinocillin pivoxil structure-activity relationships, 1583 Penicillin influence of food, 592 Pheromones B. catarrhalis, 259 amikacin, 236 S. faecalis, 547 Bacillus spp., 642 amopyroquin, 568 Phlebovirus biosynthesis apalcillin, 942 ribavirin, 331 P. chrysogenum glucokinase-deficient calcium fosfomycin, 938 Phosphatidylcholine mutant, 1061 carumonam, 354 liposomes, 966 Chlamydia sp. strain TWAR, 257 cefazolin, 33 T. b. gambiense, 966 dysgonic fermenter 2, 78 cefetamet, 573 Phospholipids H. ducreyi, 1458 cefetamet pivoxil, 573 A. lignieresii, 1354 H. influenzae, 498 cefonicid, 485 P. multocida, 1354 N. meningitidis resistance, 706 protein binding, 128 Phosphonoacetate P. multocida, 213 cefoperazone, 42 herpes simplex virus type 2, 858 S. aureus resistance, 1164 cefoperazone-sulbactam, 42, 503, 730 liposomes, 858 T. vaginalis, 1323 continuous ambulatory peritoneal dial- Phosphonoformate Penicillin G ysis, 51 herpes simplex virus type 2, 858 bite wound bacteria, 1143 cefotaxime liposomes, 858 methylene analogs protein binding, 128 Phosphonylmethoxyethyl purines antibacterial properties, 1005 cefpiramide, 33, 1360 human immunodeficiency virus, 1025 Penicillinase cefpirome, 13% Pipemidic acid P. cepacia, 838 ceftazidime, 1845 C. trachomatis, 1080 Penicillin-binding proteins ceftazidime-vancomycin, 92 Piperacillin B. fragilis, 1848 ceftizoxime A. denitrificans subsp. xylosoxidans, 276 H. influenzae, 498 protein binding, 128 B. catarrhalis, 259 Penicillium chrysogenum ciprofloxacin, 949, 982, 1537 cephaloridine nephrotoxicity, 912 P-galactosidase activity, 1061 clindamycin, 1825 combinations glucokinase-deficient mutant, 1061 dihydromycoplanecin A, 110 ciprofloxacin, 782 penicillin biosynthesis, 1061 erythromycin estolate, 561 P. maltophilia, 782 Pentamidine erythromycin ethylsuccinate, 561 dysgonic fermenter 2, 78 comparative activity fleroxacin, 1515 gentamicin nephrotoxicity, 912 dapsone, trimethoprim-dapsone, and fluconazole, 209, 369 P. maltophilia, 782 trimethoprim-sulfamethoxazole, flurithromycin, 1875 P. pseudomallei, 1435 623 ganciclovir, 1899 P. vulgaris, 1073 P. carinii, 623, 896, 1490 gentamicin, 467, 736 Piritrexim pharmacokinetics, 1490 ±2HM-HBG, 1807 P. carinii, 430 pneumonia, 623, 1490 (R,S)-9-[4-hydroxy-2(hydroxymethyl) T. gondii, 430 Pentosan polysulfate butyl]guanine, 1807 Plasma bactericidal activity cytomegalovirus, 1742 imipenem-cilastatin, 530 erythromycin estolate, 1227 herpes simplex virus, 1742 itraconazole, 1310 erythromycin ethylsuccinate, 1227 human immunodeficiency virus, 1742 renal dysfunction, 1595 Plasmids vesicular stomatitis virus, 1742 ketoconazole, 209 1-lactamases, 175, 1730 Pentostam letter to the editor, 949 DNA probes, 175 P. carinii, 896 lipid X, 37 resistance Pentylenetetrazole lomefloxacin, 1503, 1508 Acinetobacter spp., 15 BMY-26225, 758 LY163892, 1738 C. coli, 1170 cefazolin, 758 mezlocillin, 777 C. difficile, 1213 convulsive threshold, 758 minireview, 289 C. freundii, 9 imipenem-cilastatin, 758 monoclonal anti-lipid A antibody, 710 C. jejuni, 1170 rat model, 758 netilmicin, 631 E. aerogenes, 9 Peptidoglycan synthesis NY-198, 156, 1427 E. coli, 9, 1243, 1552 bacterial ofloxacin, 1590, 1640 E. corrodens, 765 adhesion, 1609 outcome of infections, 289 Enterobacteriaceae, 1289 minireview, 1609 pentamidine, 1490 Enterococcus spp., 1793 Peptococcus spp. ribavirin aerosol, 117 K. denitrificans, 765 DR-3355, 1336 rimantadine, 1699, 1813 K. pneumoniae, 9, 626, 1379, 1416, Peptostreptococcus anaerobius roxithromycin, 1461 1660 tetracycline sulbactam, 42 letter to the editor, 158 resistance, 1271 teicoplanin, 1223 N. gonorrhoeae, 158, 488, 1430 Peptostreptococcus spp. temocillin, 1705 Neisseria spp., 488, 765 daptomycin, 788 theophylline P. morganii, 9 paldimycin, 788 ciprofloxacin, effect of, 75 Pasteurella spp., 1282 VOL. 32, 1988 SUBJECT INDEX xxvii

S. aureus, 932, 1164, 1174 pneumonia, 623, 896, 1057, 1490 Propionibacterium spp. S. faecalis, 547, 1528 primaquine, 807 daptomycin, 788 S. marcescens, 9, 1289, 1379, 1834 primaquine-clindamycin, 807 paldimycin, 788 S. sonnei, 1598 pyrimethamine, 96 Prostatic tissue S. wien, 1262 quinacrine, 896 enoxacin concentrations, 1433 Staphylococcus spp., 1494 quinapyramine, 896 Protein synthesis Streptococcus spp., 1793 quinidine, 896 bacterial adhesion, 1603 sulfonamides, 1684 quinine, 896 minireyiew, 1603 Plasmodium berghei spectinomycin, 896 Proteus mirabilis cyclosporine, 462 spiramycin, 896 CS-807, 1082 stage-selective inhibition, 462 sulfadiazine, 96 cystitis, 636 Plasmodium falciparum sulfadoxine, 96 E-3846, 636 amifloxacin, 1182 sulfamethoxazole, 96 PD 117,596, 1450 amopyroquin, 568 suramin, 1158 pyelonephritis, 636 B. javanica, 1725 trimethoprim, 96 R-3746, 671 2-bromo-L-histidine, 1655 trimethoprim-dapsone, 623 U-76,252, 1082 2-chloro-L-histidine, 1655 trimethoprimn-sulfamethoxazole, 623, YTR 830, 925 chloroquine resistance, 799 1158 Proteus morganii cinchonidine, 250 trimetrexate, 324 R plasmids, 9 cinchonine, 250 Pneumonia Proteus spp. ciprofloxacin, 1182 dapsone, 1057 tigenionam, 84 coumermycin A, 1182 P. carinii, 1057, 1490 trospectomycin, 216 enoxacin, 1182 dosages and intervals, 623 Proteus vulgaris 2-fluoro-L-histidine, 1655 pentamidine, 1490 ampicillin, 1385 histidine analogs, 1655 Poliovirus f-lactamases, 1073, 1385 inositol hexaphosphate, 391 sulfated polysaccharides, 1742 1-lactams 2-iodo-L-histidine, 1655 type I paradoxical effect, 1073 5-methylthioribose analogs, 1904 P-536, 1257 resistance, 1385 minireview, 799 Polycystic kidney disease carbenicillin, 1385 nalidixic acid, 1182 ciprofloxacin, 844 cefbuperazone, 1073 norfloxacin, 1182 Polyisohexylcyanoacrylate cefmenoxime, 1073 novobiocin, 1182 ampicillin binding cefmetazole, 1073 ofloxacin, 1182 L. monocytogenes, 1204 cefoperazone, 1073 oxolinic acid, 1182 Polymorphonuclear leukocytes cefotaxime, 1073, 1385 pefloxacin, 1182 amphotericin B, 1864 cefotiam, 1073 quassinoids, 1725 miconazole, 1864 cefoxitin, 1385 quinidine, 250 P. aeruginosa ceftazidime, 1073 quinine, 250 moxalactam-induced filamentous ceftizoxime, 1073 S. amara, 1725 forms, 1565 ceftriaxone, 1073, 1385 WR 194,965 phosphate, 540 Polymorphonuclear neutrophils cefuroxime, 1073 Plasmodium spp. amodiaquine, 1124 cefuzonam, 1073 antimalarial agents chloroquine, 1124 cephaloridine, 1073, 1385 mechanisms of action, 793 mefloquine, 1124 cephalothin, 1073 minireview, 793 Polymyxin imipenem, 1385 minireview, 793 A. lignieresii, 1354 mezlocillin, 1385 Pneumococci E. coli, 308 moxalactam, 1073 U-76,253A, 443 P. multocida, 1354 piperacillin, 1073 Pneumocystis carinii Polymyxin B R-3746, 671 acquired immunodeficiency syndrome, B. bronchiseptica, 1891 Prothrombin 1057 Polyvinylpyrrolidone cefotetan effect, 1446 amicarbalide, 896 Enterobacteriaceae, 873 cefoxitin effect, 1446 ampicillin, 896 Porins Providencia rettgeri Astiban, 896 P. cepacia, 1636 ME1207, 1421 chloramphenicol, 896 Postantibiotic effect Providencia spp. chlorpromazine, 896 ampicillin, 450 R-3746, 671 clind4mycin, 807 ciprofloxarin, 450 tigemonam, 84 clindamycin-primaquine, 807 E. coli, 450 PSE-2 dapsone, 96, 623, 1057, 1158 tobramycin, 450 sequence, 134 dapsone-trimethoprim, 623 Pseudomonas aeruginosa dehydroemetine, 896 Primaquine A-61827, 27 diaveridine, 96 combinations amikacin-ceftazidime, 231 difluoromethylornithine, 896 clindamycin, 807 resistance, development of, 231 DL-a-difluoromethylornithine, 1158 P. carinii, 807 aminoglycoside resistance, 689 diminazene, 896 P. carinii, 807 ampicillin, 552 aceturate, 1158 Pristinamycin antibodies ethidium, 896 aerobic bacteria, 1094 monoclonal, 649 gentamicin, 896 comparative activity aztreonam, 552 imidocarb, 896 cefoxitin, chloramphenicol, clindamy- P-lactamases, 1443 isom.etamidium, 896 cin, metronidazole, penicillin, heterogeneity, 1893 methylglyoxal bis(guanylhydrazone), 896 pristinamnycin group IA, and carumonam, 1593 pentamidine, 623, 896, 1490 pristinamycin group IIA, 1094 cefepime resistance, 1443 Pentostam, 896 Procaine cefixime, 1896 piritrexim, 430 E. coli permeability, 153 cefoperazone-ceftazidime, 298 xxviii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

cefotaxime resistance, 1443 difloxacin, 782 Quinacrine cefpirome, 1396 gentamicin, 782 P. carinii, 896 cefpodoxime, 1896 imipenem, 782 Quinapyramine ceftazidime resistance, 1443 mezlocillin, 782 P. carinii, 896 ceftazidime-amikacin, 231 norfloxacin, 782 Quinidine resistance, development of, 231 piperacillin, 782 P. carinii, 8% ceftazidime-cefoperazone, 298 Sch 34343, 782 P. falciparum, 250 ceftriaxone, 552, 1896 T-3262, 663 Quinine ciprofloxacin resistance, 535 ticarcillin, 782 E. coli permeability, 153 CS-807, 1082 tobramycin, 782 P. carinii, 896 cystitis, 636 Pseudomonas pseudomallei P. falciparum, 250 DuP 105, 580 amifloxacin, 928 Quinolones DuP 721, 580 amoxicillin, 1435 C. freundii resistance, 922 E1040, 693, 1666 amoxicillin-clavulanic acid, 1435 cleavable-complex assay, 1086 E-3846, 636 carumonam, 1435 DNA gyrase resistance, 104 endocarditis, 231 cefotaxime, 1435 DNA synthesis, 1113 enhanced antibiotic binding, 649 ceftazidime, 1435 E. coli, 1113 etoposide, 1456 ceftriaxone, 1435 permeation, 438 fluoroquinolone resistance, 1285 ciprofloxacin, 928, 1435 fecal binding, 1869 gentamicin, 552 enoxacin, 928 GABA receptor, 1624 imipenem resistance, 1267 imipenem, 1435 y-aminobutyric acid receptor, 1624 immunoblotting, 649 norfloxacin, 928, 1435 inhibition of y-aminobutyric acid binding in vitro simulation of serious infections, ofloxacin, 928 to receptor sites, 190 552 piperacillin, 1435 P. aeruginosa resistance, 785 keratitis, 978 ticarcillin, 1435 liposome-swelling assay, 1267 ticarcillin-clavulanic acid, 1435 R-3746 lomefloxacin, 617 Pseudomonas spp. Bacteroides spp., 671 moxalactam-induced filamentous forms amiloride, 395 Branhamella spp., 671 human granulocytes, 1565 cystic fibrosis, 395 C. diversus, 671 norfloxacin, 1292 E-1040, 1666 C. freundii, 671 outer membrane lomefloxacin, 656 Clostridium spp., 671 permeability, 1267 PD 117,5%, 1450 comparative activity proteins, 785 PD 127,391, 1278 amoxicillin-clavulanic acid, cefaclor, PD 127,391, 1251, 1278 R-3746, 671 cefixime, cephalexin, and trimeth- pefloxacin, 231 tigemonam, 84, 346 oprim-sulfamethoxazole, 671 pyelonephritis, 636 tobramycin, 395 E. aerogenes, 671 quinolone resistance, 785 U-76,253A, 443 E. cloacae, 671 T-3262, 663, 827 Puerperal infections E. coli, 671 tobramycin, 978 letter to the editor, 407 Enterococcus spp., 671 binding to alginate, 518 ticarcillin-clavulanic acid, 407 H. influenzae, 671 tolA mutant, 649 Pulmonary aspergillosis K. pneumoniae, 671 U-76,252, 1082 Pseudomonas cepacia amphotericin B, 1676 Morganella spp., 671 ,B-lactam resistance, 1636 Punta Toro virus N. gonorrhoeae, 671 P-lactamase, 838 ribavirin, 331 P. mirabilis, 671 cystic fibrosis, 1636 Pyelonephritis P. vulgaris, 671 E-1040, 1666 daptomycin, 81 Providencia spp., 671 ME1207, 1421 daptomycin-gentamicin, 81 Pseudomonas spp., 671 outer membrane permeability, 1636 E-3846, 636 S. marcescens, 671 penicillinase, 838 gentamicin, 81, 736 S. pneumoniae, 671 porins, 1636 gentamicin-daptomycin, 81 Salmonella spp., 671 T-3262, 663 S. faecalis, 81 Shigella spp., 671 Pseudomonas maltophilia Pyrazinamide streptococci, 671 A-56620, 782 letter to the editor, 285 Yersinia spp., 671 amikacin, 782 M. tuberculosis, 125, 285 Radiochemical method aztreonam, 782 pHs, different, 1002 E. coli biofilms, 770 P-lactamase radiometric method, 1002 Radiometric method cloning of operon on E. coli, 819 susceptibility testing, 125 M. tuberculosis, 125 carbenicillin, 782 Pyrazofurin pyrazinamide, 125 cefoperazone, 782 influenza viruses, 906 Rat granuloma pouch cefsulodin, 782 ceftazidime, 782 Pyridinium-2-azo-p-dimethylaniline chro- cefpirome, 1396 ciprofloxacin, 782 mophore Recombinant DNA ciprofloxacin-amikacin, 782 P-lactamase assay, 1040 minireview, 1465 ciprofloxacin-aztreonam, 782 Pyrimethamine Streptomyces spp., 1465 ciprofloxacin-cefoperazone, 782 P. carinii, 96 Renal cyst infection ciprofloxacin-cefsulodin, 782 T. gondii, 303 ciprofloxacin, 844 ciprofloxacin-ceftazidime, 782 Pyrimidine deoxynucleotide metabolism Reovirus ciprofloxacin-gentamicin, 782 herpes simplex virus type 1, 1100 sulfated polysaccharides, 1742 ciprofloxacin-imipenem, 782 Respiratory syncytial virus ciprofloxacin-mezlocillin, 782 Quassinoids immunoglobulin, intravenous, 1269 ciprofloxacin-piperacillin, 782 E. histolytica, 1725 interferon alpha-2a, recombinant, 589 ciprofloxacin-tobramycin, 782 P. falciparum, 1725 intravenous immunoglobulin, 1269 VOL. 32, 1988 SUBJECT INDEX xxix

Reuterin M. avium, 1131 Salmonella typhimurium high-performance liquid chromatogra- M. tuberculosis, 1208, 1441 A-61827, 27 phy, 1854 Rifampin-trimethoprim allicin, 1763 isolation, 1854 comparative activity ampicillin, 57 production, 1854 sulfamethoxazole-trimethoprim, 802 chloramphenicol, 57 Reverse transcriptases urinary tract infections, 802 ciprofloxacin, 57 human immunodeficiency virus, 1887 Rifamycin diallyl thiosulfinate, 1763 human immunodeficiency virus type 1, A. lignieresii, 1354 fleroxacin, 791 684, 1733 P. multocida, 1354 letter to the editor, 791 human immunodeficiency virus type 2, Rikamycin Salmonella wien 1733 C. trachomatis, 1350 FIme plasmid, 1262 simian immunodeficiency virus, 1733, Rimantadine R plasmid, 1262 1887 metabolism, 1699 tetracycline resistance, class B, 1262 Rhinovirus pharmacokinetics, 1699, 1813 TnJO-like transposon, 1262 alpha-2b interferon, 47 RO 23-6240 Sarcina lutea colds chemotherapy, 409 C. trachomatis, 1080 etoposide, 1456 enviroxime, 890 Nocardia spp., 1078 Scrub typhus interferon, recombinant alfa-2b, 224 Rokitamycin chloramphenicol, 285 ipratropium bromide, 1644 comparative activity, 1710 ciprofloxacin, 285 minireview, 409 Rosaramicin gentamicin, 285 Ribavirin Arthrobacter spp., 420 SDZ 89-485 aerosol Staphylococcus spp., 420 S. schenckii, 1619 pharmacokinetics, 117 Rosoxacin sporotrichosis, 1619 Argentine hemorrhagic fever, 1304 C. trachomatis, 1350 Sedecamycin influenza B virus, 761 H. ducreyi, 1458 comparative activity influenza viruses, 906 Roxithromycin carbadox, lincomycin, and tiamulin, Phlebovirus, 331 Bordetella spp., 137 458 Punta Toro virus, 331 C. trachomatis, 1350 T. hyodysenteriae, 458 small-particle aerosol, 761 combinations Serindeia werneckei vesicular stomatitis virus transcription, M. avium complex, 1149 B. gingivalis, 598 492 tumor necrosis factor, 1149 B. melaninogenicus, 598 Ribonucleotide reductase comparative activity, 1710 Serratia marcescens herpes simplex virus type 1, 1100 clarithromycin and erythromycin, 1758 6'-N-acetyltransferase type 4, 1289 Rickettsia conorii M. avium complex, 1149 amikacin resistance, 1289, 1379 erythromycin, 255 M. leprae, 1758 gentamicin resistance, 1379 josamycin, 255 pharmacokinetics, 1461 kanamycin resistance, 1379 spiramycin, 255 T. gondii, 524 netilmicin resistance, 1379 Rickettsia rickettsii T. pallidum, resistant, 164 PD 117,596, 1450 erythromycin, 255 tonsillectomy, 1461 R-3746, 671 josamycin, 255 toxicity, 1541 R plasmid, 9, 1289, 1379, 1834 spiramycin, 255 tigemonam, 84 Rifabutin uptake and distribution, 1541 tobramycin resistance, 1379 combinations Serratia spp. amikacin, 1400 S-6123 E-1040, 1666 ciprofloxacin, 1392 comparative activity Serum bactericidal activity clofazimine, 1392 ampicillin, ciprofloxacin, clindamycin, cefoxitin, 1511 ethambutol, 1392 tetracycline, and trimethoprim- ceftizoxime, 1511 M. avium complex, 1392, 1400 sulfamethoxazole, 1341 SF 86-327 human immunodeficiency virus type 1, E. coli, 1341 combinations 684 Enterococcus spp., 1341 ketoconazole, 1237 Rifampin gram-negative bacteria, 1341 T. (S.) cruzi, 1237 B. bronchiseptica, 1891 H. influenzae, 1341 T. (S.) cruzi, 1237 B. catarrhalis, 259 mechanism of action, 1341 Shigella sonnei Bordetella spp., 137 Staphylococcus spp., 1341 R plasmids, 1598 C. trachomatis, 1350 Streptococcus spp., 1341 trimethoprim resistance, 1598 combinations S-25930 Shigella spp. ciprofloxacin, 1392 Nocardia spp., 1078 amikacin, 20 erythromycin, 1392 S-25932 ampicillin, 20 ethambutol, 1392 Nocardia spp., 1078 ampicillin-sulbactam, 20 M. avium complex, 1392 S26308 cefamandole, 20 trimethoprim, 802 678 cefoperazone, 20 urinary tract infections, 802 cytomegalovirus, cefotaxime, 20 comparative activity interferon, 678 ceftazidime, 20 demeclocycline, doxycycline, erythro- Saccharomyces cerevisiae ceftriaxone, 20 mycin, minocycline, nalidixic cilofungin, 1331 cefuroxime, 20 acid, oxytetracycline, and tetracy- Salmonella paratyphi A cephalothin, 20 cline, 986 ampicillin resistance, 195 chloramphenicol, 20 dysgonic fermenter 2, 78 cross-resistant mutant, 195 ciprofloxacin, 20 E. coli mutation, pleiotropic, 195 enoxacin, 20 heat treatment, 1680 Salmonella spp. gentamicin, 20 E. risticii, 986 lomefloxacin, 656 kanamycin, 20 H. ducreyi, 1458 R-3746, 671 lomefloxacin, 656 H. influenzae, 180 tigemonam, 84 moxalactam, 20 xxx SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

nalidixic acid, 20 Sporotrichosis daptomycin, 63, 279 norfloxacin, 20 amphotericin B, 1619 disodium EDTA, 1627 ofloxacin, 20 itraconazole, 1619 DuP 105, 580 pefloxacin, 20 SDZ 89-485, 1619 DuP 721, 580 R-3746, 671 terbinafine, 1619 endocarditis, 63 streptomycin, 20 Staphylococcus aureus methicillin resistance sulfanmethoxazole, 20 A-61827, 27 cloning in S. carnosus, 1494 tetracycline, 20 acriflavin resistance, 932 R plasmid, 1494 tigemonam, 84 acrinol resistance, 932 T-3262, 661 trimethoprimn, 20 amikacin resistance, 932 vancomycin, 63, 1627 trimethoprim-sulfamethoxazole, bactericidal testing, 1614 Staphylococcus spp. 20 benzalkonium chloride resistance, 932 A-61827, 27 Simarouba amara ,-lactamase, 1614, 1754 carbomycin, 420 E. histolytica, 1725 transposon, 1164 cefixime, 18% P. falciparum, 1725 cefazolin, 262 cefpodoxime, 18% quassinoids, 1725 cefotaxime-chloramphenicol, 1375 ceftriaxone, 1896 Simian immunodeficiency virus cefpirome, 13% celesticetin, 420 3'-azido-3'-deoxythyiidine triphosphate, ceftriaxone-chloramphenicol, 1375 cephalexin hydrochloride, 882 1733 cephalexin hydrochloride, 882 cephalexin monohydrate, 882 AZT triphosphate, 1733 cephalexin monohydrate, 882 clindamycin, 420 foscarnet, 1733 cephalosporins, 170 coagulase negative reverse transcriptase, 1733, 1887 cephalothin, 374 P-lactamase, 1754 Simian varicella-zoster virus chlorhexidine resistance, 932 oxacillin susceptibility, 1754 +2HM-HBG, 1807 cinoxacin, 1192 conjunctivitis, 1820 (R,S)-9-[4-hydroxy-2(hydroxymethyl) ciprofloxacin, 747, 1192 CS-807, 1082 butyl]guanite, 1807 conjunctivitis, 1820 daptomycin, 24, 279 Sindbis virus daptomycin, 279, 454 DR-3355, 1336 carrageenans, 1742 difloxacin, 262 DuP 105, 150 dextran sulfate, 1742 DNA gyrase, 1192 DuP 721, 150 fucoidan, 1742 DuP 105, 580 E-1040, 1666 pentosan polysulfate, 1742 DuP 721, 580 E-3846, 636 sulfated polysaccharides, 1742 endocarditis, 262, 747, 919 erythromycin, 420 SK&F 88070 enoxacin, 262 halovinylglycine compounds, 319 M. tuberculosis, 1441 ethidium bromide resistance, 932 L-norvalyl peptide derivatives, Skin infections etoposide, 1456 319 cefonicid, 485 fluoroquinolone resistance, 1285 josamycin, 420 cephalexin hydrochloride, 882 fosfomycin, 919 lincomycin, 420 cephalexin monohydrate, 882 fosfomycin-pefloxacin, 919 resistance, 420 Skin structure infections gentamicin resistance, 932, 1174 lomefloxacin, 617, 656 cefonicid, 485 imipenem sub-MICs ME1207, 1421 Sodium hydroxide digestion method killing, 1012 norfloxacin, 1820 gentamicin, 595 phagocytosis, 1012 nosocomial infections SodiUim hypochlorite serum sensitivity, 1012 cardiac surgery, 202 Enterobacteriaceae, 873 kanamycin resistance, 932 coronary angioplasty, 202 Soft tissue infections letter to the editor, 1464 ocular infections, 1820 cephalexin hydrochloride, 882 LY163892, 131 oleandomycin, 420 cephalexin monohydrate, 882 MBC reproducibility, 374 PD 127,391, 1251 Spectinomycin nalidixic acid, 1192 rosaramicin, 420 E. coli norfloxacin, 1192, 1820 S-6123, 1341 lipopolysaccharide, 1247 ocular infections, 1820 spiramycin, 420 gonorrhea ofloxacin, 1192 T-3262, 827 disk zone diameter as predictor of out- oxacillin, 374, 1614 tobramycin, 1820 come, 775 susceptibility, 1754 trospectomycin, 216 f. ducreyi, 1458 PD 117,596, 1450 tylosin, 420 P. carinii, 896 pefloxacin, 919 U-76,252, 1082 Spectrophotometric assay pefloxacin-fosfomycin, 919 U-76,253A, 443 protein binding of penems, 159 penicillin resistance, 1164 vernamycin B, 420 Spermine R plasmids, 932, 1164, 1174 Stearylamine E. coli, 308 resistance phenotype, 170 liposomes, %6 Spiramycin susceptibility testing, 1464 T. b. gambiense, 966 T-3262, 663 Arthrobacter spp., 420 tobramycin, 1820 Stomatitis, denture comparative activity, 1710 resistance, 932 C. albicans, 1859 P. carinii, 896 U-76,253A, 443 fluconazole, 1859 R. conorii, 255 vancomycin, 374, 454 Streptococci R. rickettsii, 255 Staphylococcus carnosus alpha-hemolytic Staphylococcus spp., 420 methicillin resistance. conjunctivitis, 1820 T. gondii, 303, 524 cloning from S. epidermidis, norfloxacin, 1820 Sporothrix schenckii 1494 ocular infections, 1820 amphotericin B, 1619 Staphylococcus epidermidis tobramycin, 1820 itraconazole, 1619 catheters, 1627 group B SDZ 89-485, 1619 cefamandole, 63 cefotaxime-chloramphenicol, 1375 terbinafine, 1619 cefazolin, 63 ceftriaxone-chloramphenicol, 1375 VOL . 32, 1988 SUBJECT INDEX xxxi

Streptococcus faecalis T-3262, 827 human immunodeficiency virus, 1742 P-lactamase, 122, 547, 768 tetracycline parainfluenza virus, 1742 cystitis, 636 resistance, 1271 poliovirus, 1742 daptomycin, 81, 877 tigemonam, 84, 346 reovirus, 1742 effect on translocation, 337 trospectomycin, 216 Sindbis virus, 1742 daptomycin-gentamicin, 81, 877 U-76,252, 1082 vaccinia virus, 1742 E-3846, 636 U-76,253A, 443 vesicular stomatitis virus, 1742 endocarditis, 877 Streptomyces avermitilis Sulfisoxazole erythromycin resistance, 547 avermectin production B. catarrhalis, 259 gentamicin, 81, 736 glucose metabolism, 282 Chlamydia sp. strain TWAR, 257 resistance, 547 Streptomyces spp. H. influenzae, 180 gentamicin-daptomycin, 81, 877 antibiotic biosynthetic genes, 1472 hyperbilirubinemia gentamicin-penicillin G procaine, 877 biosynthetic genes, 1472 centrifugal ultrafiltration, 1571 gentamicin-vancomycin, 877 cloned genes, 1465, 1472 Sulfonamides penicillin G procaine, 877 minireviews, 1465, 1472 dihydropteroate synthase (sullI) gene, penicillin G procaine-gentamicin, 877 recombinant DNA, 1465 1684 pheromones, 547 Streptomycin resistance plasmids, 1684 pyelonephritis, 81, 636 adenylyltransferase sulII gene R plasmid, 547 B. subtilis, 949 nucleotide sequence, 1684 vancomycin, 877 letter to the editor, 949 Suramin vancomycin-gentamicin, 877 combinations P. carinii, 1158 Streptococcus faecium enterococci, 1769 Susceptibility testing aminoglycoside resistance, 1528 streptomycin, 1769 B. catarrhalis, 1747 gentamicin resistance, 1528 enterococci, 1769 C. trachomatis, 1350 R plasmids, 1528 fecal flora resistance, 1801 minireview, 1295 Streptococcus pneumoniae M. avium, 1131 monoclonal antibodies, 1295 ampicillin, 552 M. tuberculosis, 1208, 1441 ceftibuten, 1576 aztreonam, 552 Shigella spp., 20 Enterobacteriaceae, 1365 ceftriaxone, 552 Sulbactam gram-negative bacteria, 385 conjunctivitis, 1820 bioassay, 1347 H. influenzae, 1747 daptomycin, 24 combinations chloramphenicol, 1484 gentamicin, 552 ampicillin, 1830 letter to the editor, 1464 in vitro simulation of serious infections, B. fragilis, 403 LY163892, 1477 552 B. fragilis-E. coli, 1830 M. avium, 1131 ME1207, 1421 cefoperazone, 403 M. tuberculosis, 125 norfloxacin, 1820 pharmacokinetics, 42 minireview, 1747 ocular infections, 1820 Sulbenicillin N. gonorrhoeae, 1747 PD 127,391, 1251 biliary excretion pyrazinamide, 125 R-3746, 671 ursodeoxycholate, 726 S. aureus, 1464 tigemonam, 84 percutaneous transhepatic biliary drain- T. pallidum subsp. pallidum, 68 tobramycin, 1820 age, 726 Streptococcus pyogenes Sulfadiazine T-25 A-61827, 27 P. carinii, 96 influenza viruses, 906 berberine sulfate Sulfadimethoxine T-26 fibronectin, 1370 B. bronchiseptica, 1891 influenza viruses, 906 hexadecane, 1370 Cryptosporidium sp., 1907 T-3262 host cell adherence, 1370 letter to the editor, 1907 B. catarrhalis, 663 cephalexin hydrochloride, 882 Sulfadoxine B. fragilis, 663, 1437 cephalexin monohydrate, 882 P. carinii, 96 C. trachomatis, 1080 Streptococcus sanguis T. gondii, 303 comparative activity etoposide, 1456 Sulfamethoxazole ceftazidime, ciprofloxacin, gentamicin, Streptococcus sobrinus C. trachomatis, 1350 imipenem, and ofloxacin, 663 C31G, 350 combinations ciprofloxacin, ofloxacin, norfloxacin, Streptococcus spp. trimethoprim, 802 and pipemidic acid, 827 A-61827, 27 urinary tract infections, 802 E. coli, 663, 827 C31G, 350 H. ducreyi, 1458 E. faecalis, 663 Campylobacter resistance gene, 1793 hyperbilirubinemia Enterobacteriaceae, 663, 827 ceftibuten, 1576 centrifugal ultrafiltration, 1571 Enterococcus spp., 827 CS-807, 1082 N. asteroides, 1776 H. influenzae, 663 daptomycin, 141 P. carinii, 96 N. gonorrhoeae, 663 DuP 105, 150, 580 Shigella spp., 20 P. 827 DuP 721, 150, 580 Sulfamethoxazole-trimethoprim aeruginosa, 663, E-1040, 1666 Bordetella spp., 137 P. cepacia, 663 endocarditis, 141 comparative activity P. maltophilia, 663 erythromycin estolate, 1227 rifampin-trimethoprim, 802 S. aureus, 663 erythromycin ethylsuccinate, 1227 urinary tract infections, 802 S. epidermidis, 663 lomefloxacin, 617 Sulfamonomethoxine Staphylococcus spp., 827 LY163892, 268 B. bronchiseptica, 1891 Streptococcus spp., 827 PD 117,596, 1450 Sulfated polysaccharides Talampicillin penicillin G, 141 adenovirus, 1742 dental granuloma, 566 R-3746, 671 coxsackievirus, 1742 Teicoplanin R plasmids, 1793 cytomegalovirus, 1742 combinations S-6123, 1341 herpes simplex virus, 1742 Corynebacterium group JK, 434 xxxii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

gentamicin and tobramycin, 434 Theophylline E. coli, 450 Corynebacterium group JK, 434 GABA receptor, 1624 lipopolysaccharide, 1247 pharmacokinetics, 1223 y-aminobutyric acid receptor, 1624 Enterobacteriaceae, 873 Temafloxacin pharmacokinetics H. influenzae, 1820 comparative activity ciprofloxacin, effect of, 75 iontophoretic application, 978 erythromycin, 1500 norfloxacin, 510 K. pneumoniae resistance, 1379 M. hominis, 1500 Thiamphenicol keratitis, 978 M. pneumoniae, 1500 H. ducreyi, 1458 ocular infections, 1820 U. urealyticum, 1500 Ticarcillin P. aeruginosa, 978 Temocillin B. catarrhalis, 259 alginate binding, 518 A. denitrificans subsp. xylosoxidans, dysgonic fermenter 2, 78 P. maltophilia, 782 276 Enterobacteriaceae, 873 pharmacokinetics infusion system, 1705 P. maltophilia, 782 charcoal, effect of, 274 K. pneumoniae, 1705 P. pseudomallei, 1435 postantibiotic effect, 450 meningitis, 1705 Ticarcillin-clavulanic acid Pseudomonas spp., 395 pharmacokinetics, 1705 A. denitrificans subsp. xylosoxidans, 276 S. aureus, 1820 Terbinafine B. catarrhalis, 259 resistance, 932 Aspergillus spp., 780 Bacillus spp., 642 S. marcescens resistance, 1379 comparative activity comparative activity S. pneumoniae, 1820 amphotericin B and ketoconazole, 780 clindamycin-amikacin, 1557 Staphylococcus spp., 1820 S. schenckii, 1619 head and neck surgery in cancer streptococci, alpha-hemolytic, 1820 sporotrichosis, 1619 patients, 1557 Tobramycin-ampicillin Terminalia glaucescens letter to the editor, 407 biliary tract infections, 1231 B. gingivalis, 598 P. pseudomallei, 1435 comparative activity B. melaninogenicus, 598 puerperal infections, 407 cefoperazone, 1231 Testosterone wound infections, 1557 Tonsillectomy fluconazole, 646 Ticarcillin-potassium clavulanate erythromycin ketoconazole, 646 Enterobacteriaceae resistance, 1365 acistrate, 1019 Tetracaine Tigemonam stearate, 1019 E. coli permeability, 153 A. hydrophila, 84 tissue and plasma concentrations, Tetracycline Acinetobacter spp., 84 1019 B. bronchiseptica, 1891 B. catarrhalis, 84 roxithromycin, 1461 B. catarrhalis, 259 Bacteroides spp., 84 Torulopsis glabrata B. fragilis resistance, 1271 C. diversus, 84 cilofungin, 1331 Bacillus spp., 642 comparative activity Total hip arthroplasty bite wound bacteria, 1143 aztreonam, cefaclor, and trimetho- vancomycin bone concentrations, 1320 Bordetella spp., 137 prim-sulfamethoxazole, 346 Toxoplasma gondii C. trachomatis, 1350 E. aerogenes, 84 A-56268, 524 Campylobacter resistance, 1793 E. cloacae, 84 azithromycin, 524, 755 Chlamydia sp. strain TWAR, 257 E. coli, 84, 346 enzyme-linked immunosorbent assay, comparative activity Enterobacter spp., 84 303 demeclocycline, doxycycline, erythro- Enterobacteriaceae, 84 ornithine decarboxylase inhibitors, 303 mycin, minocycline, nalidixic Enterococcus spp., 84 piritrexim, 430 acid, oxytetracycline, and rifam- Haemophilus spp., 84 pyrimethamine, 303 pin, 986 Klebsiella spp., 84 roxithromycin, 524 cryptic resistance determinant on Listeria spp., 84 spiramycin, 303, 524 Tn4400, 1797 Morganella spp., 84 sulfadoxine, 303 detoxification, 1797 Neisseria spp., 84 Translocation E. risticii, 986 Proteus spp., 84 enterococci, 1769 efflux, 1797 Providencia spp., 84 Treponema hyodysenteriae Eubacterium spp. resistance, 1271 Pseudomonas spp., 84, 346 sedecamycin, 458 F. nucleatum resistance, 1271 S. marcescens, 84 Treponema pallidum fecal flora resistance, 1801 S. pneumoniae, 84 erythromycin resistance, 164 H. ducreyi, 1458 Salmonella spp., 84 roxithromycin resistance, 164 H. influenzae, 180 Shigella spp., 84 Treponema pallidum subsp. pallidum letter to the editor, 951 Streptococcus spp., 84, 346 susceptibility testing, 68 N. gonorrhoeae resistance, 488, 951 Y. enterocolitica, 84 Triazoles N. perflava-N. sicca resistance, 1271 Tinidazole minireview, 1 Neisseria resistance, 488 T. vaginalis, 144 Trichodermin oral bacteria, 1271 Tobramycin M. racemosus, 341 P. anaerobius resistance, 1271 A. denitrificans subsp. xylosoxidans, Trichomonas vaginalis P. multocida, 213 276 aminoglycosides, 144 periodontal disease, 1271 B. catarrhalis, 259 amphotericin B, 1323 resistance combinations anisomycin, 144 degradation, 1797 amiloride, 395 antifungal agents, 144 E. corrodens, 765 ampicillin, 1231 P-lactams, 144 efflux, 1797 biliary tract infections, 1231 chemotaxis, 1323 K. denitrificans, 765 ciprofloxacin, 782 folic acid antagonists, 144 Neisseria spp., 765 P. maltophilia, 782 furazolidone, 144 S. wien resistance, 1262 Pseudomonas spp., 395 gentamicin, 1323 Shigella spp., 20 comparative activity imidazoles, 1323 Streptococcus spp. resistance, 1271 norfloxacin, 1820 ketoconazole, 1323 V. parvula resistance, 1271 conjunctivitis, 1820 macrolides, 144 VOL. 32, 1988 SUBJECT INDEX xxxiii

mebendazole, i44 Trypanosoma cruzi ceftazidime, 1031 metronidazole, 144, 1323 nifurtimox, 241 ciprofloxacin, 1327 miconazole, 1323 immune response, effect on, 241 Enterobacteriaceae, 1327 Nonoxynol-9, 1323 P536, 1412 gentamicin, 473 penicillin, 1323 UDP-glucose analog, 1412 norfloxacin, 1292 tinidazole, 144 Trypanosoma (Schizotrypanum) cruzi rifampin-trimethoprim, 802 Trichophyton spp. ketoconazole, 1237 sulfamethoxazole-trimethoprim, 802 G2, 1586 ketoconazole-SF 86-327, 1237 trimethoprim-sulfamethoxazole, 1327 Trimethoprim SF 86-327, 1237 Ursodeoxycholate combinations Tubercidin biliary excretion dapsone, 623 influenza viruses, 906 cefotiam, 726 P. carinii, 623 Tumor necrosis factor sulbenicillin, 726 pneumonia, 623 combinations rifampin and sulfamethoxazole, 802 amikacin, azithronycin, and Vaccinia virus urinary tract infections, 802 roxithromycin, 1149 P-536, 1257 Enterobacteriaceae, 873 M. avium complex, 1149 sulfated polysaccharides, 1742 H. ducreyi, 1458 Tylosin Vancomycin H. influenzae resistance, 477 Arthrobacter spp., 420 Bacillus spp., 642 P. carinii, 96 E. coli bone concentrations S. sonnei resistance, 1598 heat treatment, 1680 osteomyelitis, 1320 Shigella spp., 20 Staphylococcus spp., 420 total hip arthroplasty, 1320 Trimethoprim-sulfamnethoxazole cardiopulmonary bypass, 631 A. denitrificans subsp. xylosoxidans, U-76,252 catheters, 1627 276 A. hydrophila, 1082 combinations B. catarrhalis, 259 B. catarrhalis, 1082 Corynebacterium group JK, 434 Bacillus spp., 642 C. diversus, 1082 gentamicin and tobramycin, 434 comparative activity comparative activity comparative activity ciprofloxacin, 1327 amoxicillin, amoxicillin-clavulanic cefamandole, cefazolin, and daptomy- dapsone, pentamidine, and trimetho- acid, cefaclor, cefuroxime, cepha- cin, 63 prim-dapsone, 623 lexin, and erythromycin, 1082 daptomycin, 454 cystitis, 1640 E. coli, 1082 Corynebacterium group JK, 434 dysgonic fermenter 2, 78 E. faecalis, 1082 dysgonic fermenter 2, 78 E. coli, 1640 Enterobacteriaceae; 1082 E. coli Enterobacteriaceae, 1327 H. influenzae, 1082 heat treatment, 1680 H. ducreyi, 1458 Klebsiella spp., 1082 endocarditis, 63 H. influenzae, 180 P. aeruginosa, 1082 pharmacokinetics, 92, 631, 848 P. carinii, 623, 1158 P. mirabilis, 1082 S. aureus, 454 P. multocida, 213 Staphylococcus spp., 1082 MBCs, 374 pharmacokinetics, 1640 Streptococcus spp., 1082 S. epidermidis, 63, 1627 pneumonia, 623 U-76,253A Vancomycin-ceftazidime Shigella spp., 20 Acinetobacter spp., 443 pharmacokinetics, 92 urinary tract infections, 1327 B. catarrhalis, 443 Varicella-zoster virus Trimetrexate comparative activity acyclovir triphosphate, 1137 high-pressure liquid chromatography, amoxicillin, amoxicillin-clavulanic 3'-azido-3'-deoxythymidine, 265 324 acid, cefaclor, cefixime, and cef- AZT, 265 P. carinii, 324 uroxime, 443 B-220, 1720 pharmacokinetics, 324 Enterobacteriaceae, 443 buciclovir triphosphate, 1137 Tromethamine fosfomycin enterococci, 443 9-(3,4-dihydroxybutyl)guanine triphos- pharmacokinetics, 938 H. influenzae, 443 phate, 1137 young and elderly adults, 938 Neisseria spp., 443 DNA polymerases, 1137 Trospectomycin pneumococci, 443 9-[4-hydroxy-2(hydroxymethyl)butyl] B. catarrhalis, 216 Pseudomonas spp., 443 guanine triphosphate, 1137 B. fragilis, 584 S. aareus, 443 9-(2-hydroxyethoxymethyl)guanine tri- Bacteroides spp., 216, 584 Staphylococcus spp., 443 phosphate, 1137 C. trachomatis, 216 Streptococcus spp., 443 Veillonella parvula C. difficile, 216 UDP-glucose analogs tetracycline Chlamydia sp. strain TWAR, 257 herpes simplex virus type 1, 1257 resistance, 1271 Clostridium spp., 216 P-536, 1257, 1412 Vernamycin B comparatiVe activity T. cruzi, 1412 Arthrobacter spp., 420 ampicillin, cefaclor, cefoxitin, clinda- Ureaplasma urealyticum Staphylococcus spp., 420 mycin, and doxycycline, 584 A-63075, 1500 Vernonia amygdalina ampicillin, gentamicin, and clarithromycin, 1500 B. gingivalis, 598 spectinomycin, 216 difloxacin; 1500 B. melaninogenicus, 598 Enterobacteriaceae, 216 erythromycin, 1500 Vesicular stomatitis virus H. influenzae, 216 temafloxacin, 1500 carrageenans, 1742 N. gonorrhoeae, 216 Uridine dextran sulfate, 1742 Proteus spp., 216 3'-azido-3'-deoxythymidine toxicity, fucoidan, 1742 Staphylococcus spp., 216 997 P-536, 1257 Streptococcus spp., 216 AZT toxicity, 997 pentosan polysulfate, 1742 Trypanosoma brucei gambiense Urinary tract infections ribavirin, phosphorylated, 492 stearylamine- and phosphatidylcholine- berberine sulfate, 1274 sulfated polysaccharides, 1742 liposomes, 966 carumonam, 473, 1031 transcription, 492 xxxiv SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Virus-antigen assays Xanthomonas maltophilia comparative activity human immunodeficiency virus type 1, E-1040, 1666 clavulanic acid and sulbactam, 684 Xylotubercidin 925 Vitamin K influenza viruses, 906 E. cloacae, 925 cefotetan effect on metabolism, 1446 E. coli, 925 cefoxitin effect on metabolism, 1446 Yersinia enterocolitica K. aerogenes, 925 tigemonam, 84 mechanisms of action, 925 Wound infections Yersinia spp. P. mirabilis, 925 clindamycin-amikacin, 1557 R-3746, 671 ticarcillin-clavulanic acid, 1557 YTR 830 Zinc WR 194,965 phosphate 1-lactamases, 925 common cold, 605, 606, 608 crystal and molecular structure, 540 C. freundii, 925 letters to the editor, 605, 606, 608